[
  {
    "id": "EP2229356B1",
    "text": "1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis AbstractThe present invention provides a compound of formula (I):   \nwherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP. Claims (\n12\n)\n\n\n\n\n \n\n\nA compound of formula (I):\n\n \n \n\n\nR1 is alkyl-O-C(O)-, alkanoyl or heterocyclyl, wherein said heterocyclyl is optionally substituted with one to three substituents selected from halogen, dialkylamino, alkoxy, heterocyclyl, wherein the substituent heterocyclyl is further optionally substituted with one to three substituents selected from alkyl, hydroxy and alkanoyl,\n\n\nR2 is alkyl, cycloalkyl, or cycloalkyl-alkyl-, wherein each alkyl or cycloalkyl is optionally substituted with one to three substituents selected from alkyl, alkoxy or halogen;\n\n\nR3 is R8-O-C(O)-, (R8)(R9)N-C(O)-, R8-C(O)-, aryl, heterocyclyl or heteroaryl,\n\nwherein each aryl may optionally be substituted by 1-4 substituents selected from alkyl, haloalkyl, cycloalkyl, halogen, hydroxy, alkoxy, alkyl-C(O)-O--, alkyl-O-alkyl-, amino, acyl, thiol, alkyl-S--, nitro, cyano, carboxy, alkyl-O-C(O)--, carbamoyl, alkyl-S(O)--, sulfonyl, sulfonamido, alkenyl, haloalkoxy, cycloalkoxy, alkenyloxy, alkoxycarbonyl, alkyl-SO--, alkyl-SO\n2\n--, amino, mono- or di-substituted (alkyl, cycloalkyl, aryl and/or aryl alkyl) amino and H\n2\nN-SO\n2\n, and\n\nwherein each heterocyclyl may optionally be substituted with 1, 2 or 3 substiutents selected from alkyl; haloalkyl, hydroxy, halogen; oxo; amino, mono- or di-substituted (alkyl, cycloalkyl, aryl and/or aryl alkyl) amino; alkoxy; cycloalkyl; alkenyl; carboxy; alkyl-O-C(O)--; mercapto; HSO\n3\n; nitro; cyano; sulfamoyl or sulfonamido; alkyl-C(O)-O--; aryl-C(O)-O--; cycloalkoxy; alkenyloxy; alkoxycarbonyl; carbamoyl; alkyl-S--; alkyl-SO--, alkyl-SO\n2\n--; formyl; acyl; and\n\nwherein each heteroaryl may optionally be substituted by 1-4 substituents selected from alkyl, haloalkyl, cycloalkyl, halogen, hydroxy, alkoxy, alkyl-C(O)-O--, alkyl-O-alkyl, amino, acyl, thiol, alkyl-S--, nitro, cyano, carboxy, alkyl-O-C(O)--, carbamoyl, alkyl-S(O)--, sulfonyl, sulfonamido, heterocyclyl optionally substituted with a substituent selected from hydroxy, oxo, carboxy, -C(O)alkyl, halogen; alkoxy, -C(O)Oalkyl, alkenyl, haloalkoxy, cycloalkoxy, alkenyloxy, alkoxycarbonyl, alkyl-SO--, alkyl-SO\n2\n--, amino, mono- or di-substituted (alkyl, cycloalkyl) amino and H\n2\nN-SO\n2\n;\n\nwherein R8 and R9 are independently hydrogen, alkyl, -C(O)O-alkyl, alkyl-O(O)C-alkyl-, amino-(O)C-alkyl-, cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl-alkyl-, heteroaryl-alkyl-, heterocyclyl-alkyl- or cycloalkyl-alkyl-, wherein each alkyl, cycloalkyl, aryl, aryl-alkyl- or cycloalkyl-alkyl- is optionally substituted with one to three substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl,\n\n\nR8 and R9 may be taken together to form a 5 or 6-membered heterocyclyl or heteroaryl, which can be substituted with substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl;\n\n\nR4 is hydrogen or aryl-alkyl- optionally substituted by one to three alkyl or halogen; R6 and R7 are independently halogen, alkyl, haloalkyl or alkoxy;\n\nwherein the term \"alkyl\" refers to a fully saturated branched or unbranched hydrocarbon moiety comprising 1 to 20 carbon atoms;\n\nwherein the term \"cycloalkyl\" refers to a saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon group of 3-12 carbon atoms\n\nwherein the term \"aryl\" refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6-20 carbon atoms in the ring portion;\n\nwherein the term \"heterocyclyl\" refers to a fully saturated or unsaturated, aromatic or nonaromatic cyclic group which is a 4- to 7-membered monocyclic, 7- to 12-membered bicyclic or 10- to 15-membered tricyclic ring system, which has at least one heteroatom selected from N, O or S in at least one carbon atom containing ring;\n\nwherein the term \"heteroaryl\" refers to a 5-14 membered monocyclic- or bicyclic- or fused polycyclic-ring system, having 1 to 8 heteroatoms selected from N, O or S;\n\nor a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers.\n\n\n\n\n \n \n\n\nThe compound according to claim 1 wherein\n\nR1 is alkyl-O-C(O)-, alkanoyl or heterocyclyl, wherein said heterocyclyl is optionally substituted with one to three substituents selected from halogen, dialkylamino, alkoxy, heterocyclyl, wherein the substituent heterocyclyl is further optionally substituted with one to three substituents selected from alkyl, hydroxy and alkanoyl,\n\nR2 is alkyl, cycloalkyl, or cycloalkyl-alkyl-, wherein each alkyl or cycloalkyl is optionally substituted with one to three substituents selected from alkyl, alkoxy or halogen;\n\nR3 is R8-O-C(O)-, (R8)(R9)N-C(O)-, R8-C(O)-, aryl, heterocyclyl or heteroaryl,\n\nwherein R8 and R9 are independently hydrogen, alkyl, -C(O)O-alkyl, alkyl-O(O)C-alkyl-, amino-(O)C-alkyl-, cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl-alkyl-, heteroaryl-alkyl-, heterocyclyl-alkyl- or cycloalkyl-alkyl-, wherein each alkyl, cycloalkyl, aryl, aryl-alkyl- or cycloalkyl-alkyl- is optionally substituted with one to three substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl,\n\nR8 and R9 may be taken together to form a 5 or 6-membered heterocyclyl or heteroaryl, which can be substituted with substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl;\n\nR4 is hydrogen or aryl-alkyl-, optionally substituted by one to three alkyl or halogen; R6 and R7 are independently halogen, alkyl, haloalkyl or alkoxy;\n\nwherein the term \"alkyl\" refers to a fully saturated branched or unbranched hydrocarbon moiety comprising 1 to 20 carbon atoms;\n\nwherein the term \"cycloalkyl\" refers to a saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon group of 3-12 carbon atoms;\n\nwherein the term \"aryl\" refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6-20 carbon atoms in the ring portion;\n\nwherein the term \"heterocyclyl\" refers to a fully saturated or unsaturated, aromatic or nonaromatic cyclic group which is a 4- to 7-membered monocyclic, 7- to 12-membered bicyclic or 10- to 15-membered tricyclic ring system, which has at least one heteroatom selected from N, O or S in at least one carbon atom containing ring;\n\nwherein the term \"heteroaryl\" refers to a 5-14 membered monocyclic- or bicyclic- or fused polycyclic-ring system, having 1 to 8 heteroatoms selected from N, O or S;\n\nor a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers.\n\n\n\n\n \n \n\n\nThe compound according to claim 1 or 2 wherein\n\nR1 is heterocyclyl, alkyl-O-C(O)- or alkanoyl, wherein said heterocyclyl is optionally substituted with one to three substituents selected from halogen, alkoxy, and heterocyclyl; wherein the substituent heterocyclyl is further optionally substituted with one to three substituents selected from hydroxy and alkanoyl;\n\nR2 is alkyl;\n\nR3 is R8-O-C(O)--, (R8)(R9)N-C(O)--, R8-C(O)-, or heteroaryl;\n\nR8 is hydrogen, alkyl, cycloalkyl, aryl, aryl-alkyl- or cycloalkyl-alkyl-; or\n\na pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers.\n\n\n\n\n \n \n\n\nThe compound according to Claim 1 or 2, wherein\n\nR2 is alkyl;\n\nR3 is alkyl-O-C(O)-, cycloalkyl-C(O)-, or heteroaryl.\n\n\n\n\n \n \n\n\nThe compound according to Claim 1, 2 or 3, wherein\n\nR1 is (C1-C7)alkyl-O-C(O)-, or 5- or 6-membered heterocyclyl, wherein said heterocyclyl is optionally substituted with one to three substituents selected from halogen, dialkylamino, (C1-C7) alkoxy, or 5- or 6-membered heterocyclyl, wherein said heterocyclyl is further optionally substituted with one to three substituents selected from (C1-C7)alkanoyl or hydroxy;\n\nR2 is (C1-C7) alkyl;\n\nR3 is (C1-C7)alkyl-O-C(O)-, 5- or 6-membered cycloalkyl-C(O)-, or heteroaryl;\n\nR4 is hydrogen; and\n\nR6 and R7 are independently halogen, (C1-C7) alkyl, (C1-C7) haloalkyl or (C1-C7) alkoxy.\n\n\n\n\n \n \n\n\nA pharmaceutical composition, comprising:\n\na therapeutically effective amount of a compound of formula (I) according to any of claims 1 to 5 and\n\n\na pharmaceutically acceptable carriers.\n \n\n\n\n\n \n \n\n\nA pharmaceutical composition, comprising:\n\na therapeutically effective amount of the compound according to any of claims 1 to 5 and\n\n\none or more therapeutically active agents selected from the group consisting of a:\n\n(i) HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof,\n\n\n(ii) angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof,\n\n\n(iii) angiotensin converting enzyme (ACE) Inhibitor or a pharmaceutically acceptable salt thereof,\n\n\n(iv) calcium channel blocker or a pharmaceutically acceptable salt thereof,\n\n\n(v) aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof,\n\n\n(vi) aldosterone antagonist or a pharmaceutically acceptable salt thereof,\n\n\n(vii) dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt thereof,\n\n\n(viii) endothelin antagonist or a pharmaceutically acceptable salt thereof,\n\n\n(ix) renin inhibitor or a pharmaceutically acceptable salt thereof,\n\n\n(x) diuretic or a pharmaceutically acceptable salt thereof, and\n\n\n(xi) an ApoA-1 mimic.\n \n \n\n\n\n\n \n \n\n\nA compound of formula (I) according to any of claims 1 to 5 for use as a medicament.\n\n\n\n\n \n \n\n\nUse of a compound of formula (I) according to any of claims 1 to 5, for the preparation of a medicament for the treatment of a disorder or disease in a subject mediated by CETP or responsive to inhibition of CETP,\n\nwherein the disorder or the disease is selected from hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity or endotoxemia etc.\n\n\n\n\n \n \n\n\nThe compound according to claim 1 selected from the group consisting of\n\n(2S,3S,5R)-2-Benzyl-3-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-5-ethylpyrrolidine-1-carboxylic acid tert-butyl ester;\n\n(2S,3S,5R)-2-Benzyl-3-[(5-bromo-pyrimidin-2-yl)-(3-chloro-5-trifluoromethyl-benzyl)-amino]-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester;\n\n(2S,3S,5R)-2-Benzyl-3-{(3-chloro-5-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-carboxy-cyclohexyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-carboxy-cyclohexyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2-carboxy-2-methyl-propyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-3-methyl-butyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-cyclobutyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-carboxy-cyclohexylmethyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-cyclobutyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-carboxy-cyclopentylmethyl ester; 4-{[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-ethyl-amino]-methyl}-cyclohexanecarboxylic acid; (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-pyrrolidine-2-carboxylic acid; (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperidine-2-carboxylic acid; 4-[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-amino]-cyclohexanecarboxylic acid; 4-[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-methyl-amino]-cyclohexanecarboxylic acid; ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-oxo-acetic acid ethyl ester; 1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-ethanone; 1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-3-methyl-butan-1-one; ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-cyclohexyl-methanone; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isobutyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2,2-dimethyl-propyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-methoxycarbonyl-cyclohexyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2-methoxycarbonyl-2-methyl-propyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-ethoxycarbonyl-1-methyl-ethyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-y)]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-ethoxycarbonyl-3-methyl-butyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tetrahydro-pyran-4-yl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methoxycarbonyl-phenyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tetrahydro-pyran-4-ylmethyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methoxycarbonyl-cyclobutyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methoxycarbonyl-cyclobutyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-methoxycarbonyl-cyclohexylmethyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid cyclohexylmethyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-methoxycarbonyl-cyclopentylmethyl ester;\n\n-(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-phenyl ester;\n\n-(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-ethyl-propyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2,2,2-trifluoro-ethyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid cyclopentyl ester;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid (R)-sec-butyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid (S)-sec-butyl ester; (5R)-3-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-5-ethyl-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-((S)-3-hydroxy-pyrrolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester; (2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-morpholin-4-yl-pyrimidin-2-yl)-amino]-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2-carbamoyl-2-methyl-propyl ester; (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid isopropyl ester; 2-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-oxazole-4-carboxylic acid ethyl ester; ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-pyrrolidin-1-yl-methanone; 4-{[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-ethyl-amino]-methyl}-cyclohexanecarboxylic acid methyl ester; ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-piperidin-1-yl-methanone; (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperidine-3-carboxylic acid ethyl ester; (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperidine-2-carboxylic acid methyl ester; ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-cyclohexyl-methanone; 1-[4-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperazin-1-yl]-ethanone; ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-(2-cyclohexyl-pyrrolidin-1-yl)-methanone; 4-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperazin-2-one; ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-morpholin-4-yl-methanone;\n\n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid dimethylamide;\n\n(S)-3-{(3-Chloro-5-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-pyrrolidine-1-carboxylic acid isopropyl ester;\n\n(2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethylpyrrolidine-1-carboxylic acid isopropyl ester;\n\n(2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-morpholin-4-yl-pyrimidin-2-yl)-amino]-2-ethylpyrrolidine-1-carboxylic acid isopropyl ester;\n\n(3,5-Bis-trifluoromethyl-benzyl)-[(3S,5R)-5-ethyl-1-(5-trifluoromethyl-pyridin-2-yl)-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;\n\n(3,5-Bis-trifluoromethyl-benzyl)-[(3S,5R)-1-(6-chloro-pyrimidin-4-yl)-5-ethyl-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;\n\n1-[4-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-((S)-3-hydroxy-pyrrolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidin-4-ol;\n\n1-[4-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidin-4-ol;\n\n1-[5-chloro-4-((2R,4S)-4-{[3,5-Bis(trifluoromethyl)-benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-pyrimidin-2-yl]-piperidine-4-carboxylic acid;\n\n1-(4-{(2R,4R)-4-[2-(3,5-Bis-trifluoromethyl-phenyl)-1-(5-morpholin-4-yl-pyrimidin-2-yl)-ethyl]-2-ethyl-pyrrolidin-1-yl}-5-chloro-pyrimidin-2-yl)-piperidine-4-carboxylic acid;\n\nor a pharmaceutically acceptable salt thereof.\n\n\n\n\n \n \n\n\nThe compound according to claim 1, wherein R1 is selected from\n\n \n \n\nand pyridyl, wherein each is unsubstituted or substituted by halogen or hetereocyclyl.\n\n\n\n\n \n \n\n\nThe compound according to claim 11, wherein R1 is selected from Description\n\n\n\n\n \n \n \nThe present invention related to novel compound of formula (I):\n\n \n \n\n\n \n \n \nR1 is heterocyclyl, alkyl-O-C(O)- or alkanoyl, wherein said heterocyclyl is optionally substituted with one to three substituents selected from halogen, dialkylamino, alkoxy, heterocyclyl, wherein the substituent heterocyclyl is further optionally substituted with one to three substituents selected from alkyl, hydroxy and alkanoyl,\n \nR2 is alkyl, cycloalkyl, or cycloalkyl-alkyl-, wherein each alkyl or cycloalkyl is optionally substituted with one to three substituents selected from alkyl, alkoxy or halogen;\n \nR3 is R8-O-C(O)-, (R8)(R9)N-C(O)-, R8-C(O)-, aryl, heterocyclyl or heteroaryl,\n\nwherein each aryl may optionally be substituted by 1-4 substituents selected from alkyl, haloalkyl, cycloalkyl, halogen, hydroxy, alkoxy, alkyl-C(O)-O--, alkyl-O-alkyl-, amino, acyl, thiol, alkyl-S--, nitro, cyano, carboxy, alkyl-O-C(O)--, carbamoyl, alkyl-S(O)--, sulfonyl, sulfonamido, alkenyl, haloalkoxy, cycloalkoxy, alkenyloxy, alkoxycarbonyl, alkyl-SO--, alkyl-SO\n2\n--, amino, mono- or di-substituted (alkyl, cycloalkyl, aryl and/or aryl alkyl) amino or H\n2\nN-SO\n2\n, and\n\nwherein each heterocyclyl may optionally be substituted with 1, 2 or 3 substiutents selected from alkyl; haloalkyl, hydroxy, halogen; oxo; amino, mono- or di-substituted (alkyl, cycloalkyl, and) amino; alkoxy; cycloalkyl; alkenyl; carboxy; alkyl-O-C(O)--; mercapto; HSO\n3\n; nitro; cyano; sulfamoyl or sulfonamido; alkyl-C(O)-O--; aryl-C(O)-O--; cycloalkoxy; alkenyloxy; alkoxycarbonyl; carbamoyl; alkyl-S--; alkyl-SO--, alkyl-SO\n2\n--; formyl; acyl; and\n\nwherein each heteroaryl may optionally be substituted by 1-4 substituents selected from alkyl, haloalkyl, cycloalkyl, halogen, hydroxy, alkoxy, alkyl-C(O)-O--, alkyl-O-alkyl, amino, acyl, thiol, alkyl-S--, nitro, cyano, carboxy, alkyl-O-C(O)--, carbamoyl, alkyl-S(O)--, sulfonyl, sulfonamido, heterocyclyl optionally substituted with a substituent selected from hydroxy, oxo, carboxy, -C(O)alkyl, halogen; alkoxy, -C(O)Oalkyl, alkenyl, haloalkoxy, cycloalkoxy, alkenyloxy, alkoxycarbonyl, alkyl-SO--, alkyl-SO\n2\n--, amino, mono- or di-substituted (alkyl, cycloalkyl) amino or H\n2\nN-SO\n2\n;\n\nwherein R8 and R9 are independently hydrogen, alkyl, -C(O)O-alkyl, alkyl-O(O)C-alkyl-, amino-(O)C-alkyl-, cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl-alkyl-, heteroaryl-alkyl-, heterocyclyl-alkyl- or cycloalkyl-alkyl-, wherein each alkyl, cycloalkyl, aryl, aryl-alkyl- or cycloalkyl-alkyl- is optionally substituted with one to three substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl,\n \nR8 and R9 may be taken together to form a 5 or 6-membered heterocyclyl or heteroaryl, which can be substituted with substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl;\n \nR4 is hydrogen or aryl-alkyl- optionally substituted by one to three alkyl or halogen;\n \nR6 and R7 are independently halogen, alkyl, haloalkyl or alkoxy;\n\nwherein the term \"alkyl\" refers to a fully saturated branched or unbranched hydrocarbon moiety comprising 1 to 20 carbon atoms;\n\nwherein the term \"cycloalkyl\" refers to a saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon group of 3-12 carbon atoms\n\nwherein the term \"aryl\" refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6-20 carbon atoms in the ring portion;\n\nwherein the term \"heterocyclyl\" refers to a fully saturated or unsaturated, aromatic or nonaromatic cyclic group which is a 4- to 7-membered monocyclic, 7- to 12-membered bicyclic or 10- to 15-membered tricyclic ring system, which has at least one heteroatom selected from N, O or S in at least one carbon atom containing ring;\n\nwherein the term \"heteroaryl\" refers to a 5-14 membered monocyclic- or bicyclic- or fused polycyclic-ring system, having 1 to 8 heteroatoms selected from N, O or S;\n \n\nor a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers.\n    \n \n \n \nThe present invention also relates to a process for the preparation of these compounds, to the use of these compounds and to pharmaceutical preparations containing such a compound I in free form or in the form of a pharmaceutically acceptable salt.\n\n\n \n \n \n \nExtensive pharmacological investigations have shown that the compounds I and their pharmaceutically acceptable salts, for example, have pronounced selectivity in inhibiting CETP (cholesteryl ester transfer protein). CETP is involved in the metabolism of any lipoprotein in living organisms, and has a major role in the reverse cholesterol transfer system. Namely, CETP has drawn attention as a mechanism for preventing accumulation of cholesterol in peripheral cells and preventing arteriosclerosis. In fact, with regard to HDL having an important role in this reverse cholesterol transfer system, a number of epidemiological researches have shown that a decrease in CE (cholesteryl ester) of HDL in blood is one of the risk factors of coronary artery diseases. It has been also clarified that the CETP activity varies depending on the animal species, wherein arteriosclerosis due to cholesterol-loading is hardly induced in animals with lower activity, and in reverse, easily induced in animals with higher activity, and that hyper-HDL-emia and hypo-LDL (low density lipoprotein)-emia are induced in the case of CETP deficiency, thus rendering the development of arteriosclerosis difficult, which in turn led to the recognition of the significance of blood HDL, as well as significance of CETP that mediates transfer of CE in HDL into blood LDL. While many attempts have been made in recent years to develop a drug that inhibits such activity of CETP, a compound having a satisfactory activity has not been developed yet.\n\n\n \nDetailed Description of the Invention\n\n\n \n \n \nFor purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.\n\n\n \n \n \n \nAs used herein, the term \"alkyl\" refers to a fully saturated branched or unbranched hydrocarbon moiety. The alkyl comprises 1 to 20 carbon atoms, more preferably 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, \nn-\npropyl, \niso\npropyl, \nn-\nbutyl, \nsec-\nbutyl, \niso-\nbutyl, \ntert\n-butyl, \nn-\npentyl, isopentyl, neopentyl, \nn-\nhexyl, 3-methylhexyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, \nn-\nheptyl, \nn-\noctyl, \nn-\nnonyl, \nn-\n decyl and the like. When an alkyl group includes one or more unsaturated bonds, it is referred to as an alkenyl (double bond) or an alkynyl (triple bond) group.\n\n\n \n \n \n \nThe term \"aryl\" refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6-20 carbon atoms in the ring portion. Preferably, the aryl is a (C\n8\n-C\n10\n) aryl. Non-limiting examples include phenyl, biphenyl, naphthyl or tetrahydronaphthyl, most preferably phenyl.\n\n\n \n \n \n \nAs used herein, the term \"alkoxy\" refers to alkyl-O-, wherein alkyl is defined herein above. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, \ntert\n-butoxy, pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- and the like. Preferably, alkoxy groups have about 1-7, more preferably about 1-4 carbons.\n\n\n \n \n \n \nAs used herein, the term \"acyl\" refers to a group R-C(O)- of from 1 to 10 carbon atoms of a straight, branched, or cyclic configuration or a combination thereof, attached to the parent structure through carbonyl functionality. Such group can be saturated or unsaturated, and aliphatic or aromatic. Preferably, R in the acyl residue is alkyl, or alkoxy, or aryl, or heteroaryl. When R is alkyl then the moiety is referred to a alkanoyl. Also preferably, one or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include but are not limited to, acetyl, benzoyl, propionyl, isobutyryl, t- butoxycarbonyl, benzyloxycarbonyl and the like. Lower acyl refers to acyl containing one to four carbons.\n\n\n \n \n \n \nAs used herein, the term \"acylamino\" refers to acyl-NH--, wherein \"acyl\" is defined herein.\n\n\n \n \n \n \nAs used herein, the term \"carbamoyl\" refers to H\n2\nNC(O)-, alkyl-NHC(O)-, (alkyl)\n2\nNC(O)-, aryl-NHC(O)-, alkyl(aryl)-NC(O)-, heteroaryl-NHC(O)-, alkyl(heteroaryl)-NC(O)-, aryl-alkyl-NHC(O)-, alkyl(aryl-alkyl)-NC(O)- and the like.\n\n\n \n \n \n \nAs used herein, the term \"sulfonyl\" refers to R-SO\n2\n--, wherein R is hydrogen, alkyl, aryl, hereoaryl, aryl-alkyl, heteroaryl-alkyl, aryl-O--, heteroaryl-O--, alkoxy, aryloxy, cycloalkyl, or heterocyclyl.\n\n\n \n \n \n \nAs used herein, the term \"sulfonamido\" refers to alkyl-S(O)\n2\n-NH-, aryl-S(O)\n2\n-NH-, aryl-alkyl-S(O)\n2\n-NH-, heteroaryl-S(O)\n2\n-NH-, heteroaryl-alkyl-S(O)\n2\n-NH-, alkyl-S(O)\n2\n-N(alkyl)-, arylS(O)\n2\n-N(alkyl)-, aryl-alkyl-S(O)\n2\n-N(alkyl)-, heteroaryl-S(O)\n2\n-N(alkyl)-, heteroarrl-alkyl-S(O)\n2\n-N(alkyl)- and the like.\n\n\n \n \n \n \nAs used herein, the term \"alkoxycarbonyl\" or \"alkyl-O-C(O)-\" refers to alkoxy-C(O)--, wherein alkoxy is defined herein.\n\n\n \n \n \n \nAs used herein, the term \"alkanoyl\" refers to alkyl-C(O)--, wherein alkyl is defined herein.\n\n\n \n \n \n \nAs used herein, the term \"alkenyl\" refers to a straight or branched hydrocarbon group having 2 to 20 carbon atoms and that contains at least one double bonds. The alkenyl groups preferably have about 2 to 8 carbon atoms.\n\n\n \n \n \n \nAs used herein, the term \"alkenyloxy\" refers to alkenyl-O--, wherein alkenyl is defined herein.\n\n\n \n \n \n \nAs used herein, the term \"cycloalkoxy\" refers to cycloalkyl-O--, wherein cycloalkyl is defined herein.\n\n\n \n \n \n \nAs used herein, the term \"heterocyclyl\" or \"heterocyclo\" refers to a fully saturated or unsaturated, aromatic or nonaromatic cyclic group, e.g., which is a 4- to 7-membered monocyclic, 7- to 12-membered bicyclic or 10- to 15-membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized. The heterocyclic group may be attached at a heteroatom or a carbon atom.\n\n\n \n \n \n \nExemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, triazolyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, piperazinyl, piperidinyl, 4-piperidonyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl, 1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl and the like.\n\n\n \n \n \n \nExemplary bicyclic heterocyclic groups include indolyl, dihydroidolyl, benzothiazolyl, benzoxazinyl, benzoxazolyl, benzothienyl, benzothiazinyl, quinuclidinyl, quinolinyl, tetrahydroquinolinyl, decahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]-pyridinyl] or furo[2,3-b]pyridinyl), dihydroisoindolyl, 1,3-dioxo-1,3-dihydroisoindol-2-yl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), phthalazinyl and the like.\n\n\n \n \n \n \nExemplary tricyclic heterocyclic groups include carbazolyl, dibenzoazepinyl, dithienoazepinyl, benzindolyl, phenanthrolinyl, acridinyl, phenanthridinyl, phenoxazinyl, phenothiazinyl, xanthenyl, carbolinyl and the like.\n\n\n \n \n \n \nWhen heterocyclyl is aromatic, this moiety is referred to as \"heteroaryl\".\n\n\n \n \n \n \nAs used herein, the term \"heteroaryl\" refers to a 5-14 membered monocyclic- or bicyclic- or fused polycyclic-ring system, having 1 to 8 heteroatoms selected from N, O or S. Preferably, the heteroaryl is a 5-10 membered ring system. Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5- pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2, 3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4- , or 5-pyrazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl.\n\n\n \n \n \n \nThe term \"heteroaryl\" also refers to a group in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include but are not limited to 1-, 2-, 3-, 5-, 6-, 7-, or 8- indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8- purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoliyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinoliyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-, 3-, 4-, 5-, or 6-naphthyridinyl, 2-, 3- , 5-, 6-, 7-, or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-4aH carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-carbzaolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1- , 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-perimidinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10-phenathrolinyl, 1-, 2- , 3-, 4-, 6-, 7-, 8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenoxazinyl, 2-, 3-, 4-, 5-, 6-, or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10- benzisoqinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanyl, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10 -, or 11-7H-pyrazino[2,3-c]carbazolyl,2-, 3-, 5-, 6-, or 7-2H- furo[3,2-b]-pyranyl, 2-, 3-, 4-, 5-, 7-, or 8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3-, or 5-1 H-pyrazolo[4,3-d]-oxazolyl, 2-, 4-, or 54H-imidazo[4,5-d] thiazolyl, 3-, 5-, or 8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5-, or 6- imidazo[2,1-b] thiazolyl, 1-, 3-, 6-, 7-, 8-, or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10, or 11-4H-pyrido[2,3-c]carbazolyl, 2-, 3-, 6-, or 7-imidazo[1,2-b][1,2,4]triazinyl, 7-benzo[b]thienyl, 2-, 4-, 5- , 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-, or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-1H-pyrrolo[1,2-b][2]benzazapinyl. Typical fused heteroaryl groups include, but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5- , 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl.\n\n\n \n \n \n \nA heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic.\n\n\n \n \n \n \nAs used herein, the term \"cycloalkyl\" refers to saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon groups of 3-12 carbon atoms. Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl and the like. Exemplary bicyclic hydrocarbon groups include bornyl, indyl, hexahydroindyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl and the like. Exemplary tricyclic hydrocarbon groups include adamantyl and the like.\n\n\n \n \n \n \nAs used herein, the term \"sulfamoyl\" refers to H\n2\nNS(O)\n2\n-, alkyl-NHS(O)\n2\n-, (alkyl)\n2\nNS(O)\n2\n-, aryl-NHS(O)\n2\n-, alkyl(aryl)-NS(O)\n2\n-, (aryl)\n2\nNS(O)\n2\n-, heteroaryl-NHS(O)\n2\n-, aryl-alkyl-NHS(O)\n2\n-, heteroaryl-alkyl-NHS(O)\n2\n- and the like.\n\n\n \n \n \n \nAs used herein, the term \"aryloxy\" refers to both an --O-aryl and an --O- heteroaryl group, wherein aryl and heteroaryl are defined herein.\n\n\n \n \n \n \nAs used herein, the term \"halogen\" or \"halo\" refers to fluoro, chloro, bromo, and iodo.\n\n\n \n \n \n \nAs used herein, the term \"haloalkyl\" refers to an alkyl as defined herein, that is substituted by one or more halo groups as defined herein. Preferably the haloalkyl can be monohaloalkyl, dihaloalkyl or polyhaloalkyl including perhaloalkyl. A monohaloalkyl can have one iodo, bromo, chloro or fluoro within the alkyl group. Dihaloalky and polyhaloalkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl. Preferably, the polyhaloalkyl contains up to 12, 10, or 8, or 6, or 4, or 3, or 2 halo groups. Non-limiting examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. A perhaloalkyl refers to an alkyl having all hydrogen atoms replaced with halo atoms.\n\n\n \n \n \n \nAs used herein, the term \"dialkylamino\" refers to an to an amino group which is di-substituted by alkyl, whereby the alkyl can be the same or different, as defined herein. Preferably the dialkylamino can have the same alkyl substitutent. Non-limiting examples of dialkylamino include dimethylamino, diethylamino and diisopropylamino.\n\n\n \n \n \n \nAs used herein, the term \"aryl alkyl\" is interchangeable for \"aryl-alkyl-\", wherein aryl and alkyl are defined herein.\n\n\n \n \n \n \nAs used herein, the term \"cycloalkyl-alkyl-\" is interchangeable for \"cycloalkyl alkyl\", wherein cycloalkyl and alkyl are defined herein.\n\n\n \n \n \n \nAs used herein, the term \"isomers\" refers to different compounds that have the same molecular formula. Also as used herein, the term \"an optical isomer\" refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. \"Enantiomers\" are a pair of stereoisomers that are non- superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a \"racemic\" mixture. The term is used to designate a racemic mixture where appropriate. \"Diastereoisomers\" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either \nR\n or \nS\n. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (\nR\n)- or (\nS\n)-. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (\nR\n)- and (\nS\n)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.\n\n\n \n \n \n \nAs used herein, the term \"pharmaceutically acceptable salts\" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which are not biologically or otherwise undesirable. Non-limiting examples of the salts include non-toxic, inorganic and organic base or acid addition salts of compounds of the present invention. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, \np-\n toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Lists of additional suitable salts can be found, e.g., in \nRemington's Pharmaceutical Sciences, 20th ed., Mack Publishing Company, Easton, Pa., (1985\n).\n\n\n \n \n \n \nAs used herein, the term \"pharmaceutically acceptable carrier\" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, \nRemington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329\n. Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.\n\n\n \n \n \n \nThe term \"therapeutically effective amount\" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, or ameliorate symptoms, slow or delay disease progression, or prevent a disease, etc. In a preferred embodiment, the \"effective amount\" refers to the amount that inhibits or reduces expression or activity of CETP.\n\n\n \n \n \n \nAs used herein, the term \"subject\" refers to an animal. Preferably, the animal is a mammal. A subject also refers to for example, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In a preferred embodiment, the subject is a human.\n\n\n \n \n \n \nAs used herein, the term \"a disorder\" or \"a disease\" refers to any derangement or abnormality of function; a morbid physical or mental state. See\n Dorland's Illustrated Medical Dictionary, (W.B. Saunders Co. 27th ed. 1988\n).\n\n\n \n \n \n \nAs used herein, the term \"inhibition\" or \"inhibiting\" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process. Preferably, the condition or symptom or disorder or disease is mediated by CETP activity or responsive to the inhibition of CETP.\n\n\n \n \n \n \nAs used herein, the term \"treating\" or \"treatment\" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment \"treating\" or \"treatment\" refers to ameliorating at least one physical parameter, which may not be discernible by the patient. In yet another embodiment, \"treating\" or \"treatment\" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, \"treating\" or \"treatment\" refers to preventing or delaying the onset or development or progression of the disease or disorder.\n\n\n \n \n \n \nIn one embodiment, the invention is related to a compound of formula I wherein\n\nR1 is alkyl-O-C(O)-, alkanoyl or heterocyclyl, wherein said heterocyclyl is optionally substituted with one to three substituents selected from halogen, dialkylamino, alkoxy, heterocyclyl, wherein the substituent heterocyclyl is further optionally substituted with one to three substituents selected from alkyl, hydroxy and alkanoyl,\n\nR2 is alkyl, cycloalkyl, or cycloalkyl-alkyl-, wherein each alkyl or cycloalkyl is optionally substituted with one to three substituents selected from alkyl, alkoxy or halogen;\n\nR3 is R8-O-C(O)-, (R8)(R9)N-C(O)-, R8-C(O)-, aryl, heterocyclyl or heteroaryl,\n\nwherein R8 and R9 are independently hydrogen, alkyl, -C(O)O-alkyl, alkyl-O(O)C-alkyl-, amino-(O)C-alkyl-, cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl-alkyl-, heteroaryl-alkyl-, heterocyclyl-alkyl- or cycloalkyl-alkyl-, wherein each alkyl, cycloalkyl, aryl, aryl-alkyl- or cycloalkyl-alkyl- is optionally substituted with one to three substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl,\n\nR8 and R9 may be taken together to form a 5 or 6-membered heterocyclyl or heteroaryl, which can be substituted with substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO\n3\n-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-haloalkyl, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO\n2\n-, amino, H\n2\nN-SO\n2\n-, and heterocyclyl;\n\nR4 is hydrogen or aryl-alkyl- optionally substituted by one to three alkyl or halogen;\n\nR6 and R7 are independently halogen, alkyl, haloalkyl or alkoxy;\n\nor\n\na pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers.\n\n\n \n\n\nPreferred definitions for R1\n\n\n\n\n \n \n \nPreferably, R1 is heterocyclyl, such as heteroaryl, alkanoyl or alkoxycarbonyl, wherein each heterocyclyl is optionally substituted with one to three substituents selected from halogen, alkoxy, dialkylaminoor heterocyclyl.. Preferred examples for the heterocyclyl substituent of the heterocyclyl moiety for R1 is a 5- to 6-membered ring containing at least one heteroatom selected from O, N or S, more preferably N, most preferably it has more than one nitrogen in the ring, such as pyrazole and tetrazole.\n\n\n \n \n \n \nA preferred meaning of variable R1 is heteroaryl as preferably represented by formulae\n\n \n \n\nor pyridyl, especially\n\n \n \n\nwhich are each unsubstituted or substituted by halo, especially Br, or is C\n1\n-C\n4\n-alkoxy-carbonyl, C\n1\n-C\n4\n-alkyl-carbonyl, or is hereocyclyl such as pyrrolidyl, piperidyl, piperazinyl, pyrazoyl, methylpyrazoyl or morpholinyl, especially methylpyrazoyl. For example R1 may be\n\n \n \n\n\n \n \n \n\n\n \n\n\nPreferred Definitions for R2\n\n\n\n\n \n \n \nPreferably, R2 is straight chain or branched C\n1\n-C\n6\n alkyl as defined herein. Examples include methyl, ethyl, isopropyl, n-propyl, isobutyl, n-butyl or sec-butyl, more preferably ethyl or isobutyl, most preferably ethyl.\n\n\n \n\n\nPreferred Definitions for R3\n\n\n\n\n \n \n \nPreferably R3 is alkyl-O-C(O)--, cycloalkyl-O-C(O)--, aryl-alkyl-O-C(O)--, (alkyl)\n2\nN-C(O)--, alkanoyl, aryl-alkyl-C(O)-, or heteroaryl.\n\n\n \n \n \n \nPreferred examples of alkyl-O-C(O)-- include moieties where alkyl is selected from straight chain or branched, preferably branched, C\n1\n-C\n6\n alkyl as defined herein, such as methyl, ethyl, isopropyl, isobutyl or tert-butyl, most preferably isopropyl.\n\n\n \n \n \n \nPreferred examples of cycloalkyl-O-C(O)-- include moieties where cycloalkyl is selected from C\n3\n to C\n12\n cycloalkyl as defined herein, such as cyclohexyl or adamantyl.\n\n\n \n \n \n \nPreferred examples of aryl-alkyl-O-C(O)-- include moieties where aryl is selected from C\n6\n to C\n20\n aryl as defined herein, such as phenyl or naphthyl, more preferably phenyl. Preferred examples of aryl-alkyl- include benzyl, phenethyl, more preferably benzyl.\n\n\n \n \n \n \nPreferred examples of (alkyl)\n2\nN-C(O)-- include moieties where alkyl is selected from straight chain or branched, preferably straight chain, C\n1\n-C\n6\n alkyl as defined herein, such as methyl, ethyl, isopropyl, isobutyl or tert-butyl, most preferably methyl or ethyl.\n\n\n \n \n \n \nPreferred examples of alkanoyl include moieties where alkyl is selected from straight chain or branched, preferably branched, C\n1\n-C\n6\n alkyl as defined herein, such as methyl, ethyl, isopropyl, isobutyl or tert-butyl, most preferably tert-butyl.\n\n\n \n \n \n \nPreferred examples of aryl-alkyl-C(O)-- include moieties where aryl is selected from C\n6\n to C\n20\n aryl as defined herein, such as phenyl or naphthyl, more preferably phenyl. Preferred examples of aryl-alkyl- include benzyl, phenethyl, more preferably benzyl.\n\n\n \n \n \n \nPreferred examples of heteroaryl include where heteroaryl is selected from substituted or unsubstituted pyridyl or pyrimidyl, more preferably substituted pyrimidyl.\n\n\n \n \n \n \nMost preferably, R3 is alkyl-O-C(O)-as defined herein.\n\n\n \n\n\nPreferred Definitions for R4\n\n\n\n\n \n \n \nPreferably R4 is hydrogen or benzyl, wherein each benzyl is optionally substituted with one to three substituents selected from alkyl, or halogen.\n\n\n \n \n \n \nMost preferably, R4 is hydrogen or benzyl.\n\n\n \n\n\nPreferred Definitions for R6 and R7\n\n\n\n\n \n \n \nPreferably, R6 and R7 are independently alkyl, haloalkyl, halogen, or alkoxy.\n\n\n \n \n \n \nMore preferably, R6 and R7 are independently alkyl or haloalkyl, such as trifluoromethyl.\n\n\n \n \n \n \nIn a preferred embodiment, both R6 and R7 are the same and are as defined herein, most preferably trifluoromethyl.\n\n\n \n \n \n \nThe positions of R6 and R7 on the phenyl ring are preferably as follows:\n\n \n \n \n\n\n \n \n \n \nAny asymmetric carbon atom on the compounds of the present invention can be present in the (\nR\n)-, (\nS\n)- or (\nR\n,\nS\n)- configuration, preferably in the (\nR\n)- or (\nS\n)- configuration. Substituents at atoms with unsaturated bonds may, if possible, be present in \ncis-\n (\nZ\n)- or \ntrans-\n (\nE\n)- form. Therefore, the compounds of the present invention can be in the form of one of the possible isomers or mixtures thereof, for example, as substantially pure geometric (\ncis\n or \ntrans\n) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.\n\n\n \n \n \n \nPreferred isomers of the compound of the present invention can be represented by the following formula:\n\n \n \n\nin particular:\n\n \n \n \n\n\n \n \n \n \nAny resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.\n\n\n \n \n \n \nAny resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, the pyrrolidine moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-\nO\n,\nO\n'-\np-\ntoluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.\n\n\n \n \n \n \nFinally, compounds of the present invention are either obtained in the free form, as a salt thereof, or as prodrug derivatives thereof.\n\n\n \n \n \n \nWhen a basic group is present in the compounds of the present invention, the compounds can be converted into acid addition salts thereof, in particular, acid addition salts with the pyrazole moiety or morpholine moiety of the structure, preferably pharmaceutically acceptable salts thereof. These are formed, with inorganic acids or organic acids. Suitable inorganic acids include but are not limited to, hydrochloric acid, sulfuric acid, a phosphoric or hydrohalic acid. Suitable organic acids include but are not limited to, carboxylic acids, such as (C\n1\n-C\n4\n)alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, e.g., acetic acid, such as saturated or unsaturated dicarboxylic acids, e.g., oxalic, succinic, maleic or fumaric acid, such as hydroxycarboxylic acids, e.g., glycolic, lactic, malic, tartaric or citric acid, such as amino acids, e.g., aspartic or glutamic acid, organic sulfonic acids, such as (C\n1\n-C\n4\n)alkylsulfonic acids, e.g., methanesulfonic acid; or arylsulfonic acids which are unsubstituted or substituted, e.g., by halogen. Preferred are salts formed with hydrochloric acid, methanesulfonic acid and maleic acid.\n\n\n \n \n \n \nWhen an acidic group is present in the compounds of the present invention, the compounds can be converted into salts with pharmaceutically acceptable bases. Such salts include alkali metal salts, like sodium, lithium and potassium salts; alkaline earth metal salts, like calcium and magnesium salts; ammonium salts with organic bases, e.g., trimethylamine salts, diethylamine salts, \ntris\n(hydroxymethyl)methylamine salts, dicyclohexylamine salts and \nN\n-methyl-\nD\n-glucamine salts; salts with amino acids like arginine, lysine and the like. Salts may be formed using conventional methods, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. From the solutions of the latter, the salts may be precipitated with ethers, e.g., diethyl ether. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained.\n\n\n \n \n \n \nWhen both a basic group and an acid group are present in the same molecule, the compounds of the present invention can also form internal salts.\n\n\n \n \n \n \nThe present invention also provides pro-drugs of the compounds of the present invention that converts \nin vivo\n to the compounds of the present invention. A pro-drug is an active or inactive compound that is modified chemically through \nin vivo\n physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a subject. The suitability and techniques involved in making and using pro-drugs are well known by those skilled in the art. Prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. See \nThe Practice of Medicinal Chemistry, Ch. 31-32 (Ed. Wermuth, Academic Press, San Diego, Calif., 2001\n). Generally, bioprecursor prodrugs are compounds are inactive or have low activity compared to the corresponding active drug compound, that contains one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity. Typically, the formation of active drug compound involves a metabolic process or reaction that is one of the follow types:\n\n \n \n \n1. Oxidative reactions, such as oxidation of alcohol, carbonyl, and acid functions, hydroxylation of aliphatic carbons, hydroxylation of alicyclic carbon atoms, oxidation of aromatic carbon atoms, oxidation of carbon-carbon double bonds, oxidation of nitrogen-containing functional groups, oxidation of silicon, phosphorus, arsenic, and sulfur, oxidative N-delakylation, oxidative O- and S-delakylation, oxidative deamination, as well as other oxidative reactions.\n \n2. Reductive reactions, such as reduction of carbonyl groups, reduction of alcoholic groups and carbon-carbon double bonds, reduction of nitrogen-containing functions groups, and other reduction reactions.\n \n3. Reactions without change in the state of oxidation, such as hydrolysis of esters and ethers, hydrolytic cleavage of carbon-nitrogen single bonds, hydrolytic cleavage of non-aromatic heterocycles, hydration and dehydration at multiple bonds, new atomic linkages resulting from dehydration reactions, hydrolytic dehalogenation, removal of hydrogen halide molecule, and other such reactions.\n \n\n\n \n \n \nCarrier prodrugs are drug compounds that contain a transport moiety, e.g., that improve uptake and/or localized delivery to a site(s) of action. Desirably for such a carrier prodrug, the linkage between the drug moiety and the transport moiety is a covalent bond, the prodrug is inactive or less active than the drug compound, and any released transport moiety is acceptably non-toxic. For prodrugs where the transport moiety is intended to enhance uptake, typically the release of the transport moiety should be rapid. In other cases, it is desirable to utilize a moiety that provides slow release, e.g., certain polymers or other moieties, such as cyclodextrins. See, \n \nCheng et al., US20040077595\n \n, application Ser. No. \n \n10/656,838\n \n. Such carrier prodrugs are often advantageous for orally administered drugs. Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, and/or improvement in drug formulation (e.g., stability, water solubility, suppression of an undesirable organoleptic or physiochemical property). For example, lipophilicity can be increased by esterification of hydroxy groups with lipophilic carboxylic acids, or of carboxylic acid groups with alcohols, e.g., aliphatic alcohols. \nWermuth, The Practice of Medicinal Chemistry, Ch. 31-32, Ed. Werriuth, Academic Press, San Diego, Calif., 2001\n.\n\n\n \n \n \n \nExemplary prodrugs are, e.g., esters of free carboxylic acids and \nS\n-acyl and \nO\n-acyl derivatives of thiols, alcohols or phenols, wherein acyl has a meaning as defined herein. Preferred are pharmaceutically acceptable ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di-substituted lower alkyl esters, such as the -(amino, mono- or di-lower alkylamino, carboxy, lower alkoxycarbonyl)-lower alkyl esters, the -(lower alkanoyloxy, lower alkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, such as the pivaloyloxymethyl ester and the like conventionally used in the art. In addition, amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases \nin vivo\n releasing the free drug and formaldehyde (\nBundgaard, J. Med. Chem. 2503 (1989\n)). Moreover, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (\nBundgaard, Design of Prodrugs, Elsevier (1985\n)). Hydroxy groups have been masked as esters and ethers. \n \nEP 039,051\n \n (Sloan and Little) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.\n\n\n \n \n \n \nIn view of the close relationship between the compounds, the compounds in the form of their salts and the pro-drugs, any reference to the compounds of the present invention is to be understood as referring also to the corresponding pro-drugs of the compounds of the present invention, as appropriate and expedient.\n\n\n \n \n \n \nFurthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.\n\n\n \n \n \n \nThe compounds of the present invention have valuable pharmacological properties. The compounds of the present invention are useful as inhibitors for cholesteryl ester transfer protein (CETP). CETP is a 74KD glycopeptide, it is secreted by the liver and is a key player in facilitating the transfer of lipids between the various lipoproteins in plasma. The primary function of CETP is to redistribute cholesteryl esters (CE) and triglycerides between lipoproteins. See\n Assmann, G et al., \"\nHDL cholesterol and protective factors in atherosclerosis,\n\" Circulation, 109: 1118-1114 (2004\n). Because most triglycerides in plasma originate in VLDLs and most CEs are formed in HDL particles in the reaction catalyzed by lecithin:cholesterol acyltransferase, activity of CETP results in a net mass transfer of triglycerides from VLDLs to LDLs and HDLs and a net mass transfer of CEs from HDLs to VLDLs and LDLs. Thus, CETP potentially decreases HDL-C levels, increases LDL-cholesteryl (LDL-C) levels and reduces HDL and LDL particles size, and inhibition of CETP could be a therapeutic strategy for raising HDL-cholesteryl (HDL-C), have a favorable impact on the lipoprotein profile, and reduce the risk of cardiovascular diseases. Accordingly, the compounds of the present invention as CETP inhibitors are useful for the delay of progression and/or treatment of a disorder or disease that is mediated by CETP or responsive to inhibition of CETP. Disorders, conditions and diseases that can be treated with the compounds of the present invention include but are not limited to, hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity, infection or egg embryonation of schistosoma, or endotoxemia etc..\n\n\n \n \n \n \nAdditionally, the present invention provides:\n\n \n \n \na compound of the present invention as described herein above for use as a medicament;\n \nthe use of a compound of the present invention as described herein above for the preparation of a pharmaceutical composition for the delay of progression and/or treatment of a disorder or disease mediated by CETP, or responsive to inhibition of CETP.\n \nthe use of a compound of the present invention as described herein above for the preparation of a pharmaceutical composition for the delay of progression and/or treatment of a disorder or disease selected from hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity or endotoxemia etc.\n \n\n\n \n \n \nThe compounds of formula (I) can be prepared by the procedures described in the following sections.\n\n\n \n \n \n \nGenerally, the compounds of formula (I) can be prepared according to the following general procedures and schemes. In all these Schemes the variants R1, R2, R3, R4, R5, R6, R7 and R8 have the meaning as set forth herein unless defined otherwise.\n\n\n \n1. General procedure A: using alkoxypyrrolidine A1\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n1.1. \nRoute AI when R4 is hydrogen:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, methoxymethyl, \nt\n-butyldimethylsilyl, tetrahydrofuranyl, Bn, allyl. R9 is as defined herein e.g. Me, Et, i-Pr, t-Bu, Bn, 2,2,2-trichloroethyl, allyl, 9-fluorenylmethyl.\n\n\n \n \n \n \nIn step a) standard methods to reduce the carboxylic acid are employed, such as the use of a hydride agent, e.g. BH\n3\n or its complexes such as picoline borane and borane-pyridine, LiAlH\n4\n, 9-BBN, Alpine borane\n\n, LiB(s-Bu)\n3\nH, LiB(Sia)\n3\nH, or via activation of the carboxylic acid as acid chloride, mixed anhydride or ester followed by reduction by a hydride reagent such as NaBH4.\n\n\n \n \n \n \nIn step b) standard methods for the conversion of the alcohol to a leaving group (LG; e.g. a mesylate, tosylate, or bromide) are employed. The methods include the use of MsCl/base or TsCl/base or SOCl\n2\n or NBS/PPh\n3\n or CBr\n4\n/PPh\n3\n or Tf\n2\nO using conditions well known in the art.\n\n\n \n \n \n \nIn step c) standard conditions for nucleophilic substitution are employed, such as R5Mx (Mx; e.g. Li, MgCl, MgBr, or Mgl) in the presence of Cul (R5 = alkyl), or a hydride reagent (R5 = H).\n\n\n \n1.2. \nRoute All when R4 is hydrogen:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, methoxymethyl, \nt-\nbutyldimethylsilyl, tetrahydrofuranyl, Bn, allyl. R9 is as defined herein e.g. Me, Et, i-Pr, t-Bu, Bn, 2,2,2-trichloroethyl, allyl, 9-fluorenylmethyl. R10 is as defined herein e.g. H, Me, Et, \nt-\nBu, \ni-\nBu, Ph, methoxymethyl, Bn, 2,2,2-trichloroethyl, allyl, triethylsilyl, t-butyldimethylsilyl.\n\n\n \n \n \n \nIn step a) standard methods to reduce the carboxyl group are employed, such as the use of a hydride agent, e.g. BH\n3\n or its complexes such as picoline borane and borane-pyridine complex, LiAlH\n4\n, 9-BBN, Alpine borane\n\n, LiB(s-Bu)\n3\nH, LiB(Sia)\n3\nH, or via activation of the carboxylic acid as acid chloride, mixed anhydride or ester followed by reduction by a hydride reagent such as NaBH4.\n\n\n \n \n \n \nIn step b) standard methods to oxidize the alcohol are employed, such as the use of a chromium complex (e.g. PDC, PCC or Na2Cr2O7), Pr4NRuO4, Raney nickel, NCS/TEMPO, a hypervalent iodine reagent (e.g. Dess-Martin periodinane, Phl(OAc)2/TEMPO), NCS/DMS/base or a DMSO based reagent (e.g. DMSO/DCC/H3PO4, DMSO/oxalyl chloride/base or DMSO/SO3/pyridine).\n\n\n \n \n \n \nAlternatively, step a) and b) can be replaced by conversion to acid chloride followed by such as reduction with LiAl(OtBu)3 or hydrogenolysis with H2 and Pd-BaS04, by conversion to thiolester followed by Et3SiH/Pd-C reduction, by conversion to amide followed by reduction with a hydride reagent e.g. LiAlH4, DIBAL, LiAl(O-t-Bu)3, disiamylborane or Ph2SiH2-Ti(OiPr)4, by treatment of the carboxylic acid with Li in MeNH2 or NH3 followed by hydrolysis, or by reduction of the carboxylic ester with a hydride reagent e.g. DIBAL or LiAlH4-Et2NH.\n\n\n \n \n \n \nIn step c) standard methods for the conversion of aldehyde are employed, such as the use of Tebbe reagent or Wittig reagent or Horner-Wadsworth-Emmons reagents, and followed by hydrogenation of the double bond with a suitable reducing agent (e.g. Pd/C, Pd(OH)2, PtO2, or Raney nickel using conditions well known in the art).\n\n\n \n1.3. \nRoute AIII when R4 is hydrogen:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, MOM, TBS, tetrahydrofuranyl, Bn, allyl. R9 is as defined herein e.g. Me, Et, i-Pr, t-Bu, Bn, 2,2,2-trichloroethyl, allyl. Y = O or S.\n\n\n \n \n \n \nIn step a) \nN\n-methoxy-\nN\n-methyl amide (called Weinreb amide) are prepared by employing \nN\n,\nO\n-dimethylhydroxylamine with the use of activating reagent (e.g. DCC, thionyl chloride or oxalyl chloride) of carboxylic acid.\n\n\n \n \n \n \nIn step b) standard methods to alkylation are employed, such as R5Mx (Mx; e.g. Li, MgCl, MgBr, Mgl).\n\n\n \n \n \n \nIn step c) standard methods for the deoxygenaiton of ketone are employed, such as:\n\n \n \n \ni) the use of Raney nickel following preparation of thiocarbonyl group or thioacetal\n \nii) Wolff-Kishner reaction condition\n \niii) Clemmensen reduction condition\n \n\n\n1.4. \nRoute AIV when R4 is hydrogen:\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nIn step a) standard methods for 1,3-dipolar cycloaddition of nitrile oxide are employed, such as using i) HONH\n2\n [oxime formation] ii) either simultaneous treatment with or stepwise treatment via nitrile formation with Chloramine T, alpha, beta-unsaturated ester (see above) whereby R10 is for example Me, Et.\n\n\n \n \n \n \nIn step b) standard methods for hydrogenation of isoxazoline with a suitable reducing agent (e.g. Pd/C, Pd(OH)2, PtO2, Raney nickel or Mg using conditions well known in the art), followed by the cyclization to give gamma-lactam.\n\n\n \n \n \n \nIn step c) standard methods to reduce the amide group are employed to give the corresponding amine, such as the use of a hydride agent, e.g. BH\n3\n or its complexes such as picoline borane and borane-pyridine complex, LiAlH\n4\n, 9-BBN, Alpine borane\n\n, LiB(s-Bu)\n3\nH, LiB(Sia)\n3\nH, NaBH(OAc)3, NaBH3CN, NaBH4 or LiBH4.\n\n\n \n \n \n \nIn step d) standard methods for the introduction of R3 which are defined in the claims are employed to protect amine part from undesired reaction.\n\n\n \n1.5. \nRoute AV:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, MOM, TBS, tetrahydrofuranyl, Bn, allyl. R11 is as defined herein e.g. H, MOM, Bn, TMS, TBS, allyl. Mx is e.g. MgBr, Mgl, MgCl, Li, also combination with Cu species.\n\n\n \n \n \n \nConversion of R3, R8 and R11 can be effected by standard functional group manipulation as well known in the art or as specifically described herein (except for H as R3, R8 or R11).\n\n\n \n \n \n \nIn step b) standard methods for the conversion of the alcohol to a leaving group (LG; e.g. mesylate, tosylate, or bromide) are employed. The methods include the use of MsCl/base or TsCl/base or SOCl\n2\n or NBS/PPh\n3\n or CBr\n4\n/PPh\n3\n or Tf\n2\nO using conditions well known in the art.\n\n\n \n \n \n \nIn step c) standard methods for the nucleophilic substitution reaction with CN anion species (e.g. NaCN, KCN) were employed.\n\n\n \n \n \n \nIn step g) cyclization reaction with R12X (R12 is substituted or unsubstituted aryl, or substituted or unsubstituted alkyl, X = halogen or OMs, OTs, OTf) was conducted in the presence of cat. Pd species, an additional ligand and a base. An illustrative example of this chemistry is outlined in \nOrganic Letters, 2007, Vol. 9, pp. 457-460\n.\n\n\n \n1.6. \nRoute AVI:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, MOM, TBS, tetrahydrofuranyl, Bn, allyl.\n\n\n \n \n \n \nConversion of R3 and R8 can be effected by standard functional group manipulation as well known in the art or as specifically described herein (except for H as R4, R8).\n\n\n \n \n \n \nIn step a) standard methods for aldol reaction with acrolein are employed in the presence of a strong base such as NaH, KO\nt\nBu, LHMDS or LDA.\n\n\n \n \n \n \nIn step b) standard methods for the introduction of the primary amine are employed, such as using:\n\n \n \n \nan NH\n3\n equivalent [e.g. NH\n3\n/EtOH, NH\n4\nCl, NH\n4\nOH], a hydride reagent [e.g. NaBH(OAc)\n3\n, NaBH\n3\n CN or a combination of Ti(OiPr)\n4\n with hydride agents such as NaBH\n4\n]\n \ni) either simultaneous treatment with or stepwise treatment via imine formation with BnNH\n2\n, a hydride reagent (see above), ii) cat. Hydrogenation\n \na treatment with BnNH\n2\n under cat. Hydrogenation condition\n \ni) either simultaneous treatment with or stepwise treatment via imine formation with PMBNH\n2\n, hydride reagent (see above), ii) CAN or DDQ (oxidative debenzylation) or TFA\n \ni) either simultaneous treatment with or stepwise treatment via imine formation with Ph\n2\nCHNH\n2\n (benzhydrylamine), hydride reagent (see above), ii) deprotection with TFA/Et\n3\nSiH or cat. Hydrogenation\n \ni) RONH\n2\n [oxime formation] ii) Na or BH\n3\n or cat. hydrogenation (e.g. Ra-Ni, Pd-C, Pt-C) [reduction of oxime] whereby R is for example benzyl, \np-\nmethoxybenzyl, or allyl.\n \ni) a hydride reagent [reduction to alcohol] ii) Mitsunobu condition using PPh\n3\n, DEAD, N\n3\n anion or mesylation with MsCl and base then N\n3\n anion or bromination with conditions such as NBS/PPh\n3\n, PBr\n3\n/PPh\n3\n,CBr\n4\n/PPh\n3\n then N\n3\n anion or PBr\n3\n/PPh\n3\n then N\n3\n anion iii) PR\n3\n or cat. Hydrogenation [reduction of azide] whereby R is for example ethyl or phenylln step c) standard methods for the nucleophilic substitution reaction with CN anion species (e.g. NaCN, KCN) are employed.\n \n\n\n \n \n \nIn step e) cyclization reaction with R12X (R12 is substituted or unsubstituted aryl, or substituted or unsubstituted alkyl, X = halogen or OMs, OTs, OTf) is performed in the presence of cat. Pd species, an additional ligand and a base. An illustrative example of this chemistry is outlined in \nOrganic Letters, 2007, Vol. 9, pp. 457-460\n.\n\n\n \n1.7. \nRoute AVII:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, MOM, TBS, tetrahydrofuranyl, Bn, allyl. Mx is e.g. MgBr, Mgl, MgCl, Li, also combination with ZnCl\n2\n or Cu species.\n\n\n \n \n \n \nConversion of R3 and R8 can be effected by standard functional group manipulation as well known in the art or as specifically described herein (except for H as R3, R8).\n\n\n \n \n \n \nIn step a) standard methods for the introduction of the aminoalcohol are employed, such as using:\n\n \n \n \ni) RNH2 [imine formation: e.g. R = Boc, alkylsulfinyl, alkoxy] ii) AllylMx (see above) iii) acidic hydrolysis (e.g. HCl aq) iv) protection with R3 source v) ozone oxidation follwed by reduction (e.g. PPh3 or DMS) vi) VinylMx (Mx is e.g. MgBr, Mgl, MgCl, Li, also combination with Zn or Cu species).\n \ni) RNH2 [imine formation: e.g. R = Boc, alkylsulfinyl, alkoxy] ii) 3-ButenylMx (see above) iii) allylic oxidation (e.g. SeO2)\n \n\n\n \n \n \nIn step c) cyclization reaction with R12X (R12 is substituted or unsubstituted aryl, or substituted or unsubstituted alkyl, X = halogen or OMs, OTs, OTf) is performed in the presence of cat. Pd species, an additional ligand and a base. An illustrative example of this chemistry is outlined in \nOrganic Letters, 2007, Vol. 9, pp. 457-460\n \n\n\n \n1.8. \nRoute AVIII:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, MOM, TBS, tetrahydrofuranyl, Bn, allyl. R13 is an electron withdrawing group (e.g. CHO, COOMe, COOEt, COOBn, CN).\n\n\n \n \n \n \nConversion of R3 and R8 can be effected by standard functional group manipulation as well known in the art or as specifically described herein (except for H as R3, R8).\n\n\n \n \n \n \nIn step a) standard methods for the introduction of the aminoalcohol are employed, such as using:\n\n \n \n \ni) RR'NH [imine formation: e.g. R = H, Bn, Boc, alkylsulfinyl, alkoxy, siloxy; R' = H, Bn, Boc, alkylsulfinyl, alkoxy, siloxy] in the presence of a Lewis aicd ii) Reduction of R13 (except for R13 =CHO) to give the corresponding aldehyde iii) VinylMx (Mx is e.g. MgBr, Mgl, MgCl, Li, also combination with Zn or Cu species).\n \n\n\n \n \n \nIn step c) cyclization reaction with R12X (R12 is substituted or unsubstituted aryl, or substituted or unsubstituted alkyl, X = halogen or OMs, OTs, OTf) is performed in the presence of cat. Pd species, an additional ligand and a base. An illustrative example of this chemistry is outlined in \nOrganic Letters, 2007, Vol. 9, pp. 457-460\n.\n\n\n \n1.9. \nRoute AIX:\n \n\n\n \n \n \n \n \n \n\nwherein R8 is as defined herein e.g. H, Me, MOM, TBS, tetrahydrofuranyl, Bn, allyl. R14 is an electron withdrawing group (e.g. COOMe, COOEt, COOBn, CN)\n\n\n \n \n \n \nConversion of R3, R8 can be effected by standard functional group manipulation as well known in the art or as specifically described herein (except for H as R3, R8).\n\n\n \n \n \n \nIn step a) standard methods for aza-Michael reaction are employed, such as using:\n\n \n \n \n \nMacMillan's method (see: Journal of the American Chemical Society, 2006, Vol. 128, No. 29, pp. 9328-9329\n) when R14 is CHO.\n \n \nBadia's method (see: The Journal of Organic Chemistry, 2004, Vol. 69, No. 7, 2588-2590\n, and references cited therein) when R14 is e.g. dialkyl or diaryl amide or alkyl ester, followed by reduction for the preparation of the corresponding aldehyde.\n \n\n\n \n \n \nIn step c) standard method for the addition of VinylMx (Mx is e.g. MgBr, Mgl, MgCl, Li, also combination with Zn or Cu species) are employed.\n\n\n \n \n \n \nIn step d) cyclization reaction with R12X (R12 is substituted or unsubstituted aryl, or substituted or unsubstituted alkyl, X = halogen or OMs, OTs, OTf) is performed in the presence of cat. Pd species, an additional ligand and a base. An illustrative example of this chemistry is outlined in \nOrganic Letters, 2007, Vol. 9, pp. 457-460\n.\n\n\n \n1.10. \nRoute AX:\n \n\n\n \n \n \nCompounds of formula (A1) can be prepared following the synthetic route outlined in \n \nWO2006002004 A1\n \n either directly or analogously.\n\n\n \n1.11. \nRoute AXI:\n \n\n\n \n \n \nCompounds of formula (A1) can be prepared following the synthetic route outlined in \nSynlett, 2001, No. 10, 1602-1604\n either directly or analogously.\n\n\n \n1.12. \nRoute AXII:\n \n\n\n \n \n \nCompounds of formula (A1) can be prepared following the synthetic route outlined in \nThe Journal of Organic Chemistry, 1194, Vol. 59, No. 8, 1958-1960\n either directly or analogously.\n\n\n \n1.13. \nRoute AXIII\n:\n\n\n \n \n \nCompounds of formula (A1) can be prepared following the synthetic route outlined in \nJournal of Medicinal Chemistry, 2006, Vol. 49, No. 15, pp. 4745-4761\n either directly or analogously.\n\n\n \n \n \n \nUsing any of the routes AI to AXIII above, the alkoxypyrrolidine A1 can be converted into the compound of formula (I) using one of the routes AXIV, AXV or AXVI shown below.\n\n\n \n1.14. \nRoute AXIV:\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nIn step a) Removal of R8 can be effected by standard functional group manipulation as well known in the art or as specifically described herein.\n\n\n \n \n \n \nIn step b) standard methods to oxidize the alcohol are employed, such as the use of a chromium complex (e.g. PDC, PCC or Na\n2\nCr\n2\nO\n7\n), Pr\n4\nNRuO\n4\n Raney nickel, NCS/TEMPO, a hypervalent iodine reagent (e.g. Dess-Martin periodinane, Phl(OAc)\n2\n/TEMPO), NCS/DMS/base or a DMSO based reagent (e.g. DMSO/DCC/H\n3\nPO\n4\n, DMSO/oxalyl chloride/base or DMSO/SO\n3\n/pyridine).\n\n\n \n \n \n \nIn step c) standard methods for reductive amination are employed, such as ArCH\n2\nNH\n2\n, hydride reagent [ex. NaBH(OAc)\n3\n, NaBH\n3\n CN, NaBH\n3\n CN, NaBH\n4\n, LiBH\n4\n, BH\n3\n, picoline borane, borane-pyridine complex]; or Ti(OiPr)\n4\n; then hydride reagent such as NaBH(OAc)\n3\n, NaBH\n3\n CN, NaBH\n4\n, LiBH\n4\n, borane, picoline borane, borane-pyridine complex, LiAlH\n4\n, 9-BBN, Alpine borane\n\n, LiB(s-Bu)\n3\nH, LiB(Sia)\n3\nH; or imine formation catalyzed or uncatalyzed by acid followed by reduction by hydride agents (see above).\n\n\n \n \n \n \nIn step d) group R1 is introduced by usual functional group manipulation in the amine, such as alkylation, carbamate formation, urea formation, S\nRN\n1 substitution, aryl amination and reductive amination.\n\n\n \n \n \n \nThe group R3 may be modified at an appropriate stage to have the desired definition as set forth in the claims by standard nitrogen protecting group chemistry as known in the art or as described herein.\n\n\n \n1.15. \nRoute AXV:\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nIn step a) Removal of R8 can be effected by standard functional group manipulation as well known in the art or as specifically described herein.\n\n\n \n \n \n \nIn step b) standard methods to oxidize the alcohol are employed, such as the use of a chromium complex (e.g. PDC, PCC or Na\n2\nCr\n2\nO\n7\n), Pr\n4\nNRuO\n4\n, Raney nickel, NCS/TEMPO, a hypervalent iodine reagent (e.g. Dess-Martin periodinane, Phl(OAc)\n2\n/TEMPO), NCS/DMS/base or a DMSO based reagent (e.g. DMSO/DCC/H\n3\nPO\n4\n, DMSO/oxalyl chloride/base or DMSO/SO\n3\n/pyridine).\n\n\n \n \n \n \nIn step c) standard methods for the introduction of the primary amine are employed, such as using:\n\n \n \n \nan NH\n3\n equivalent [e.g. NH\n3\n/EtOH, NH\n4\nCl, NH\n4\nOH], a hydride reagent [e.g. NaBH(OAc)\n3\n, NaBH\n3\n CN or a combination of Ti(OiPr)\n4\n with hydride agents such as NaBH\n4\n]\n \ni) either simultaneous treatment with or stepwise treatment via imine formation with BnNH\n2\n, a hydride reagent (see above), ii) cat. Hydrogenation\n \na treatment with BnNH\n2\n under cat. Hydrogenation condition\n \ni) either simultaneous treatment with or stepwise treatment via imine formation with PMBNH\n2\n, hydride reagent (see above), ii) CAN or DDQ (oxidative debenzylation) or TFA\n \ni) either simultaneous treatment with or stepwise treatment via imine formation with Ph\n2\nCHNH\n2\n (benzhydrylamine), hydride reagent (see above), ii) deprotection with TFA/Et\n3\nSiH or cat. Hydrogenation\n \ni) RONH\n2\n [oxime formation] ii) Na or BH\n3\n or cat. hydrogenation (e.g. Ra-Ni, Pd-C, Pt-C) [reduction of oxime] whereby R is for example benzyl, \np-\nmethoxybenzyl, or allyl.\n \ni) a hydride reagent [reduction to alcohol] ii) Mitsunobu condition using PPh\n3\n, DEAD, N\n3\n anion or mesylation with MsCl and base then N\n3\n anion or bromination with conditions such as NBS/PPh\n3\n, PBr\n3\n/PPh\n3\n, CBr\n4\n/PPh\n3\n then N\n3\n anion or PBr\n3\n/PPh\n3\n then N\n3\n anion iii) PR\n3\n or cat. Hydrogenation [reduction of azide] whereby R is for example ethyl or phenyl\n \n\n\n \n \n \nIn steps d) and e), group R1 or the substituted benzyl ring, respectively, are introduced by usual functional group manipulation in the amine, such as alkylation, carbamate formation, urea formation, S\nRN\n1 substitution, aryl amination and reductive amination for step d) and preferably alkylation and reductive amination for step e).\n\n\n \n \n \n \nThe group R3 may be modified at an appropriate stage to have the desired definition as set forth in the claims by standard nitrogen protecting group chemistry as known in the art or as described herein.\n\n\n \n1.16. \nRoute AXVI:\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nIn step a) Removal of R8 can be effected by standard functional group manipulation as well known in the art or as specifically described herein.\n\n\n \n \n \n \nIn step b) standard methods for the introduction of the primary amine are employed, such as using: i) Mitsunobu condition using PPh\n3\n, DEAD, N\n3\n anion or mesylation with MsCl and base then N\n3\n anion or bromination with conditions such as NBS/PPh\n3\n, PBr\n3\n/PPh\n3\n, CBr\n4\n/PPh\n3\n then N\n3\n anion or PBr\n3\n/PPh\n3\n then N\n3\n anion ii) PR\n3\n or cat. Hydrogenation [reduction of azide]\n\n\n \n \n \n \nIn steps c) and d), group R1 or the substituted benzyl ring, respectively, are introduced by usual functional group manipulation in the amine, such as alkylation, carbamate formation, urea formation, S\nRN\n1 substitution, aryl amination and reductive amination for step c) and preferably alkylation and reductive amination for step d).\n\n\n \n2. General procedure B: using nitropyrrolidine B1\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nCompounds of formula (B1) can be prepared following the synthetic route outlined in\n Synlett, 2007, No. 15, pp.2355-2358\n either directly or analogously.\n\n\n \n \n \n \nUsing the above route, the nitropyrrolidine B1 can be converted into the compound of formula (I) such as using the route BI shown below.\n\n\n \n2.1. \nRoute BI:\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nIn step a) standard methods for the Nef reaction are employed, such as using a oxidizing agent (e.g. KMNO4, Oxone) and H2O or a base followed by a protic acid (e.g. HCl, H2SO4, AcOH) and H2O.\n\n\n \n \n \n \nIn step b) standard methods for the introduction of the primary amine are employed as described above in the procedure A.\n\n\n \n \n \n \nIn step c) standard methods for the reduction of nitro group to give the corresponding primary amine are employed, such as using Zn/HCl, Sml2, NiCl2/NaBH4, Et3SiH/RhCl(PPh3)3, or Pd/C.\n\n\n \n \n \n \nIn step d) this pyrrolidine can also be further reacted to form a compound of formula (I) by alkylation methods and nitrogen protecting group manipulations as described above in the procedure A.\n\n\n \n3. General procedure C: using Ynoate chemistry\n\n\n \n \n \nCompounds of formula (I) can be prepared following the synthetic route outlined in\n Synlett, 2004, No. 1, pp. 119-121\n, \nThe Journal of Organic Chemistry, 2005, Vol. 70, No. 5, pp. 1791-1795\n or \nThe Journal of Organic Chemistry, 1992, Vol. 57, No. 5, pp. 1323-1324\n either directly or analogously.\n\n\n \n4. General procedure D: using \nN\n-acyliminium ion chemistry\n\n\n \n \n \nCompounds of formula (I) can be prepared following the synthetic route outlined in \nChemistry Letters, 1991, Vol. 20, No. 1, pp. 81-84\n either directly or analogously.\n\n\n \n5. General procedure E: preparation from substituted pyrrole\n\n\n \n \n \nCompounds of formula (I) can be prepared from substituted pyrrole analogously and converting the obtained pyrrolidine by methods outlined in e.g. routes AXIV, AXV, AXVI or BI above. An illustrative example of substituted pyrrolidine from pyrrole is outlined in \nJournal of Organic Chemistry, 2002, Vol. 67, No. 10, pp. 3479-3486\n.\n\n\n \n6. General procedure F: Using 1,3-dipolar cycloaddition chemistry\n\n\n \n \n \nCompounds of formula (I) can be prepared from an azomethine ylides and a enamine analogously. An illustrative example of this chemistry is outlined in \nTetrahedron, 1999, Vol. 55, No. 31, pp. 9535-9558\n.\n\n\n \n7. General procedure G: Using ,-diamino acid chemistry\n\n\n \n \n \nCompounds of formula (I) can be prepared from nitroolefin and -amino ester (or -amino amide) followed by hydrogenolysis analogously and converting the obtained pyrrolidine by methods outlined in e.g. routes AXIV, AXV, AXVI or BI above. An illustrative example of this chemistry is outlined in \nChemical Communications, 2001, No. 2, pp. 207-208\n.\n\n\n \n \n \n \nRacemates and diastereomer mixtures obtained can be separated into the pure isomers or racemates in a known manner on the basis of the physicochemical differences of the components, for example by fractional crystallization or by chiral chromotagraphy or HPLC separation utilizing chiral stationery phases. Racemates obtained may furthermore be resolved into the optical antipodes by known methods, for example by recrystallization from an optically active solvent, chromatography on chiral adsorbents, with the aid of suitable microorganisms, by cleavage with specific immobilized enzymes, via the formation of inclusion compounds, for example using chiral crown ethers, only one enantiomer being complexed, or by conversion into diastereomeric salts, for example by reaction of a basic final substance racemate with an optically active acid, such as a carboxylic acid, for example tartaric or malic acid, or sulfonic acid, for example camphorsulfonic acid, and separation of the diastereomer mixture obtained in this manner, for example on the basis of its differing solubilities, into the diastereomers from which the desired enantiomer can be liberated by the action of suitable agents. The more active enantiomer is advantageously isolated.\n\n\n \n \n \n \nThe present invention includes all pharmaceutically acceptable isotopically-labeled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.\n\n\n \n \n \n \nExamples of isotopes suitable for inclusion in the compounds of the invention comprises isotopes of hydrogen, such as \n2\nH and \n3\nH, carbon, such as \n11\nC, \n13\nC and \n14\nC, chlorine, such as \n38\nCl, fluorine, such as \n18\nF, iodine, such as \n123\nI and \n125\nI, nitrogen, such as \n13\nN and \n15\nN, oxygen, such as \n15\nO, \n17\nO and \n18\nO, phosphorus, such as \n32\nP, and sulphur, such as \n35\nS.\n\n\n \n \n \n \nSubstitution with heavier isotopes such as deuterium, \ni.e\n. \n2\nH, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased \nin vivo\n half-life or reduced dosage requirements, and hence may be preferred in some circumstances.\n\n\n \n \n \n \nIsotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations Sections using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.\n\n\n \n \n \n \nIn starting compounds and intermediates which are converted to the compounds of the invention in a manner described herein, functional groups present, such as amino, thiol, carboxyl and hydroxy groups, are optionally protected by conventional protecting groups that are common in preparative organic chemistry. Protected amino, thiol, carboxyl and hydroxy groups are those that can be converted under mild conditions into free amino thiol, carboxyl and hydroxy groups without the molecular framework being destroyed or other undesired side reactions taking place.\n\n\n \n \n \n \nThe purpose of introducing protecting groups is to protect the functional groups from undesired reactions with reaction components under the conditions used for carrying out a desired chemical transformation. The need and choice of protecting groups for a particular reaction is known to those skilled in the art and depends on the nature of the functional group to be protected (hydroxy group, amino group, etc.), the structure and stability of the molecule of which the substituent is a part and the reaction conditions.\n\n\n \n \n \n \nWell-known protecting groups that meet these conditions and their introduction and removal are described, e.g., in \nMcOmie, \"\nProtective Groups in Organic Chemistry\n\", Plenum Press, London, NY (1973\n); and \nGreene and Wuts, \"\nProtective Groups in Organic Synthesis\n\", John Wiley and Sons, Inc., NY (1999\n).\n\n\n \n \n \n \nThe above-mentioned reactions are carried out according to standard methods, in the presence or absence of diluent, preferably, such as are inert to the reagents and are solvents thereof, of catalysts, condensing or said other agents, respectively and/or inert atmospheres, at low temperatures, room temperature or elevated temperatures, preferably at or near the boiling point of the solvents used, and at atmospheric or super-atmospheric pressure. The preferred solvents, catalysts and reaction conditions are set forth in the appended illustrative Examples.\n\n\n \n \n \n \nThe invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed \nin situ\n under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure antipodes.\n\n\n \n \n \n \nCompounds of the invention and intermediates can also be converted into each other according to methods generally known \nper se\n.\n\n\n \n \n \n \nIn another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc. In addition, the pharmaceutical compositions of the present invention can be made up in a solid form including capsules, tablets, pills, granules, powders or suppositories, or in a liquid form including solutions, suspensions or emulsions. The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifers and buffers etc.\n\n\n \n \n \n \nPreferably, the pharmaceutical compositions are tablets and gelatin capsules comprising the active ingredient together with\n\n \n \n \na) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;\n \nb) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also\n \nc) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired\n \nd) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or\n \ne) absorbents, colorants, flavors and sweeteners.\n \n\n\n \n \n \nTablets may be either film coated or enteric coated according to methods known in the art.\n\n\n \n \n \n \nSuitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.\n\n\n \n \n \n \nInjectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, preferably about 1-50%, of the active ingredient.\n\n\n \n \n \n \nSuitable compositions for transdermal application include an effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.\n\n\n \n \n \n \nSuitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.\n\n\n \n \n \n \nThe present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water can facilitate the degradation of some compounds. For example, the addition of water (e.g., 5%) is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g.,\n Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, N.Y., 1995, pp. 379-80\n. In effect, water and heat accelerate the decomposition of some compounds. Thus, the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.\n\n\n \n \n \n \nAnhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.\n\n\n \n \n \n \nAn anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.\n\n\n \n \n \n \nThe invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as \"stabilizers,\" include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.\n\n\n \n \n \n \nThe invention likewise relates to a combination of a compound of formula (I), (I A) or (I B), respectively, or a pharmaceutically acceptable salt thereof with a further active principle.\n\n\n \n \n \n \nThe combination may be made for example with the following active principles, selected from the group consisting of a:\n\n \n \n \n(i) HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof,\n \n(ii) angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof,\n \n(iii) angiotensin converting enzyme (ACE) Inhibitor or a pharmaceutically acceptable salt thereof,\n \n(iv) calcium channel blocker or a pharmaceutically acceptable salt thereof,\n \n(v) aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof,\n \n(vi) aldosterone antagonist or a pharmaceutically acceptable salt thereof,\n \n(vii) dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt thereof,\n \n(viii) endothelin antagonist or a pharmaceutically acceptable salt thereof,\n \n(ix) renin inhibitor or a pharmaceutically acceptable salt thereof,\n \n(x) diuretic or a pharmaceutically acceptable salt thereof, and\n \n(xi) an ApoA-I mimic.\n \n\n\n \n \n \nAn angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof is understood to be an active ingredients which bind to the AT\n1\n-receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the inhibition of the AT\n1\n receptor, these antagonists can, for example, be employed as antihypertensives or for treating congestive heart failure.\n\n\n \n \n \n \nThe class of AT\n1\n receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. For example, mention may be made of the compounds which are selected from the group consisting of valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, the compound with the designation E-1477 of the following formula\n\n \n \n\nthe compound with the designation SC-52458 of the following formula\n\n \n \n\nand the compound with the designation ZD-8731 of the following formula\n\n \n \n\nor, in each case, a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nPreferred AT\n1\n-receptor antagonist are those agents which have been marketed, most preferred is valsartan or a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nHMG-Co-A reductase inhibitors (also called -hydroxy--methylglutaryl-co-enzyme-A reductase inhibitors) are understood to be those active agents that may be used to lower the lipid levels including cholesterol in blood.\n\n\n \n \n \n \nThe class of HMG-Co-A reductase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds that are selected from the group consisting of atorvastatin, cerivastatin, compactin, dalvastatin, dihydrocompactin, fluindostatin, fluvastatin, lovastatin, pitavastatin, mevastatin, pravastatin, rivastatin, simvastatin, and velostatin, or, in each case, a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nPreferred HMG-Co-A reductase inhibitors are those agents which have been marketed, most preferred is fluvastatin and pitavastatin or, in each case, a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nThe interruption of the enzymatic degradation of angiotensin I to angiotensin II with so-called ACE-inhibitors (also called angiotensin converting enzyme inhibitors) is a successful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment of congestive heart failure.\n\n\n \n \n \n \nThe class of ACE inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group consisting alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril, or, in each case, a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nPreferred ACE inhibitors are those agents that have been marketed, most preferred are benazepril and enalapril.\n\n\n \n \n \n \nThe class of CCBs essentially comprises dihydropyridines (DHPs) and non-DHPs such as diltiazem-type and verapamil-type CCBs.\n\n\n \n \n \n \nA CCB useful in said combination is preferably a DHP representative selected from the group consisting of amlodipine, felodipine, ryosidine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine, and nivaldipine, and is preferably a non-DHP representative selected from the group consisting of flunarizine, prenylamine, diltiazem, fendiline, gallopamil, mibefradil, anipamil, tiapamil and verapamil, and in each case, a pharmaceutically acceptable salt thereof. All these CCBs are therapeutically used, e.g. as anti-hypertensive, anti-angina pectoris or anti-arrhythmic drugs.\n\n\n \n \n \n \nPreferred CCBs comprise amlodipine, diltiazem, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, and verapamil, or, e.g. dependent on the specific CCB, a pharmaceutically acceptable salt thereof. Especially preferred as DHP is amlodipine or a pharmaceutically acceptable salt, especially the besylate, thereof. An especially preferred representative of non-DHPs is verapamil or a pharmaceutically acceptable salt, especially the hydrochloride, thereof.\n\n\n \n \n \n \nAldosterone synthase inhibitor is an enzyme that converts corticosterone to aldosterone to by hydroxylating cortocosterone to form 18-OH-corticosterone and 18-OH-corticosterone to aldosterone. The class of aldosterone synthase inhibitors is known to be applied for the treatment of hypertension and primary aldosteronism comprises both steroidal and non-steroidal aldosterone synthase inhibitors, the later being most preferred.\n\n\n \n \n \n \nPreference is given to commercially available aldosterone synthase inhibitors or those aldosterone synthase inhibitors that have been approved by the health authorities.\n\n\n \n \n \n \nThe class of aldosterone synthase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group consisting of the non-steroidal aromatase inhibitors anastrozole, fadrozole (including the (+)-enantiomer thereof), as well as the steroidal aromatase inhibitor exemestane, or, in each case where applicable, a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nThe most preferred non-steroidal aldosterone synthase inhibitor is the (+)-enantiomer of the hydrochloride of fadrozole (\n \nUS patents 4617307\n \n and \n \n4889861\n \n) of formula\n\n \n \n \n\n\n \n \n \n \nA preferred steroidal aldosterone antagonist is eplerenone of the formula\n\n \n \n\nor spironolactone.\n\n\n \n \n \n \nA preferred dual angiotensin converting enzyme/neutral endopetidase (ACE/NEP) inhibitor is, for example, omapatrilate (cf. \n \nEP 629627\n \n), fasidotril or fasidotrilate, or, if appropriable, a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nA preferred endothelin antagonist is, for example, bosentan (cf. \n \nEP 526708 A\n \n), furthermore, tezosentan (cf. \n \nWO 96/19459\n \n), or in each case, a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nA renin inhibitor is, for example, a non-peptidic renin inhibitor such as the compound of formula\n\n \n \n\nchemically defined as 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide. This representative is specifically disclosed in \n \nEP 678503 A\n \n. Especially preferred is the hemi-fumarate salt thereof.\n\n\n \n \n \n \nA diuretic is, for example, a thiazide derivative selected from the group consisting of chlorothiazide, hydrochlorothiazide, methylclothiazide, and chlorothalidon. The most preferred is hydrochlorothiazide.\n\n\n \n \n \n \nAn ApoA-I mimic is, for example, D4F peptide, especially of formula D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F\n\n\n \n \n \n \nPreferably, the jointly therapeutically effective amounts of the active agents according to the combination of the present invention can be administered simultaneously or sequentially in any order, separately or in a fixed combination.\n\n\n \n \n \n \nThe structure of the active agents identified by generic or tradenames may be taken from the actual edition of the standard compendium \"The Merck Index\" or from databases, e.g. IMS LifeCycle (e.g. IMS World Publications). Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.\n\n\n \n \n \n \nFurthermore, the combinations as described above can be administered to a subject via simultaneous, separate or sequential administration (use). Simultaneous administration (use) can take place in the form of one fixed combination with two or more active ingredients, or by simultaneously administering two or more compounds that are formulated independently. Sequential administration(use) preferably means administration of one (or more) compounds or active ingredients of a combination at one time point, other compounds or active ingredients at a different time point, that is, in a chronically staggered manner, preferably such that the combination shows more efficiency than the single compounds administered independently (especially showing synergism). Separate administration (use) preferably means administration of the compounds or active ingredients of the combination independently of each other at different time points, preferably meaning that two compounds are administered such that no overlap of measurable blood levels of both compounds are present in an overlapping manner (at the same time).\n\n\n \n \n \n \nAlso combinations of two or more of sequential, separate and simultaneous administrations are possible, preferably such that the combination compound-drugs show a joint therapeutic effect that exceeds the effect found when the combination compound-drugs are used independently at time intervals so large that no mutual effect on their therapeutic efficiency can be found, a synergistic effect being especially preferred.\n\n\n \n \n \n \nAdditionally, the present invention provides:\n\n \n \n \na pharmaceutical composition or combination of the present invention for use as a medicament;\n \nthe use of a pharmaceutical composition or combination of the present invention for the delay of progression and/or treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.\n \nthe use of a pharmaceutical composition or combination of the present invention for the delay of progression and/or treatment of a disorder or disease selected from hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity or endotoxemia etc.\n \n\n\n \n \n \nThe pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredients for a subject of about 50-70 kg, preferably about 5-500 mg of active ingredients. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.\n\n\n \n \n \n \nThe above-cited dosage properties are demonstrable \nin vitro\n and \nin vivo\n tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied \nin vitro\n in the form of solutions, e.g., preferably aqueous solutions, and \nin vivo\n either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage \nin vitro\n may range between about 10\n-3\n molar and 10\n-9\n molar concentrations. A therapeutically effective amount \nin vivo\n may range depending on the route of administration, between about 0.1-500 mg/kg, preferably between about 1-100 mg/kg.\n\n\n \n \n \n \nThe CETP inhibitory effect of the compounds of the present invention can be determined by using the test models or assays known in the art. For example, \n \nEP1115695B1\n \n describes both the \nin vitro\n and \nin vivo\n CETP activity assays. In particular, the following assays are used.\n\n\n \n(1) \nCETP in vitro assay:\n \n\n\n \n \n \nCETP Activity Kit (#RB-RPAK) was purchased from Roar Biochemical, Inc. (New York, NY, USA). To each well of a 96-well NBS half-area plate (costar #3686), 1.2 ng/well of the donor solution, 1 L of the acceptor solution and 5 L compound solution diluted in 100% DMSO were added in a 38 L of buffer containing 10 mM Tris, 150 mM NaCl and 2 mM EDTA, pH 7.4. Then, the plate was sealed with Themowell\n\n Sealers (costar #6524) and followed by a mixing on a plate shaker by MICROPLATE MIXER MPX-96 (IWAKI) at power 3 for 10 sec at room temperature. After 10-min incubation at 37C, the reaction was started by adding 5 L of rhCETP solution (Cardiovascular Target, New York, NY, USA) and mixed on the plate shaker for 10 sec, then the fluorescence intensity at 0 min was measured by a ARVO SX (Perkin Elmerr, USA) at excitation wavelength of 465 nm and emission wavelength of 535 nm. After 120 min-incubation at 37C, fluorescence intensity was measured again. The inhibition of rhCETP activity by a compound was calculated by the following calculation. Inhibition%= {1- (F120 - F0) / (f120 - f0)}x 100 F: measured fluorescence intensity with compound at 0 or 120 min. f: measured fluorescence intensity of without compound at 0 or 120 min.\n\nThe IC\n50\n values are determined from the dose-effect curve by Origin software. IC\n50\n values, especially from about 0.1 nM to about 50 M, are determined for the compounds of the present invention or a pharmaceutically acceptable salt thereof.\n\n\n \n(2) \nEffects on plasma HDL levels in hamster:\n \n\n\n \n \n \nEffects of compounds on HDL-cholesterol level in hamsters are investigated by the method reported previously with some modifications (\nEur, J. Phamacol, 466 (2003) 147-154\n). In brief, male Syrian hamsters (10-11 week-old age, SLC, Shizuoka, Japan) are fed a high cholesterol diet for two weeks. Then, the animals are dosed singly with the compound suspended with carboxyl methyl cellulose solution. HDL-cholesterol levels are measured by using commercially available kit (Wako Pure Chemical, Japan) after the precipitation of apolipoprotein B (apoB)-containing lipoproteins with 13% polyethylene glycol 6000.\n\n\n \n(3) \nPreparation of human pro-apolipoprotein AI (pro-apoAl)\n \n\n\n \n \n \nThe cDNA of human pro-apoal (NCBI accession number: NMR_000039) is cloned from human liver Quick-Clone\n\n cDNA (Clontech, CA) and inserted to a pET28a vector (Novagen, Germany) for bacterial expression. Expressed protein as a fusion protein with 6xHis-tag at N-terminus in BL-21 Gold (DE3) (Strategene, CA) is purified using HiTrap Chelating (GE Healthcare, CT).\n\n\n \n(4) \nPreparation of donor microemulsion\n \n\n\n \n \n \nPro-apoAI containing microemulsion as a donor particle is prepared following previous reports (\nJ. Biol. Chem., 280:14918-22\n). Glyceryl trioleate (62.5 ng, Sigma, MO), 3-sn-phosphatidylcholine (583 ng, Wako Pure Chemical Industries, Japan), and cholesteryl BODIPY\n\n FL C\n12\n (250 ng, Invitrogen, CA) are dissolved in 1 mL of chloroform. The solution is evaporated, then residual solvent is removed in vacuum for more than 1 hr. The dried lipid mixture is dissolved in 500 L of the assay buffer (50 mM Tris-HCl (pH7.4) containing 150 mM NaCl and 2 mM EDTA) and sonicated at 50C with a microtip (MICROSON\n\n ULTRASONIC CELL DISRUPTOR, Misonix, Farmingdale, NY) at output power 006 for 2 min. After sonication, the solution is cooled to 40C, added to 100 g of human pro-apoAl, and sonicated at output power 004 for 5 min at 40C. The solution, BODIPY-CE microemulsion as a donor molecule is stored at 4C after filtration through a 0.45 m PVDF filter.\n\n\n \n(5) \nIn vitro CETP activity assay in human plasma\n \n\n\n \n \n \nHuman EDTA plasma samples from healthy men are purchased from New Drug Development Research Center, Inc. Donor solution is prepared by a dilution of donor microemulsion with assay buffer. Human plasma (50 L), assay buffer (35 L) and test compound dissolved in dimethylsulfoxide (1 L) are added to each well of 96 well half area black flat bottom plate. The reaction is started by the addition of donor solution (14 L) into each well. Fluorescence intensities are measured every 30 min at 37C with excitation wave length of 485 nm and emission wavelength of 535 nm. The CETP activity (Fl/min) is defined as the changes of fluorescence intensity from 30 to 90 min. The IC\n50\n value is obtained by the logistic equation (Y=Bottom + (Top-Bottom)/(1+(x/IC\n50\n)^Hill slope) using Origin software, version 7.5 SR3. The compounds of formula I exhibit inhibitory activity with an IC50 value in the range from approximately from 0.001 to 100 M, especially from 0.01 to 10 M.\n\n\n \n \n \n \nThe compounds of the present invention or a pharmaceutically acceptable salt thereof have superior CETP inhibitory activity in mammals (e.g., human, monkey, bovine, horse, dog, cat, rabbit, rat, mouse and the like), and can be used as CETP activity inhibitors. In addition, utilizing the superior CETP inhibitory activity of a compound of the present invention or a pharmaceutically acceptable salt thereof, the compounds of the present invention are useful as pharmaceutical agents effective for the prophylaxis or treatment of or delay progression to overt to diseases in which CETP is involved (e.g., hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity or endotoxemia etc.), particularly as prophylactic or therapeutic agents for hyperlipidemia or arteriosclerotic diseases.\n\n \nTable 1: Inhibitory Activity of Compounds\n \n \n \n \nExample No\n \n \n \nIC50 (nM)\n \n \n \n \n \n5-3\n \n92\n \n \n \n6\n \n23\n \n \n \n6-1\n \n69\n \n \n \n6-2\n \n47\n \n \n \n7-4\n \n60\n \n \n \n7-6\n \n46\n \n \n \n9\n \n53\n \n \n \n9-1\n \n41\n \n \n \n9-2\n \n59\n \n \n \n9-3\n \n70\n \n \n \n9-4\n \n21\n \n \n \n9-5\n \n54\n \n \n \n9-6\n \n70\n \n \n \n11\n \n72\n \n \n \n14\n \n34\n \n \n \n16\n \n39\n \n \n \n16-2\n \n25\n \n \n \n17\n \n32\n \n \n \n18\n \n63\n \n \n \n23-6\n \n110\n \n \n \n23-10\n \n30\n \n \n \n32\n \n77\n \n \n \n33-2\n \n130\n \n \n \n \n \n\n\n \n\n\n\n\nAbbreviations\n\n\n\n\n\n\n \n \n \n\n\n \n \n\n\nAc: Acetyl\n\n\naq: aqueous\n\n\nAr: aromatic\n\n\nBBN: borabicyclo[3.3.1]nonane\n\n\ndba:dibenzylideneacetone\n\n\nBn: benzyl\n\n\nBoc: \ntert\n-butoxycarbonyl\n\n\nBu: n-butyl\n\n\nCAN: ceric ammonium nitrate\n\n\nDDQ: 2,3-dichloro-5,6-dicyano-\np-\nbenzoquinone\n\n\nDEAD: diethyl azodicarboxylate\n\n\nDIPEA: \nN,N\n-diisopropylethylamine\n\n\nDMAP: \nN\n,\nN\n-dimethylaminopyridine\n\n\nDME: 1,2-dimethoxyethane\n\n\nDMF: \nN,N\n-dimethylformamide\n\n\nDMSO: dimethyl sulfoxide\n\n\ndppf: 1,1-bis(diphenylphosphino)ferrocene\n\n\nEDTA: ethylenediaminetetraacetic acid\n\n\nESI: electrospray ionization\n\n\nEt: ethyl\n\n\nEtOAc: ethyl acetate\n\n\nh: hours\n\n\nHCl: hygrogen chloride\n\n\nHOAt: 1-hydroxy-7-azabenzotriazole\n\n\nHOBt: 1-hydroxybenzotriazole\n\n\nHPLC: high pressure liquid chromatography\n\n\nIPA: 2-propanol\n\n\niPr: isopropyl\n\n\nIR: infrared\n\n\nKHMDS: potassium hexamethyldisilazanide\n\n\nLC: liquid chromatography\n\n\nLDA: lithium diisopropylamide\n\n\nLHMDS: lithium hexamethyldisilazanide\n\n\nMe: methyl\n\n\nmin: minutes\n\n\nMS: mass spectrometry\n\n\nMs: mesyl, methanesulfonyl\n\n\nNBS: \nN\n-bromosuccinimide\n\n\nNMR: nuclear magnetic resonance\n\n\nPh: phenyl\n\n\nPMB: \np\n-methoxybenzyl\n\n\nRP: reverse phase\n\n\nRT: room temperature\n\n\ns-Bu: sec-butyl\n\n\nSia: siamyl\n\n\nSFC: supercritical fluid chromatography\n\n\nTf: triflate\n\n\nTFA: trifluoroacetic acid\n\n\nTHF: tetrahydrofuran\n\n\nTLC: thin layer chromatography\n\n\nTs: tosyl\n\n\ntBu: \ntert\n-butyl\n\n\ntol: tolyl\n\n\nWSCD: water soluble carbodiimide, 1-ethyl-3-(3-dimethylamino propyl) carbodiimide\n\n\n\n\n\n\n\n\nEXAMPLES\n\n\n\n\n\n\n \n \n \nThe following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees centrigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 mm Hg and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art. The compounds in the following examples have been found to have IC\n50\n values in the range of about 0.1 nM to about 10,000 nM for CETP.\n\n\n \n \n \n \nThe conditions for measuring the retention times are as follows:\n\n\n \nCondition A (HPLC)\n\n\n \n \n \n\n\n \n \n\n\nColumn: ACQUITY UPLCTM BEH C18 1.7 um, 50 x 2.1 mm.\n\n\nFlow rate: 0.5 ml/min\n\n\nMobile phase: A) TFA / water (0.1 / 100, v / v), B) TFA / acetonitrile (0.1 / 100,v / v) Gradient: 5% B in 0.5 min, then linear gradient from 5% B to 100% B in 1.5 min then 100% B in 1 min\n\n\nDetection: UV at 215 nm\n\n\nCondition B (HPLC)\n\n\nColumn: ACQUITY UPLCTM BEH C18 1.7 um, 50 x 2.1 mm.\n\n\nFlow rate: 0.5 ml / min\n\n\nMobile phase: A) TFA / water (0.1 / 100, v / v), B) TFA / acetonitrile (0.1 / 100, v / v) Gradient: 5% B in 0.5 min, then linear gradient from 5% B to 100% B in 5.0 min then 100% B in 1.5 min\n\n\nDetection: UV at 215 nm\n\n\nCondition C (HPLC)\n\n\nColumn: CombiScreen ODS-AM, 50 x 4.6 mm.\n\n\nFlow rate: 2.0 ml / min\n\n\nMobile phase: A) TFA / water (0.1 / 100, v / v), B) TFA / acetonitrile (0.1 / 100, v / v) Gradient: linear gradient from 5% B to 100% B in 5 min then 100% B in 2 min\n\n\nDetection: UV at 215 nm\n\n\n\n\n\n\nExample 1: Synthesis of (2S,3S,5R)-2-Benzyl-3-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-5-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-(3,5-bis-trifluoromethyl-benzylamino)-5-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (0.0377 mmol; 20 mg) and cesium carbonate (0.113 mmol; 36.8 mg) in acetonitrile (0.38 mL) is added methyl chloroformate (0.0754 mmol; 5.9 mg) at room temperature. The reaction mixture is warmed to 80 C and stirred for 3.5 hours. Additional methyl chloroformate (0.0754 mmol; 5.9 mg) is added to the mixture, and the mixture is stirred for additional 0.5 hours, and then cooled to room temperature. To the mixture is added brine and EtOAc. The organic layer is separated, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue is purified by preparative thin layer chromatography on silica gel (eluent: \nn\n-hexane / EtOAc) to give (2S,3S,5R)-2-Benzyl-3-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-5-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (11.5 mg, 52%); ESI-MS \nm\n/\nz\n: 589 [M+1]\n+\n, Retention time 2.63 min (condition A).\n\n\n \n\n\nExample 2: Synthesis of (2S,3S,5R)-2-Benzyl-3-[(5-bromo-pyrimidin-2-yl)-(3-chloro-5-trifluoromethyl-benzyl)-amino]-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a suspension of (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-(5-bromo-pyrimidin-2-ylamino)-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (0.064 mmol; 28.6 mg) and sodium hydride (60% dispersion in mineral oil, 0.19 mmol; 7.6 mg) in DMF (0.6 mL) is added 3-chloro-5-trifluoromethylbenzyl bromide (0.13 mmol; 35.6 mg) at room temperature under N2. After 3.5 hours, additional sodium hydride (60% dispersion in mineral oil, 0.19 mmol; 7.6 mg) is added to the suspension. The reaction mixture is stirred for 20 minutes, and quenched with water and saturated aqueous ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: \nn\n-hexane/EtOAc) to give (2\nS\n,3\nS\n,5\nR\n)-2-Benzyl-3-[(5-bromo-pyrimidin-2-yl)-(3-chloro-5-trifluoromethyl-benzyl)-amino]-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (30.0 mg, 73%); ESI-MS \nm\n/\nz\n: 639 [M+1]\n+\n, Retention time 2.68 min (condition A).\n\n\n \n\n\nExample 3: Synthesis of (2S,3S,5R)-2-Benzyl-3-{(3-chloro-5-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n(2\nS\n,3\nS\n,5\nR\n)-2-Benzyl-3-[(5-bromo-pyrimidin-2-yl)-(3-chloro-5-trifluoromethyl-benzyl)-amino]-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (0.042 mmol; 27 mg), tetrakis(triphenylphosphine) palladium (0.0042 mmol; 4.9 mg), 1-methylpyrazol-4-boronic acid pinacol ester (0.063 mmol; 13 mg) and sodium carbonate (0.084 mmol; 8.9 mg) are dissolved in 1,2-dimethoxyethane (0.8 mL) and water (0.08 mL) at room temperature. The mixture is stirred at 90 C for 17 hours, and then cooled to ambient temperature. To the mixture is added brine and the solution is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn-\nhexane/EtOAc) to give (2S,3S,5R)-2-Benzyl-3-{(3-chloro-5-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (13.6 mg, 51%); ESI-MS \nm\n/\nz\n: 641 [M+1]\n+\n, Retention time 2.62 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 3.\n \n\n\n \nExample 3-1: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methy)-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\nNo\n\n\nProduct\n\n\nESI-MS m/z [M+1]\n+\n \n\n\nRetention time (min)\n\n\nStarting Material\n\n\n\n\n\n\n\n\n3-1\n\n\n\n\n\n\n\n\n\n\n\n\n599\n\n\n2.37 (condition A)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nExample 4: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-carboxy-cyclohexyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n(2\nR,\n4\nS\n)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid trans-4-methoxycarbonyl-1-cyclohexyl ester (0.101 mmol; 69 mg) and lithium hydroxide monohydrate (0.381 mmol; 16 mg) are dissolved in THF (1mL), water (0.5 mL) and MeOH (0.1 mL). The solution is stirred for 3 hours at room temperature. The reaction mixture is quenched with aqueous 1M HCl (0.95 mL) and stirred for 15 minutes. To the mixture is added dichloromethane and the organic layer is separated and then concentrated under reduced pressure. The desired product, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid 4-carboxy-cyclohexyl ester, is obtained in 90% yield (60 mg); ESI-MS \nm\n/\nz\n: 669 [M+1]\n+\n, Retention time 2.13 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 4.\n \n\nExample 4-1: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-carboxy-cyclohexyl ester\n\nExample 4-2: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2-carboxy-2-methyl-propyl ester\n\nExample 4-3: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-3-methyl-butyl ester\n\nExample 4-4: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-cyclobutyl ester\n\nExample 4-5: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazo)-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-carboxy-cyclohexylmethyl ester\n\nExample 4-6: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-cyclobutyl ester\n\nExample 4-7: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-carboxy-cyclopentylmethyl ester\n\nExample 4-8: 4-{[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-ethyl-amino]-methyl}-cyclohexanecarboxylic acid\n\nExample 4-9: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-carboxymethyl-cyclohexylmethyl ester\n\nExample 4-10: (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-pyrrolidine-2-carboxylic acid\n\nExample 4-11: (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperidine-2-carboxylic acid\n\nExample 4-12: 4-[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-amino]-cyclohexanecarboxylic acid\n\nExample 4-13: 4-[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-methyl-amino]-cyclohexanecarboxylic acid\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \n \n \n \n4-1\n \n \n \n \n \n \n669\n \n2.09 (condition A)\n \n \n \n \n \n \n \n \n4-2\n \n \n \n \n \n \n643\n \n2.11 (condition A)\n \n \n \n \n \n \n \n \n4-3\n \n \n \n \n \n \n657\n \n4.26 (condition B)\n \n \n \n \n \n \n \n \n4-4\n \n \n \n \n \n \n641\n \n2.06 (condition A)\n \n \n \n \n \n \n \n \n4-5\n \n \n \n \n \n \n683\n \n2.19 (condition A)\n \n \n \n \n \n \n \n \n4-6\n \n \n \n \n \n \n641\n \n4.01 (condition B)\n \n \n \n \n \n \n \n \n4-7\n \n \n \n \n \n \n669\n \n4.85 (condition B)\n \n \n \n \n \n \n \n \n4-8\n \n \n \n \n \n \n710\n \n4.20 (condition B)\n \n \n \n \n \n \n \n \n4-9\n \n \n \n \n \n \n697\n \n2.20 (condition A)\n \n \n \n \n \n \n \n \n4-10\n \n \n \n \n \n \n639\n \n2.01 (condition A)\n \n \n \n \n \n \n \n \n4-11\n \n \n \n \n \n \n654\n \n2.06 (condition A)\n \n \n \n \n \n \n \n \n4-12\n \n \n \n \n \n \n668\n \n3.83 (condition B)\n \n \n \n \n \n \n \n \n4-13\n \n \n \n \n \n \n682\n \n3.89 (condition B)\n \n \n \n \n \n \n \n \n \n \n\n\n \nExample 5: Synthesis of ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-oxo-acetic acid ethyl ester\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (0.117 mmol; 70 mg) in dichloromethane (1.2 mL) is added trifluoroacetic acid (0.4 mL). The mixture is stirred for 1 hour, and then concentrated under reduced pressure. To a solution of the obtained residue and \nN,N\n-diisopropylethylamine (0.468 mmol; 60.5 mg) in dichloromethane (0.4 mL) is added ethyl chloroglyoxylate (0.234 mmol; 31.9 mg). The mixture is stirred for 1 hour at room temperature, and then diluted with water and dichloromethane. The organic layer is separated to concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane/EtOAc) to give ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-oxo-acetic acid ethyl ester (51 mg, 73%); ESI-MS \nm\n/\nz\n: 599 [M+1]\n+\n, Retention time 2.15 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 5\n using corresponding acid chlorides.\n\nExample 5-1: 1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-ethanone\n\nExample 5-2: 1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-3-methyl-butan-1-one\n\nExample 5-3: ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-cyclohexyl-methanone\n\n \n \n \n \n \nNo\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n5-1\n \n \n \n \n \n \n541\n \n2.02 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n5-2\n \n \n \n \n \n \n583\n \n2.32 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n5-3\n \n \n \n \n \n \n609\n \n2.08 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 6: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (0.200 mmol; 120 mg) in dichloromethane (2.0 mL) is added trifluoroacetic acid (0.7 mL). The mixture is stirred for 1 hour, and then concentrated under reduced pressure. To a mixture of the obtained residue and N,N-diisopropylethylamine (1.6 mmol; 207 mg) is added isopropyl chloroformate (0.4 mmol; 49 mg). The mixture is stirred for 1 hour at room temperature, and then diluted with water and dichloromethane. The organic layer is separated to concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn\n-hexane/EtOAc) to give (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (51 mg, 73%); ESI-MS \nm\n/\nz\n: 599 [M+1]\n+\n, Retention time 2.15 min (condition A). 1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.82 (t, \nJ\n=7.30 Hz, 3 H), 1.23 (d, \nJ\n=5.54 Hz, 6 H), 1.47 - 1.58 (m, 1 H), 1.66 - 1.74 (m, 1 H), 1.97 (br. s., 1 H), 2.26 - 2.33 (m, 1 H), 3.13 (t, \nJ\n=10.58 Hz, 1 H), 3.78 - 3.85 (m, 1 H), 3.89 - 4.00 (m, 4 H), 4.87 - 4.98 (m, 3 H), 5.17 - 5.26 (m, 1 H), 7.54 (s, 1 H), 7.66 (s, 3 H), 7.76 (s, 1 H), 8.44 (s, 2 H)\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 6\n using corresponding chloroformates.\n\nExample 6-1: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isobutyl ester\n\nExample 6-2: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2,2-dimethyl-propyl ester\n\n \n \n \n \n \nNo\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n6-1\n \n \n \n \n \n \n599\n \n4.84 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n6-2\n \n \n \n \n \n \n613\n \n2.66 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nExample 6-1\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.83 (t, \nJ\n=7.56 Hz, 3 H), 0.92 (d, \nJ\n=6.52 Hz, 6 H), 1.48 - 1.60 (m, 1 H), 1.68 - 1.76 (m, 1 H), 1.88 - 2.10 (m, 2 H), 2.28 - 2.34 (m, 1 H), 3.15 (t, \nJ\n=10.58 Hz, 1 H), 3.82 - 3.86 (m, 7 H), 4.89 - 4.98 (m, 2 H), 5.17 - 5.26 (m, 1 H), 7.54 (s, 1 H), 7.67 (br. s., 3 H), 7.76 (s, 1 H), 8.44 (s, 2 H)\n\n\n \nExample 6-2\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.84 (t, \nJ\n=7.55 Hz, 3 H), 0.93 (br. s., 9 H), 1.47 - 1.60 (m, 1 H), 1.68 - 1.84 (m, 2 H), 1.91 - 2.10 (m, 1 H), 2.27 - 2.39 (m, 1 H), 3.16 (t, \nJ\n=10.58 Hz, 1 H), 3.71 - 3.89 (m, 3 H), 3.95 (s, 3 H), 4.94 (s, 2 H), 5.15 - 5.28 (m, 1 H), 7.54 (s, 1 H), 7.67 (s, 3 H), 7.76 (s, 1 H), 8.44 (s, 2 H)\n\n\n \n\n\nExample 7: Synthesis of (2\nR\n,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid \ncis\n-4-methoxycarbonylcyclohexyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nR\n,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (0.117 mmol; 70 mg) in dichloromethane (1.2 mL) is added trifluoroacetic acid (0.4 mL). The mixture is stirred for 1 hour, and then concentrated under reduced pressure to give the crude ammonium trifluoroacetate; ESI-MS \nm\n/\nz\n: 499 [M-CF3COO+1]\n+\n, Retention time 1.82 min (condition A).\n\n\n \n \n \n \nTo a solution of cis-4-Hydroxycyclohexanecarboxylic acid methyl ester (4.05 mmol; 640 mg) and triphosgene (2.70 mmol; 801 mg) in dichloromethane (20 mL) is slowly added a solution of pyridine (4.25 mmol; 336 mg) in dichloromethane (20 mL) at 0 C. The reaction mixture is stirred for 4 hours at room temperature, and then quenched with saturated aqueous ammonium chloride solution, extracted twice with dichloromethane. The combined organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure to give the crude material (848 mg).\n\n\n \n \n \n \nNext, a mixture of 52 mg of the obtained residue and the full volume of the crude ammonium trifluoroacetate and \nN,N\n-diisopropylethylamine (0.936 mmol; 121 mg) is stirred for 2 hours at room temperature. The mixture is diluted with dichloromethane and water. The organic layer after drying is separated to concentrated under reduce pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane/EtOAc) to give (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid cis-4-methoxycarbonylcyclohexyl ester (76 mg, 95%); ESI-MS \nm\n/\nz\n: 683 [M+1]\n+\n, Retention time 2.26 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 7\n using corresponding alcohols.\n\nExample 7-1: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2-methoxycarbonyl-2-methylpropyl ester\n\nExample 7-2: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-ethoxycarbonyl-1-methyl-ethyl ester\n\nExample 7-3: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-ethoxycarbonyl-3-methyl-butyl ester\n\nExample 7-4: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tetrahydro-pyran-4-yl ester\n\nExample 7-5: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methoxycarbonyl-phenyl ester\n\nExample 7-6: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazo)-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tetrahydro-pyran-4-ylmethyl ester\n\nExample 7-7: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methoxycarbonyl-cyclobutyl ester\n\nExample 7-8: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methoxycarbonyl-cyclobutyl ester\n\nExample 7-9: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-methoxycarbonyl-cyclohexylmethyl ester\n\nExample 7-10: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid cyclohexylmethyl ester\n\nExample 7-11: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-methoxycarbonyl-cyclopentylmethyl ester\n\nExample 7-12: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-ethoxycarbonylmethyl-cyclohexylmethyl ester\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nalcohol\n \nStarting Material\n \n \n \n \n7-1\n \n \n \n \n \n \n657\n \n2.26 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-2\n \n \n \n \n \n \n657\n \n2.32 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-3\n \n \n \n \n \n \n685\n \n4.83 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-4\n \n \n \n \n \n \n627\n \n2.18 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-5\n \n \n \n \n \n \n677\n \n2.28 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-6\n \n \n \n \n \n \n641\n \n4.39 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-7\n \n \n \n \n \n \n655\n \n2.21 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-8\n \n \n \n \n \n \n655\n \n4.45 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-9\n \n \n \n \n \n \n697\n \n2.36 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-10\n \n \n \n \n \n \n639\n \n2.66 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-11\n \n \n \n \n \n \n683\n \n5.13 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n7-12\n \n \n \n \n \n \n725\n \n2.47 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nExample 7-4\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.84 (t, \nJ\n=7.30 Hz, 3 H), 1.51 - 1.77 (m, 4 H), 1.92 - 2.12 (m, 3 H), 2.29 - 2.31 (m, 1 H), 3.16 (t, \nJ\n=10.58 Hz, 1 H), 3.53 - 3.58 (m, 2 H), 3.80 - 4.00 (m, 7H), 4.88 - 4.99 (m, 3 H), 5.17 - 5.26 (m, 1 H), 7.54 (s, 1 H), 7.67 (s, 3 H), 7.77 (s, 1 H), 8.45 (s, 2 H)\n\n\n \nExample 7-6\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.83 (t, \nJ\n=7.56 Hz, 3 H), 1.32 - 1.43 (m, 2 H), 1.47 - 1.63 (m, 3 H), 1.69 - 1.77 (m, 1 H), 1.82 - 2.12 (m, 2 H), 2.27 - 2.34 (m, 1 H), 3.15 (t, \nJ\n=10.32 Hz, 1 H), 3.36 - 3.41 (m, 2 H), 3.81 - 4.00 (m, 9 H), 4.85 - 5.06 (m, 2 H), 5.16 - 5.25 (m, 1 H), 7.54 (s, 1 H), 7.66 (s, 3 H), 7.77 (s, 1 H), 8.44 (s, 2 H)\n\n\n \n\n\nExample 8: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-phenyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA mixture of (2\nR\n,4\nS)\n-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methoxycarbonylphenyl ester (0.037 mmol; 25 mg), aqueous 6M HCl (0.5 mL) and 1,4-dioxane (0.1 mL) is stirred at 100 C for 19 hours. The mixture is cooled to ambient temperature, then diluted with water and Et2O The product is extracted three times with Et2O. The combined organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: dichloromethane/methanol) to give (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-carboxy-phenyl ester (8.0 mg, 33%); ESI-MS \nm\n/\nz\n: 663 [M+1]\n+\n, Retention time 2.14 min (condition A).\n\n\n \n\n\nExample 9: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-methyl-oxetan-3-ylmethyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a mixture of 3-methyl-3-oxetanemetahnol (0.202 mmol; 20.6 mg) and sodium hydride (60% oil dispersion in mineral oil, 0.202 mmol; 8.1 mg) in THF (0.5 mL) is added a solution of (2\nR\n,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-nitro-phenyl ester (0.101 mmol; 67 mg) in THF (0.5 mL). The reaction mixture is stirred for 1 hour at room temperature, then quenched with saturated aqueous ammonium chloride. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn\n-hexane/EtOAc), followed by another silica gel column chromatography (eluent: dichloromethane/methanol) to give (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-ethylpyrrolidine-1-carboxylic acid 3-methyl-oxetan-3-ylmethyl ester (40.7 mg, 64%); ESI-MS \nm\n/\nz\n: 626 [M+1]\n+\n, Retention time 2.19 min (condition A).\n\n1H NMR (400 MHz, CHLOROFORM-d) ppm 0.84 (t, \nJ\n=7.30 Hz, 3 H) 1.32 (br s, 3 H), 1.50 - 1.60 (m, 1 H), 1.71 - 1.79 (m, 1 H) 1.84 - 2.15 (m, 1 H) 2.31 (br s, 1 H) 3.16 - 3.21 (m, 1 H) 3.81 - 3.95 (m, 5 H), 4.15 (br s, 2 H) 4.36 - 4.39 (m, 2 H) 4.51 - 4.54 (m, 2 H) 4.89 - 4.99 (m, 2 H) 5.17 - 5.26 (m, 1 H) 7.54 (s, 1 H) 7.66 (s, 3 H) 7.77 (s, 1 H) 8.44 (s, 2 H)\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 9\n using corresponding alcohols.\n\nExample 9-1: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-ethyl-propyl ester\n\nExample 9-2: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2,2,2-trifluoro-ethyl ester\n\nExample 9-3: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid cyclopentyl ester\n\nExample 9-4: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid (R)-sec-butyl ester\n\nExample 9-5: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid (S)-sec-butyl ester\n\nExample 9-6: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 3-ethyl-oxetan-3-ylmethyl ester\n\n \n \n \n \n \nNo\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n9-1\n \n \n \n \n \n \n613\n \n2.46 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n9-2\n \n \n \n \n \n \n625\n \n2.30 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n9-3\n \n \n \n \n \n \n611\n \n2.42 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n9-4\n \n \n \n \n \n \n599\n \n2.41 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n9-5\n \n \n \n \n \n \n599\n \n4.89 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n9-6\n \n \n \n \n \n \n641\n \n2.24 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nReactions (No.1, 4,& 5 in the above table) is performed at 60 C\n \n \n \n \n \n\n\n \nExample 9-1\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.83 (t, \nJ\n=7.56 Hz, 3 H), 0.89 (t, J=7.56 Hz, 6 H), 1.56-1.61 (m, 5 H), 1.70 - 1.74 (m, 1 H), 1.96 (br s, 1H), 2.27 - 2.34 (m, 1 H), 3.15 (t, \nJ\n=10.58 Hz, 1 H), 3.79 - 3.98 (m, 5 H), 4.65 (br s, 1 H), 4.89 - 4.98 (m, 2 H), 5.17 - 5.26 (m, 1 H), 7.54 (s, 1 H), 7.66 (s, 3 H), 7.76 (s, 1 H), 8.44 (s, 2 H)\n\n\n \nExample 9-2\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n): 2 rotamers at 23 C ppm 0.84 (t, \nJ\n=7.56 Hz, 3 H), 1.56 (br s, 1 H), 1.74 - 1.82 (m, 1 H), 1.88 and 2.04 (m, 1 H, rotamers), 2.31 (br s, 1 H), 3.21 - 3.24 (m, 1 H), 3.86 - 4.00 (m, 5 H), 4.44 and 4.58 (m, 2 H, rotamers) 4.86 - 5.02 (m, 2 H), 5.20 (br s, 1 H), 7.55 (s, 1 H), 7.67 (s, 3 H), 7.77 (s, 1 H), 8.45 (s, 2 H)\n\n\n \nExample 9-3\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.82 (t, \nJ\n=7.54 Hz, 3 H), 1.48 - 1.74 (m, 8 H), 1.80 - 1.85 (m, 3 H), 2.25 - 2.32 (m, 1 H), 3.12 (t, \nJ\n=10.32 Hz, 1 H), 3.78 - 4.00 (m, 5 H), 4.87 - 4.97 (m, 2 H) 5.11 (br. s., 1 H) 5.16 - 5.25 (m, 1 H) 7.54 (s, 1 H) 7.66 (s, 3 H) 7.76 (s, 1H) 8.44 (s, 2H)\n\n\n \nExample 9-4\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.82 (t, \nJ\n=7.54 Hz, 3 H), 0.88 - 0.91 (m, 3 H), 1.21 (d, \nJ\n=6.56 Hz, 3 H), 1.50 - 1.61 (m, 3 H), 1.67 - 1.75 (m, 1 H), 1.83 - 2.12 (m, 1 H), 2.27 - 2.33 (m, 1 H), 3.14 (t, \nJ\n=10.32 Hz, 1 H), 3.78 - 4.00 (m, 5 H), 4.72 - 4.77 (m, 1 H), 4.88 - 4.98 (m, 2 H), 5.18 - 5.27 (m, 1 H), 7.54 (s, 1 H), 7.66 (s, 3 H), 7.76 (s, 1 H), 8.44 (s, 2 H)\n\n\n \nExample 9-5\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.83 (t, \nJ\n=7.30 Hz, 3 H), 0.90 (t, \nJ\n=7.54 Hz, 3 H), 1.21 (d, \nJ\n=6.56 Hz, 3 H), 1.48 - 1.64 (m, 3 H), 1.67 - 1.75 (m, 1 H), 1.83 - 2.10 (m, 1 H), 2.27 - 2.33 (m, 1 H), 3.14 (t, \nJ\n=10.56 Hz, 1 H), 3.78 - 4.00 (m, 5 H), 4.72 - 4.80 (m, 1 H), 4.88 - 4.98 (m, 2 H), 5.17 - 5.26 (m, 1 H), 7.54 (s, 1 H), 7.66 (s, 3 H), 7.76 (s, 1 H), 8.44 (s, 2 H)\n\n\n \nExample 9-6\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.84 (t, \nJ\n=7.30 Hz, 3 H), 0.91 (t, \nJ\n=7.56 Hz, 3 H), 1.51 - 1.58 (m, 1 H), 1.70 - 1.79 (m, 3 H), 1.84 - 2.16 (m, 1 H), 2.31 (br s, 1 H), 3.18 (t, \nJ\n=10.32 Hz, 1 H), 3.81 - 4.00 (m, 5 H), 4.20 (br s, 2 H), 4.34 - 4.39 (m, 2 H), 4.47 - 4.49 (m, 2 H), 4.89 - 4.99 (m, 2 H), 5.17 - 5.26 (m, 1 H), 7.54 (s, 1 H), 7.67 (s, 3 H), 7.77 (s, 1 H), 8.44 (s, 2 H)\n\n\n \n\n\nExample 10: Synthesis of diastreomers of (5R)-3-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-5-ethyl-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a suspension of ruthenium(IV) oxide hydrate (10 mg) and sodium periodate (3.0 mmol; 642 mg) in water (12 mL) is added a solution of (2\nR\n,4\nS\n)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (0.5 mmol; 300 mg) in EtOAc (12 mL) at 0 C. After stirring for 2 hours at 0 C and then stirred for 1.5 hours at room temperature, another sodium periodate (3.0 mmol; 642 mg) is added to the mixture. After stirring for additional 16.5 hours at room temperature, the reaction mixture is diluted with EtOAc and water. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: dichloromethane/methanol) to give (3S,5R)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-2-oxopyrrolidine-1-carboxylic acid \ntert-\nbutyl ester (28 mg, 9%); ESI-MS \nm\n/\nz\n: 511 [M-tBuOCO+2]\n+\n, Retention time 2.43 min (condition A).\n\n\n \n \n \n \n(3\nS\n,5\nR\n)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-2-oxopyrrolidine-1-carboxylic acid \ntert\n-butyl ester (0.043 mmol; 26 mg), tetrakis(triphenylphosphine) palladium (0.0043 mmol; 5.0 mg), 1-methylpyrazol-4-boronic acid pinacol ester (0.060 mmol; 12.5 mg) and aqueous 2M sodium carbonate (0.043 mL) are dissolved in 1,2-dimethoxyethane (0.2 ml) at room temperature. The mixture is stirred at 90 C for 7 hours, and then cooled to ambient temperature. To the mixture is added brine and the solution is extracted with EtOAc. The organic layer is washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The obtained residue is subjected to column chromatography on silica gel (eluent: \nn\n-hexane/EtOAc) to give a mixture of pinacol and diastereomers of (5\nR\n)-3-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-5-ethyl-2-oxo-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester.\n\n\n \n \n \n \nTo a suspension of the crude and silica gel (0.81 g) in EtOAc (3.9 mL) is added aqueous 0.65 M sodium periodate solution (0.78 mL). After stirring for 17 hours, another silica gel (4.05 g) and EtOAc (5.6 mL) are added. After stirring for 10 min., the mixture is subjected to short column chromatography on silica gel to give pure (5\nR\n)-3-{(3,5-bis-trifluoromethylbenzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-5-ethyl-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester (16 mg, 61%) as a diastereomixture (dr= 62:38); ESI-MS \nm\n/\nz\n: 613 [M+1]\n+\n, Retention time 4.59 min (condition B).\n\n\n \n\n\nExample 11: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromthyl-benzyl)-[5-((S)-3-hydroxy-pyrrolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a mixture of (S)-(-)-1-benzyl-3-pyrrolidinol (2.84 mmol; 0.50 g) in dichloromethane (5 ml) and pyridine (5.68 mmol; 449 mg) is added benzoyl chloride (3.41 mmol; 479 mg) at 0C, and the mixture is stirred for 1 hour while warming to room temperature. After addition of saturated aqueous NaHCO3 solution, the product is extracted with EtOAc. The combined organic layer after dried over MgS04 is concentrated under reduced pressure. The resulting benzoic acid (S)-1-benzyl-pyrrolidin-3-yl ester is used in next step without further purification.\n\n\n \n \n \n \nTo a solution of the crude product (0.45 mmol; 127 mg) in 1,2-dichloroethane (1.5 mL) is added -chloroethyl chloroformate (0.59 mmol; 84 mg) at room temperature, and the mixture is heated at 90 C for 3 hours. After addition of another -chloroethyl chloroformate (1.18 mmol; 168 mg), the mixture is stirred for additional 8 hours at the same temperature. After cooling to ambient temperature, the reaction mixture is concentrated, and then the resulting mixture is diluted with MeOH (1 ml). The reaction mixture is refluxed for 1 hour. After cooling to ambient temperature, solvent are concentrated. The resulting benzoic acid (S)-pyrrolidin-3-yl ester hydrochloride is used in next step without further purification.\n\n\n \n \n \n \nThe resulting benzoic acid (S)-pyrrolidin-3-yl ester hydrochloride (0.45 mmol), (2\nR\n,4\nS\n)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (0.196 mmol; 114 mg), tris(dibenzylidneacetone)dipalladium(0) (0.0098 mmol; 9.0 mg), 2-(di-\ntert-\nbutylphosphino)biphenyl (0.0196 mmol; 5.8 mg) and sodium tert-butoxide (0.784 mmol; 75.3 mg) are dissolved in toluene (1 mL). The mixture is stirred for 2.5 hours at 100 C. To the mixture are added aqueous 1 M NaOH (5 mL), MeOH (10 mL) and THF (3 mL) at room temperature. After stirring for 5 hours, the reaction mixture is quenched with saturated aqueous ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn\n-hexane/EtOAc) to give (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethylbenzyl)-[5-((S)-3-hydroxy-pyrrolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (82 mg, 71%); ESI-MS m/z: 590 [M+1]\n+\n, Retention time 2.15 min (condition A).\n\n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.81 (t, \nJ\n=7.56 Hz, 3 H), 1.23 (d, \nJ\n=6.04 Hz, 6 H), 1.45 - 1.56 (m, 1 H), 1.61 - 1.69 (m, 1 H), 1.87 - 2.08 (m, 3 H), 2.14 - 2.22 (m, 1 H), 2.23 - 2.30 (m, 1 H), 3.08 (t, \nJ\n=10.6 Hz, 1 H), 3.20 - 3.28 (m, 2 H), 3.41 - 3.49 (m, 2 H), 3.76 - 3.82 (m, 1 H), 3.89 (br s, 1 H), 4.58 - 4.65 (m, 1 H), 4.78 - 4.93 (m, 3 H), 5.07 - 5.16 (m, 1 H), 7.66 (s, 2 H), 7.73 (s, 1 H), 7.85 (s, 2 H)\n\n\n \n\n\nExample 12: Synthesis of (2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-morpholin-4-yl-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n(2\nR\n,4\nS\n)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (0.50 mmol; 299 mg), morpholine (1.0 mmol; 87 mg), tris(dibenzylidneacetone)dipalladium(0) (0.025 mmol; 22.9 mg), 2-(di-\ntert-\nbutylphosphino)biphenyl (0.05 mmol; 14.9 mg) and sodium \ntert\n-butoxide (1.0 mmol; 96 mg) are dissolved in toluene (2.5 mL). The mixture is stirred for 3 hours at 100 C, and then cooled to ambient temperature. The reaction mixture is quenched with saturated aqueous ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn\n-hexane/EtOAc) to give (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)-(5-morpholin-4-yl-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (247 mg, 82%); ESI-MS \nm\n/\nz\n: 604 [M+1]\n+\n, Retention time 4.91 min (condition C).\n\n\n \n\n\nExample 13: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2-carbamoyl-2-methyl-propyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}2-ethyl-pyrrolidine-1-carboxylic acid 2-carboxy-2-methylpropyl ester (0.016 mmol; 10 mg), ammonium chloride (0.032 mmol; 1.7 mg), WSCD hydrochloride (0.032 mmol; 7.3 mg), HOAt (0.032 mmol; 4.4 mg) in DMF (0.4 ml) is added triethylamine (0.080 mol; 8.1 mg) at room temperature. The reaction mixture is stirred for 18.5 hours at the same temperature, and then quenched with water. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The obtained residue is purified by preparative thin layer chromatography on silica gel (eluent: dichloromethane / MeOH) to give (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid 2-carbamoyl-2-methyl-propyl ester (4.1 mg, 40%); ESI-MS \nm\n/\nz\n: 642 [M+1]\n+\n, Retention time 2.04 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 13\n using corresponding amines.\n\nExample 13-1: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 2-methyl-2-methylcarbamoyl-propyl ester\n\nExample 13-2: (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 1-dimethylcarbamoyl-1-methylethyl ester\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n13-1\n \n \n \n \n \n \n656\n \n2.08 (condition A)\n \nH\n2\nN-\n \n \n \n \n \n \n \n \n13-2\n \n \n \n \n \n \n656\n \n4.20 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 14: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (5 mmol; 970 mg) and 3,4-dihydro-2H-pyran (10 mmol; 841 mg) and \np\n-toluenesulfonic acid monohydrate (0.5 mmol; 95 mg) in 1,2-dichloroethane (25 mL) is stirred at 40 C for 2 hours. The reaction mixture is cooled to ambient temperature, and then quenched with saturated aqueous NaHCO3 solution. The product is extracted with dichloromethane. The organic layer is washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The resulting material is used in the next step without further purification.\n\n\n \n \n \n \nThe obtained 1-(tetrahydro-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1\nH-\npyrazole (ca. 0.269 mmol; 112 mg), (2\nR\n,4\nS\n)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (0.192 mmol; 112 mg), tetrakis(triphenylphosphine) palladium (0.019 mmol; 21.9 mg), and aqueous 2M sodium carbonate (0.2 mL) are dissolved in 1,2-dimethoxyethane (1 mL) at room temperature. The mixture is stirred at 90 C for 13 hours, and then cooled to ambient temperature. To the mixture is added brine and the solution is extracted three times with EtOAc. The organic layer is washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The obtained residue is subjected to column chromatography on silica gel (eluent: \nn\n-hexane/EtOAc) to give a diastereomeric mixture of (2\nR\n,4\nS\n)-4-((3,5-bis-trifluoromethylbenzyl)-{5-[1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amino)-2-ethylpyrrolidine-1-carboxylic acid isopropyl ester (99 mg).\n\n\n \n \n \n \nA solution of the obtained material and 1 M HCl (2 mL) in ethanol is stirred for 4 hours. Another 1 M HCl (2 mL) in ethanol is added to the mixture to stir additional 40 minutes. The solution is concentrated under reduced pressure, and Et2O is added to the residue. The solids are isolated by filtration, washed with Et2O and dried under vacuum to provide (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester as a HCl salt (80 mg, 69%); ESI-MS \nm\n/\nz\n: 571 [M+1]\n+\n, Retention time 2.28 min (condition A).\n\n1H NMR (400 MHz, DMSO-\nd\n \n6\n): HCl salt ppm 0.75 (t, \nJ\n=7.55 Hz, 3 H), 1.16 (d, \nJ\n=6.04 Hz, 6 H), 1.49 (br s, 1 H), 1.68 - 2.00 (m, 2 H), 2.14 - 2.25 (m, 1 H), 3.03 - 3.19 (m, 1 H), 3.62 - 4.80 (m, 5 H), 4.96 - 5.19 (m, 3 H), 7.88 (s, 2 H), 7.98 (s, 1 H), 8.04 - 8.12 (m, 2 H), 8.71 (s, 2 H)\n\n\n \n\n\nExample 15: Synthesis of 2-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-oxazole-4-carboxylic acid ethyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA solution of [3,5-bis(trifluoromethyl)benzyl]-(5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine (0.025 mmol, 12.5 mg), 2-chloro-oxazole-5-carboxylic acid ethyl ester (0.03 mmol, 5 mg) and \nN,N\n-diisopropylethylamine (0.03 mmol, 5 uL) in DMF (0.1 mL) is allowed to warm to 120C and stirred for 3 hours. The mixture is cooled to room temperature, then added with water. The mixture is extracted with CH\n2\nCl\n2\n. The combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give 2-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-oxazole-4-carboxylic acid ethyl ester (7.4 mg, 46%); ESI-MS \nm\n/\nz\n: 638 [M+1]\n+\n, Retention time 2.20 min (condition A).\n\n\n \n\n\nExample 16: Synthesis of ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-pyrrolidin-1-yl-methanone\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n[3,5-Bis(trifluoromethyl)benzyl]-((3S,5R)-5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine (84 mg, 0.17 mmol) and triphosgene (71 mg, 0.24 mmol) are dissolved in CH\n2\nCl\n2\n (2 mL). The reaction mixture is stirred at room temperature for 1 hour after addition of pyridine (15 mg, 0.19 mmol). Saturated aqueous NH\n4\nCl and EtOAc are added, then extracted with EtOAc. The combined organic layer is dried over Na\n2\nSO\n4\n then concentrated under reduced pressure. The resulting residue is dissolved in CH\n2\nCl\n2\n (1.5mL) and then pyrrolidine (60mg, 0.85mmol) is added. The reaction mixture is stirred at room temperature for 12 hours. Saturated aqueous NH\n4\nCl and CH\n2\nCl\n2\n are added, then extracted with CH\n2\nCl\n2\n. The combined organic layer is dried over MgSO\n4\n, then concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-pyrrolidin-1-yl-methanone (45 mg, 36%); ESI-MS m/z: 596 [M+1]\n+\n, Retention time 4.52 min (condition B).\n\n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.82 (t, \nJ\n=7.55 Hz, 3 H) 1.31 - 1.44 (m, 1 H) 1.61 - 1.68 (m, 1 H) 1.69 - 1.78 (m, 2 H) 1.80 - 1.93 (m, 2 H) 2.13 - 2.22 (m, 1 H) 3.16 - 3.26 (m, 3 H) 3.31 - 3.39 (m, 2 H) 3.49 (d, \nJ\n=4.03 Hz, 1 H) 3.58 - 3.63 (m, 1 H) 3.95 (s, 3 H) 4.00 - 4.09 (m, 1 H) 4.84 - 5.06 (m, 2 H) 5.17 - 5.28 (m, 1 H) 7.54 (s, 1 H) 7.66 (s, 1 H) 7.69 (s, 2 H) 7.77 (s, 1 H) 8.44 (s, 2 H)\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 16\n using corresponding amines.\n\nExample 16-1: 4-{[((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-ethyl-amino]-methyl}-cyclohexanecarboxylic acid methyl ester\n\nExample 16-2: ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-piperidin-1-yl-methanone Example 16-3: (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperidine-3-carboxylic acid ethyl ester\n\nExample 16-4: (S)-1-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperidine-2-carboxylic acid methyl ester\n\nExample 16-5: ((2R,45)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-cyclohexyl-methanone\n\nExample 16-6: 1-[4-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperazin-1-yl]-ethanone Example 16-7: ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-(2-cyclohexyl-pyrrolidin-1-yl)-methanone\n\nExample 16-8: 4-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carbonyl)-piperazin-2-one\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \namine\n \nStarting Material\n \n \n \n \n16-1\n \n \n \n \n \n \n724\n \n4.56 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n16-2\n \n \n \n \n \n \n609\n \n2.24 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n16-3\n \n \n \n \n \n \n682\n \n2.24 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n16-4\n \n \n \n \n \n \n668\n \n2.22 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n16-5\n \n \n \n \n \n \n626\n \n1.95 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n16-6\n \n \n \n \n \n \n653\n \n1.95 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n16-7\n \n \n \n \n \n \n678\n \n2.49, 2.57 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n16-8\n \n \n \n \n \n \n625\n \n3.56 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nExample 16-2\n\n\n \n \n \n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.82 (t, \nJ\n=7.45 Hz, 3 H) 1.35 - 1.53 (m, 7 H) 1.62 - 1.72 (m, 1 H) 1.74 - 1.81 (m, 1 H) 2.13 - 2.22 (m, 1 H) 3.14 - 3.19 (m, 4 H) 3.20 - 3.26 (m, 1 H) 3.95 (s, 3 H) 4.05 - 4.15 (m, 1 H) 4.87 - 5.04 (m, 2 H) 5.16 - 5.26 (m, 1 H) 7.54 (s, 1 H) 7.66 (s, 1 H) 7.68 (s, 2 H) 7.77 (s, 1 H) 8.44 (s, 2 H)\n\n\n \n\n\nExample 17: Synthesis of ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-morpholin-4-yl-methanone\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA mixture of (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-nitro-phenyl ester (0.1 mmol; 66 mg) and morpholine (1.15 mmol; 1.00 g) is stirred for 20 hours at 80 C. The reaction mixture is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give ((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-morpholin-4-yl-methanone (45 mg; 73%)%); ESI-MS m/z: 612 [M+1]\n+\n, Retention time 2.07 min (condition A).\n\n1H NMR (400 MHz, CHLOROFORM-\nd\n) ppm 0.83 (t, \nJ\n=7.56 Hz, 3 H), 1.35 - 1.46(m, 1 H), 1.67 - 1.75 (m, 1 H), 1.76 - 1.85 (m, 1 H), 2.15 - 2.21 (m, 1 H), 3.15 - 3.34 (m, 5 H), 3.57 - 3.70 (m, 5 H), 3.95 (s, 3 H), 4.08 - 4.15 (m, 1 H), 4.88 - 5.04 (m, 2 H), 5.13 - 5.22 (m, 1 H), 7.55 (s, 1 H), 7.67 - 7.68 (m, 3 H), 7.78 (s, 1 H), 8.45 (s, 2 H)\n\n\n \n\n\nExample 18: Synthesis of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid dimethylamide\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid 4-nitro-phenyl ester (0.03mmol, 20 mg) in 1mL of DMF are added \ntrans\n-4-(aminomethyl)cyclohexanecarboxylic acid methyl ester hydrochloride (0.04mmol, 8 mg) and triethylamine (0.07mmol, 0.01 mL). The mixture is stirred under microwave irradiation (150C, 5 bar), then cooled to room temperature. The mixture is poured into a saturated aqueous ammonium chloride and extracted with dichloromethane. The combined organic phases is washed by water and brine, dried over anhydrous Na\n2\nSO\n4\n and evaporated. The obtained residue is purified by column chromatography on silica gel (eluent: n-hexane-ethyl acetate) to obtain 12.3mg (59%) of (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid dimethylamide as colorless oil. ESI-MS m/z: 570 [M+1]\n+\n, Retention time 4.05 min (condition B).\n\n\n \n\n\nExample 19: Synthesis of (S)-3-{(3-Chloro-5-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a mixture of (S)-pyrrolidin-3-yl-carbamic acid \ntert\n-butyl ester (5.37 mmol, 1 g) in CH\n2\nCl\n2\n (5 mL) and aqueous NaHCO\n3\n solution (5 mL) is added isopropyl chloroformate (6.44 mmol, 0.74 mL) at 0C and the mixture is stirred for 1 hours at room temperature. The organic phase is separated, dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure to give a pale yellow oil (1.6 g). To a solution of the obtained oil in 1,4-dioxane (15 mL) is added 4M HCl solution in 1,4-dioxane (15 mL) at 0C and the mixture is stirred for 17 hours at room temperature. The mixture is concentrated under reduced pressure, then basified with 1 M aqueous NaOH. The mixture is extracted with CH\n2\nCl\n2\n. The combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure to give a pale brown oil (1.05 g). A mixture of the obtained oil, 5-bromo-2-chloro-pyrimidine and \nN,N-\ndiisopropylethylamine (6.44 mmol, 1.1 mL) in DMF (16 mL) is allowed to warm to 120C and stir for 3 hours. The mixture is cooled to room temperature, then added water. The mixture is extracted with EtOAc. The combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: hexane / EtOAc) to give (S)-3-(5-bromo-pyrimidin-2-ylamino)-pyrrolidine-1-carboxylic acid isopropyl ester (1.41 g, 80%); ESI-MS m/z: 329 [M+1]\n+\n, Retention time 1.82 min (condition A).\n\n\n \n \n \n \nTo a solution of (S)-3-(5-bromo-pyrimidin-2-ylamino)-pyrrolidine-1-carboxylic acid isopropyl ester (4.3 mmol, 1.41 g) in DMF (20 mL) is added sodium hydride (60% oil suspension, 8.6 mmol, 344 mg) at 0C and stirred at room temperature for 30 minutes. To the mixture is added 1-bromomethyl-3,5-\nbis\n-(trifluoromethyl)benzene (6.45 mmol, 0.87 mL) at 0C and stirred at room temperature for 2 hours. The mixture is added water and extracted with EtOAc. The combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give (S)-3-{(5-bromo-pyrimidin-2-yl)-[3-chloro-5-(trifluoromethyl)benzyl]-amino}-pyrrolidine-1-carboxylic acid isopropyl ester (1.9 g, 85%); ESI-MS m/z: 521 [M+1]\n+\n, Retention time 2.43 min (condition A).\n\n\n \n \n \n \nTo a mixture of (S)-3-{(5-bromo-pyrimidin-2-yl)-[3-chloro-5-(trifluoromethyl)benzyl]-amino}-pyrrolidine-1-carboxylic acid isopropyl ester (0.19 mmol, 100 mg), 1-methylpyrazol-3-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (0.23 mmol, 48 mg), tetrakis(triphenylphosphine)palladium(0) (0.02 mmol, 22 mg) and 2M aqueous sodium hydrogen carbonate (0.19 mL) in 1,2-dimethoxy-ethane (0.6 mL) is allowed to warm to 95 C and stirred for 3 hours. The mixture is cooled to room temperature and then added water. The mixture is extracted with CH\n2\nCl\n2\n. The combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: CH\n2\nCl\n2\n / EtOAc). To the obtained mixture in CH\n2\nCl\n2\n (1 mL) is added saturated aqueous sodium carbonate (0.04 mL) and NalO\n4\n (82 mg). The mixture is stirred at room temperature for 3 hours. The mixture is concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give (S)-3-{(3-Chloro-5-trifluoromethyl-benzyl)-[5-(1-methyl-1 H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-pyrrolidine-1-carboxylic acid isopropyl ester (67 mg, 67%); ESI-MS m/z: 523 [M+1]\n+\n, Retention time 2.16 min (condition A).\n\n\n \n\n\nExample 20: Synthesis of 2-{2-(3,5-Bis-trifluoromethyl-phenyl)-1-[(3R,5R)-5-ethyl-1-(2-methoxymethyl-4-trifluoromethyl-phenyl)-pyrrolidin-3-yl]-ethyl}-5-(1-methyl-1H-pyrazol-4-yl)-pyrimidine\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA mixture of [3,5-bis(trifluoromethyl)benzyl]-((3S,5R)-5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1 H-pyrazol-4-yl)-pyrimidin-2-yl]-amine (75 mg, 0.15 mmol), 2-fluoro-5-trifluoromethyl-benzaldehyde (44 mg, 0.23 mmol) and K\n2\nCO\n3\n (42 mg, 0.30 mmol) in DMF (1.5 mL) is heated at 130 C and stirred for 2 hours. After the mixture is cooled down until room temperature, H\n2\nO and EtOAc is added and then extracted with EtOAc. The combined organic layer is dried over MgSO\n4\n, then concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give 2-((2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-trifluoromethyl-benzaldehyde as a colorless oil (77 mg, 74%). ESI-MS m/z: 670 [M+1]+, Retention time 2.75 min (condition A).\n\n\n \n \n \n \nTo a mixture of 2-((2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-trifluoromethyl-benzaldehyde (75 mg, 0.11 mmol) in MeOH (2.0 mL) is added sodium borohydride (6 mg, 0.17 mmol). The reaction mixture is stirred at room temperature for 15 minutes. After addition of saturated aqueous sodium hydrogen carbonate, and the mixture is extracted with EtOAc. The combined organic layer is dried over MgSO\n4\n then concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give [2-((2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-trifluoromethyl-phenyl]-methanol as a colorless oil (72 mg, 96%). ESI-MS m/z: 672 [M+1]+, Retention time 2.36 min (condition A).\n\n\n \n \n \n \nTo a solution of [2-((2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-trifluoromethyl-phenyl]-methanol (67 mg, 0.10 mmol) in DMSO (1.5 mL) is added added NaH (60% in oil, 6 mg, 0.15 mmol) at room temperature. The reaction mixture is stirred at room temperature for 5 minutes. After addition of methyl iodide (9.6 uL 0.15 mmol), the mixture is stirred for 30 minutes. H\n2\nO and EtOAc are added, then extracted with EtOAc. The combined organic layer is dried over MgSO\n4\n, and then concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give 2-{2-(3,5-Bis-trifluoromethylphenyl)-1-[(3R,5R)-5-ethyl-1-(2-methoxymethyl-4-trifluoromethyl-phenyl)-pyrrolidin-3-yl]-ethyl}-5-(1-methyl-1H-pyrazol-4-yl)-pyrimidine as a colorless oil (52 mg, 75%). ESI-MS m/z: 686 [M+1]+, Retention time 2.72 min (condition A).\n\n\n \n\n\nExample 21: Synthesis of (2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nR\n,4\nS\n)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (0.20 mmol; 120 mg) in dichloromethane (2.0 mL) is added TFA (0.7 mL). The reaction mixture is stirred for 30 minutes, and concentrated under reduced pressure. The residue is soluted in 10 ml of dichloromethane, followed by neutralization with 2 ml of saturated aqueous NaHCO\n3\n solution. After stirring for 15 minutes, the product is extracted with dichloromethane. The organic layer after dried is separated and concentrated under reduced pressure.\n\n\n \n \n \n \nA mixture of the obtained residue, \nN,N\n-diisopropylethylamine (1.6 mmol; 207 mg) and isopropyl chloroformate (0.4 mmol; 49.0 mg) is stirred for 11.5 hours at room temperature. The reaction mixture is diluted with dichloromethane and then quenched with saturated ammonium chloride solution. The product is extracted with dichloromethane. The organic layer after dried is separated and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give (2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethylpyrrolidine-1-carboxylic acid isopropyl ester (112 mg, 96%).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 21.\n \n\nExample 21-1: (2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-morpholin-4-yl-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \n \n \n \n21-1\n \n \n \n \n \n \n590\n \n2.31 (condition A)\n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 22: Synthesis of (3,5-Bis-trifluoromethyl-benzyl)-[(3S,5R)-5-ethyl-1-(5-trifluoromethyl-pyridin-2-yl)-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA mixture of [3,5-bis(trifluoromethyl)benzyl]-((3S,5R)-5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1 H-pyrazol-4-yl)-pyrimidin-2-yl]-amine (45 mg, 0.09 mmol), 2-chloro-5-trifluoromethylpyridine (50 mg, 0.27 mmol) and \ni\nPr\n2\nEtN (45 uL 0.27 mmol) in THF (1.5 mL) is stirred at 120 C under microwave irradiation. The mixture is concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: hexane / EtOAc) to give (3,5-Bis-trifluoromethyl-benzyl)-[(3S,5R)-5-ethyl-1-(5-trifluoromethyl-pyridin-2-yl)-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine as a colorless oil (38 mg, 66%). ESI-MS m/z: 643 [M+1]+, Retention time 2.45 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 22\n using corresponding chloroformates.\n\nExample 22-1: (3,5-Bis-trifluoromethyl-benzyl)-[(3S,5R)-1-(6-chloro-pyrimidin-4-yl)-5-ethyl-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n22-1\n \n \n \n \n \n \n611\n \n2.26 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 23: Synthesis of 1-[2-((3,5-bis-trifluoromethyl-benzyl)-{(3S,5R)-1-[5-chloro-2-(4-hydroxy-piperidin-1-yl)-pyrimidin-4-yl]-5-ethyl-pyrrolidin-3-yl}-amino)-pyrimidin-5-yl]-3-methyl-imidazolidin-2-one\n\n\n\n\n \n \n \n \n \n \n\nTo a mixture of 1-(2-{(3,5-bis-trifluoromethyl-benzyl)-[(3S,5R)-1-(2,5-dichloro-pyrimidin-4-yl)-5-ethyl-pyrrolidin-3-yl]-amino}-pyrimidin-5-yl)-3-methyl-imidazolidin-2-one (30 mg, 0.05 mmol) in i-PrOH (1 mL) is added piperidin-4-ol (23 mg, 0.23 mmol). The reaction mixture is stirred at 80 C for 12 hours. After removal of solvent, the mixture is washed with brine and extracted with EtOAc. The combined organic layer is dried over MgSO\n4\n then concentrated under reduced pressure to give 1-[2-((3,5-bis-trifluoromethyl-benzyl)-{(3S,5R)-1-[5-chloro-2-(4-hydroxy-piperidin-1-yl)-pyrimidin-4-yl]-5-ethyl-pyrrolidin-3-yl}-amino)-pyrimidin-5-yl]-3-methyl-imidazolidin-2-one (26 mg, 79%) after purification by silica gel column chromatography (eluent: EtOAc: MeOH = 20 :1).\n\n\n1\nH NMR (400 MHz, chloroform-d)  ppm 0.84 (t, \nJ\n = 7.5 Hz, 3H), 1.4-1.8 (m, 6H), 1.85-2.01 (m, 4H), 2.28 (dt, \nJ\n = 5.8, 11.6 Hz, 1 H), 2.89 (s, 3H), 3.14-3.23 (m, 2H), 3.5 (dt, \nJ\n = 2.3, 7.3 Hz, 2H), 3.50 (t, \nJ\n = 10.5 Hz, 1 H), 3.74 (dt, \nJ\n = 2.3, 7.3 Hz, 2H), 3.85-3.90 (m, 1 H), 3.95 (dd, \nJ\n = 7.6, 10.5 Hz, 1H), 4.20-4.40 (m, 3H), 4.90 (d, \nJ\n =17.0 Hz, 1H), 5.01 (d, \nJ\n = 17.0 Hz, 1H), 5.15-5.30 (m, 1H), 7.70 (s, 2H), 7.76(s, 1H), 7.86 (s, 1H), 8.54 (s, 2H); ESI-MS m/z: 728 [M]+, Retention time 3.62 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 23\n using corresponding amine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n23-1\n \n \n \n \n \n \n689\n \n1.88 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-2\n \n \n \n \n \n \n715\n \n1.93 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-3\n \n \n \n \n \n \n715\n \n3.60 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-4\n \n \n \n \n \n \n714\n \n3.47 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-5\n \n \n \n \n \n \n747\n \n3.42 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-6\n \n \n \n \n \n \n715\n \n3.51 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-7\n \n \n \n \n \n \n694\n \n2.12 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-8\n \n \n \n \n \n \n737\n \n1.93 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-9\n \n \n \n \n \n \n717\n \n4.10 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-10\n \n \n \n \n \n \n710\n \n1.94 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-11\n \n \n \n \n \n \n699\n \n1.97 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-12\n \n \n \n \n \n \n709\n \n2.12 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-13\n \n \n \n \n \n \n683\n \n1.75 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-14\n \n \n \n \n \n \n669\n \n1.88 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-15\n \n \n \n \n \n \n730\n \n2.12 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-16\n \n \n \n \n \n \n697\n \n1.93 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-17\n \n \n \n \n \n \n716\n \n1.99 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-18\n \n \n \n \n \n \n727\n \n1.882 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n23-19\n \n \n \n \n \n \n635\n \n1.91 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 24: Synthesis of 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-methyl-2-oxo-imidazolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a mixture of 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-methyl-2-oxo-imidazolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid ethyl ester (70 mg, 0.09 mmol) in EtOH (1 mL) is added 1 N NaOH (0.45 mL, 0.45 mmol). The reaction mixture is stirred at room temperature for 1 hour. After quench with 1 N HCl (0.45 mL, 0.45 mmol), the mixture is washed with brine and extracted with EtOAc. The combined organic layer is dried over MgSO\n4\n then concentrated under reduced pressure to give 1-[4-((2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-methyl-2-oxo-imidazolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid (66 mg, 97%).\n\n\n1\nH NMR (400 MHz, chloroform-d)  ppm 0.84 (t, \nJ\n= 7.3 Hz, 3H), 1.40-1.46 (m, 2H), 1.61-1.80 (m, 4H), 1.85-1.95 (m, 4H), 2.28 (dt, \nJ\n = 5.8, 11.6 Hz, 1 H), 2.58 (ddt, \nJ\n = 4.3, 7.1, 10.5 Hz, 1 H), 2.89 (s, 3H), 2.95-3.03 (m, 2H), 3.50 (dt, \nJ\n = 2.8, 7.6 Hz, 2H), 3.60 (t, \nJ\n = 10.5 Hz, 1 H), 3.73 (dt, \nJ\n = 2.8, 7.3 Hz, 2H), 3.95 (dd, \nJ\n = 2.8, 7.6 Hz, 1H), 4.32-4.40 (m, 1H), 4.44-4.51 (m, 2H), 4.90 (d, \nJ\n =17.2 Hz, 1H), 5.02 (d, \nJ\n = 17.2 Hz, 1 H), 5.16-5.27 (m, 1 H), 7.69 (s, 2H), 7.76 (s, 1 H), 7.87 (s, 1 H), 8.54 (s, 2H); ESI-MS m/z: 717 [M]+, Retention time 3.20 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 24.\n\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \n \n \n \n24-1\n \n \n \n \n \n \n717\n \n1.74 (condition B)\n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 25: Synthesis of 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidin-4-ol\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 25 ml round-bottom flask is charged with 1-(tetrahydro-pyran-2-yl)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (56 mg, 0.2 mmol), 1-(4-{(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidin-1-yl}-5-chloro-pyrimidin-2-yl)-piperidin-4-ol (110 mg, 0.15 mmmol) under N\n2\n. Pd(PPh3)4 (34 mg, 0.03 mmol) is added promptly and the flask is recharged with N\n2\n. Then DME (0.5 ml), Na\n2\nCO\n3\n ( 1 M in H\n2\nO, 0.3 ml, 0.3 mmol) are added. The mixture is then heated to 95 degree for 2 hours. After cooling down to rt, NalO\n4\n (103 mg, 0.48 mmol) is added into reaction mixture. Stirring is continued for 1 h to give white suspension. H\n2\nO and dichloromethane are added, then organic layer is collected with phase separator. Removal of solvent gave 1-{4-[(2R,4S)-4-((3,5-bis-trifluoromethyl-benzyl)-{5-[1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amino)-2-ethyl-pyrrolidin-1-yl]-5-chloro-pyrimidin-2-yl}-piperidin-4-ol which is used without further purification.\n\n\n \n \n \n \nA 25 ml round-bottom flask is charged with 1-{4-[(2R,4S)-4-((3,5-bis-trifluoromethyl-benzyl)-{5-[1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amino)-2-ethyl-pyrrolidin-1-yl]-5-chloro-pyrimidin-2-yl}-piperidin-4-ol (0.15 mmmol), 1N HCl (0.8 ml, 0.8 mmol) and MeOH (2 ml). The mixture is then heated to 60 degree for 30 minutes. After cooling down to rt, sat. NaHCO\n3\n and dichloromethane are added, then organic layer is collected. Removal of solvent and purification with reverse phase columnchromatography give 1-[4-((2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidin-4-ol (11.3 mg, 0.015 mmol, 10% for 2 steps).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.84 (t, \nJ\n = 8 Hz, 3H), 1.43-1.54 (m, 2H), 1.62-1.67 (m, 1 H), 1.79 (q, \nJ\n = 12 Hz, 2H), 1.92-1.97 (m, 2H), 2.26-2.33 (m, 1H), 3.44-3.50 (m, 1H), 3.55-3.66 (m, 2H), 3.71-3.84 (m, 2H), 3.91-4.04 (m, 2H), 4.37-4.41 (m, 1H), 4.92- 5.09 (m, 2H), 5.24-5.30 (m, 1H), 7.71(s, 2H), 7.77 (s, 3H), 7.86 (s, 1H), 8.48 (s, 2H). ESI-MS m/z: 696 [M+1]+, Retention time 1.89 min (condition A).\n\n\n \n\n\nExample 26: Synthesis of 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 25 ml round-bottom flask is charged with 1-(tetrahydro-pyran-2-yl)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (83 mg, 0.3 mmol), 1-(4-{(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidin-1-yl}-5-chloro-pyrimidin-2-yl)-piperidine-4-carboxylic acid ethyl ester (178 mg, 0.23 mmmol) under N\n2\n. Pd(PPh3)4 (57 mg, 0.05 mmol) is added promptly and the flask is recharged with N\n2\n. Then DME (1 ml), Na\n2\nCO\n3\n (1 M in H\n2\nO, 0.45 ml, 0.45 mmol) are added. The mixture is then heated to 95 degree for 2 hrs. After cooling down to rt, NalO\n4\n (140 mg, 0.72 mmol) is added into reaction mixture. Stirring is continued for 1 h to give white suspension. H\n2\nO and dichloromethane are added, and then organic layer is collected. Removal of solvent give 1-{4-[(2R,4S)-4-((3,5-bis-trifluoromethyl-benzyl)-{5-[1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amino)-2-ethyl-pyrrolidin-1-yl]-5-chloro-pyrimidin-2-yl}-piperidine-4-carboxylic acid ethyl ester which is used without further purification.\n\n\n \n \n \n \nA 25 ml round-bottom flask was charged with 1-{4-[(2R,4S)-4-((3,5-bis-trifluoromethylbenzyl)-{5-[1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amino)-2-ethyl-pyrrolidin-1-yl]-5-chloro-pyrimidin-2-yl}-piperidine-4-carboxylic acid ethyl ester (70 mg, 0.084 mmmol), 1 N HCl (0.8 ml, 0.8 mmol) and MeOH (2 ml). The mixture is then heated to 60 degree for 30 minutes. After cooling down to rt, Saturated NaHCO\n3\n and dichloromethane are added, then organic layer is collected. Removal of solvent give 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid ethyl ester and it is used for the next step without further purification.\n\n\n \n \n \n \nA 15 ml round-bottom flask is charged with 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid ethyl ester, 2N LiOH (0.4 ml, 0.8 mmol) THF (0.5 ml) and MeOH (1 ml). The mixture is then stirred at rt for 1 hour. PH is adjusted to 6 using 1 N HCl and resulted solution is extracted with EtOAc. The organic layer is dried over Na\n2\nSO\n4\n and removal of solvent, purification with reverse phase column give 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid (13 mg, 0.017 mmol, 20% for 3 steps).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.84 (t, \nJ\n = 8 Hz, 3H), 1.41-1.46 (m, 1H), 1.67-1.82 (m, 3H), 1.95-1.97 (m, 3H), 2.28-2.31 (m, 1H), 2.57-2.63 (m, 1H), 2.97-3.04 (m, 3H), 3.63 (t, \nJ\n = 8 Hz, 1H), 3.97 (dd, \nJ\n = 8 Hz, 8 Hz, 1 H), 4.37-4.40 (m, 1 H), 4.50 (d, \nJ\n = 12 Hz, 2H), 4.91-5.09 (m, 2H), 5.25-5.31 (m, 1H), 7.71 (s, 2H), 7.77 (s, 3H), 7.88 (s, 1 H), 8.47 (s, 2H). ESI-MS m/z: 724 [M+1]+, Retention time 1.87 min (condition A).\n\n\n \n\n\nExample 27: Synthesis of 1-(4-{(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-imidazol-1-yl-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidin-1-yl}-5-chloro-pyrimidin-2-yl)-piperidin-4-ol\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 15 ml round-bottom tube is charged with 1-(4-{(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidin-1-yl}-5-chloro-pyrimidin-2-yl)-piperidin-4-ol (32 mg, 0.044 mmol), imidazole (6 mg, 0.088 mmol), Cul (9 mg, 0.044 mmol), K\n2\nCO\n3\n (12 mg, 0.088 mmol), N,N-dimethyl glycine (5 mg, 0.044 mmol) and DMSO (0.5 ml). Then the tube is sealed and heated to 110 degree for 18 hours. After cooling to rt, saturated NH\n3\n/H\n2\nO, EtOAc is added and then filtered through Celite pad. The solution is extracted with EtOAc and organic layer was dried over MgSO\n4\n. Removal of solvent and purification with reverse phase column give 1-(4-{(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-imidazol-1-yl-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidin-1-yl}-5-chloro-pyrimidin-2-yl)-piperidin-4-ol (6.5 mg, 0.009 mmol, 20%).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.86 (dt, \nJ\n = 4 Hz, 8 Hz, 3H), 1.43-1.54 (m, 2H), 1.81 (q, \nJ\n = 12 Hz, 3H), 1.90-1.98 (m, 3H), 2.29-2.35 (m, 1 H), 3.44-3.50 (m, 1H), 3.56-3.60 (m, 1H), 3.63-3.69 (td, 1 H), 3.79-3.82 (m, 2H), 3.83-4.10 (m, 2H), 4.39-4.43 (m, 1 H), 4.94-5.10 (m, 2H), 5.23-5.29 (m, 1 H), 7.14 (s, 1 H), 7.24 (s, 1H), 7.70 (s, 3H), 7.80 (s, 1 H), 7.87 (s, 1H), 8.40 (s, 2H). ESI-MS m/z: 696 [M+1]+, Retention time 1.73 min (condition A).\n\n\n \n\n\nExample 28: Synthesis of 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 5 ml test tube for microwave reactor is charged with ethyl piperidine 4-carboxylate (104 ul, 0.68 mmol), benzoic acid 1-(2-{(3,5-bis-trifluoromethyl-benzyl)-[(3S,5R)-1-(2,5-dichloro-pyrimidin-4-yl)-5-ethyl-pyrrolidin-3-yl]-amino}-pyrimidin-5-yl)-piperidin-4-yl ester (110 mg, 0.17 mmol) and dioxane (1.5 ml). Then the test tube is set into microwave reactor at 140 degrees for 2 hours. After cooling to rt, reaction mixture is transferred into a 25 ml round-bottom flask and solvent is removed under evaporator. Then into the flask is added 2N LiOH (0.8 ml, 1.6 mmol) THF (2 ml) and MeOH (4 ml). The mixture is heated to 50 degree for 1 h. PH is adjusted to 6-7 using 1 N HCl and resulted solution is extracted with EtOAc. The organic layer is dried over MgSO4 and removal of solvent, purification with reverse phase column give 1-[4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid (36.6 mg, 0.048 mmol, 30% for 2 steps).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.91 (t, \nJ\n = 8 Hz, 3H), 1.62-1.72 (m, 2H), 1.75-1.81 (m, 3H), 1.91-1.96 (m, 1 H), 2.03-2.11 (m, 5H), 2.38 (br, 1 H), 2.68-2.72 (m, 1 H), 3.06-3.19 (m, 2H), 3.31-3.36 (m, 3H), 3.43-3.46 (m, 1 H), 3.53-3.56 (m, 1 H), 3.87 (br, 1 H), 3.99-4.02 (m, 1 H), 4.19-4.21 (br, 1 H), 4.35 (br, 1 H), 5.13-5.19 (m, 3H), 7.86 (s, 3H), 7.91 (s, 1 H), 8.48-8.49 (m, 2H). 2H). ESI-MS m/z: 757 [M+1]+, Retention time 1.84 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 28\n using corresponding amine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n28-1\n \n \n \n \n \n \n724\n \n1.73 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n28-2\n \n \n \n \n \n \n729\n \n1.86 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 29: Synthesis of (3,5-bis-trifluoromethyl-benzyl)-[(3S,5R)-5-ethyl-1-(2-ethyl-4-trifluoromethyl-phenyl)-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a mixture of 2-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-trifluoromethyl-benzaldehyde (120 mg, 0.17 mmol) in THF (3 mL) is added MeMgBr (0.24 mL, 0.23 mmol) in THF solution (0.97M). The reaction mixture is stirred at room temperature for 0.5 hour. After addition of saturated NH\n4\nCl \naq.\n, the mixture is extracted with EtOAc. The combined organic layer is dried over MgSO\n4\n then concentrated under reduced pressure to give 1-[2-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-trifluoromethyl-phenyl]-ethanol as a colorless oil (122 mg, quant.). ESI-MS m/z: 687 [M+1]+, Retention time 2.05 min (condition A).\n\n\n \n \n \n \nTo a mixture of 1-[2-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-5-trifluoromethyl-phenyl]-ethanol (29 mg, 0.04 mmol) in TFA (1 mL) and DCE (1 mL) is added triethylsilane (1 mL, 6.3 mmol) The reaction mixture is stirred at 80C for 4 hours. After removal of solvent and triethylsilane, the mixture is washed with brine and extracted with EtOAc. The combined organic layer is dried over MgSO\n4\n then concentrated under reduced pressure to give (3,5-bis-trifluoromethylbenzyl)-[(3S,5R)-5-ethyl-1-(2-ethyl-4-trifluoromethyl-phenyl)-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine as a colorless oil (2 mg, 7%.) after purification by silica gel column chromatography (eluent: \nn\n-hexane / EtOAc);\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.81 (t, 3H), 1.13 (t, 3H), 1.24-1.27 (m, 1H), 1.60-1.71 (m, 2H), 2.41-2.50 (m, 2H), 2.61-2.67 (m, 1H), 3.12 (t, 1H), 3.39 (dd, 1H), 3.60-3.63 (m, 1 H), 3.94 (s, 3H), 5.05 (d, 1 H), 5.08 (d, 1 H), 5.49-5.52 (m, 1 H), 7.04 (d, 1 H), 7.38 (d, 1 H), 7.52 (s, 1 H), 7.65 (s, 1 H), 7.71 (s, 2H), 7.77 (s, 1 H), 8.42 (s, 1 H). ESI-MS m/z: 672 [M+1]+, Retention time 2.38 min (condition A).\n\n\n \n\n\nExample 30: Synthesis of (3,5-bis-trifluoromethyl-benzyl)-[(3S,5R)-1-(2-bromo-4-trifluoromethyl-phenyl)-5-ethyl-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a mixture of (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl) -pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (1.40g, 6mmol) in dichloromethane (28mL) is added TFA (9 mL) at room temperature. The mixture is stirred for 0.5 hour, and diluted with dichloromethane. After addition of saturated NaHCO3 aq., the layers are separated, and the aqueous layer is extracted with dichloromethane. The combined organic layers (dried with MgSO\n4\n) are concentrated. The resulting crude (3,5-bis-trifluoromethyl-benzyl)-((3S,5R)-5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine was used in next step without purification.\n\n\n \n \n \n \nA mixture of [3,5-bis(trifluoromethyl)benzyl]-((3S,5R)-5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine (45 mg, 0.27 mmol), 2-chloro-5-trifluoromethylpyridine (196 mg, 0.81 mmol) and K\n2\nCO\n3\n (111 mg, 0.81 mmol) in THF (2.0 mL) in a sealed tube is stirred at 120 C for 2 hours. The mixture is concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: hexane / EtOAc) to give (3,5-bis-trifluoromethyl-benzyl)-[(3S,5R)-1-(2-bromo-4-trifluoromethyl-phenyl)-5-ethyl-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine as a colorless oil (36 mg, 18%).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.81 (t, 3H), 1.31-1.35 (m, 1H), 1.63-1.69 (m, 1H), 1.74 (q, 1 H), 2.40-2.43 (m, 1 H), 3.20 (dd, 1 H), 3.76-3.83 (m, 1 H), 3.88 (dd, 1H), 3.95 (s, 3H), 5.02 (d, 1 H), 5.16 (d, 2H), 5.45-5.50 (m, 1 H), 6.98 (d, 1 H), 7.46 (dd, 1 H), 7.52 (s, 1 H), 7.66 (s, 1H), 7.72 (s, 2H), 7.75 (d, 2H), 8.42 (s, 2H). ESI-MS m/z: 722 [M+1]+, Retention time 2.48 min (condition A).\n\n\n \n\n\nExample 31: Synthesis of (3,5-bis-trifluoromethyl-benzyl)-[(3S,5R)-5-ethyl-1-(5-methoxymethyl-2-piperidin-1-yl-pyrimidin-4-yl)-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of 4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-2-piperidin-1-yl-pyrimidine-5-carboxylic acid methyl ester (250mg, 0.33mmol) in 1.5 mL of THF is added LAH (24mg, 0.66 mmol). After stirred at room temperature for 3.5 hours, the reaction is quenched by Glauber's salt. The mixture is filtered on celite, and the filtrate is concentrated. The obtained residue is purified by silica gel column chromatography (eluent: hexane/EtOAc) to give [4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-2-piperidin-1-yl-pyrimidin-5-yl]-methanol (40 mg, 20% yields); ESI-MS m/z: 690 [M+1]\n+\n, Retention time 5.79min (condition B).\n\n\n \n \n \n \nTo a solution of [4-((2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-2-piperidin-1-yl-pyrimidin-5-yl]-methanol (40 mg, 0.06 mmol) and methyl iodide (0.004 mL, 0.7 mmol) in 1mL of DMF is added sodium hydride (2.8 mg, 0.07 mmol) and stirred at room temperature for 1 day. Saturated NH\n4\nCl aqueous solution is added at room temperature and then extracted twice with 50 mL of EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n and concentrated. Column chromatography (eluent: hexane/EtOAc) give (3,5-bis-trifluoromethyl-benzyl)-[(3S,5R)-5-ethyl-1-(5-methoxymethyl-2-piperidin-1-yl-pyrimidin-4-yl)-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine (15mg, 37% yields) as white solid.\n\n1H NMR (400 MHz, CDCl3)  ppm 0.84 (s, 3H), 1.45-1.70(m, 5H), 1.93-2.05(m, 2H), 1.93-2.05(s, 2H), 2.28-2.35(m, 2H), 3.10(s, 3H), 3.45-3.55(m, 1H), 3.65-3.75 (m, 4H), 3.95(s, 3H), 4.09(s, 2H), 4.13-4.23(s, 1 H), 4.33-4.45(s, 1 H), 4.99(d, 2H), 5.15-5.25(m, 1 H), 7.54(s, 1 H), 7.66(s, 1H), 7.70(s, 1H), 7.77(s, 1H), 7.82(s, 1H), 8.43(s, 2H). ESI-MS m/z: 704 [M+1]+, Retention time 4.17 min (condition B).\n\n\n \n\n\nExample 32: Synthesis of 1-[5-chloro-4-((2R,4S)-4-{[3,5-bis(trifluoromethyl)-benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-pyrimidin-2-yl]-piperidine-4-carboxylic acid\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA mixture of 3,5-bis(trifluoromethyl)benzyl-[(3S,5R)-1-(2,5-dichloro-pyrimidin-4-yl)-5-ethyl-pyrrolidin-3-yl]-[5-(1-methyl-1\nH\n-pyrazol-4-yl)-pyrimidin-2-yl]-amine (50.6 mg, 0.0784 mmol), ethyl isonipecoate (31 L, 0.196 mmol) and diisopropyl-ethylamine (21 L, 0.118 mmol) in sec-butanol (2 mL) is stirred at 120 C for 10 hour. After addition of ethyl isonipecoate (12 L, 0.0784 mmol) and diisopropyl-ethylamine (27L, 0.157 mmol), the mixture is stirred for additional 8 hours. The mixture is diluted with dichloromethane and washed with waterm 1N HCl aq, and the brine, dried over sodium sulfate and ceoncentrated in vacuo. The obtained residue is purified by silica gel column chromatography (n-hexane: AcOEt = 1:2 to 5% MeOH in AcOEt) to give (1-[5-chloro-4-((2R,4S)-4-{[3,5-bis(trifluoromethyl)-benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-pyrimidin-2-yl]-piperidine-4-carboxylic acid ethyl ester, 34.7 mg). The obtained solid is dissolved in MeOH (2.5 mL), 1N NaOH aq (225 L, 0.225 mmol) and water (0.3 mL), and the resulting mixture was stirred at room temperature for 18 hour. 1N HCl (225 L, 0.225 mmol) and then MeOH were added to the mixture and the solvent was removed by evaporation. The residue was dissolved in dichloromethane and then filtered. The filtrate was evaporated to give 1-[5-chloro-4-((2R,4S)-4-{[3,5-bis(trifluoromethyl)-benzyl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidin-1-yl)-pyrimidin-2-yl]-piperidine-4-carboxylic acid (29.2 mg, 51%).\n\n1H NMR (400 MHz, chloroform-d)  ppm: 0.84 (t, 3H), 1.38-1.50 (m, 1H), 1.61-1.80 (m, 4H), 1.90-2.01 (m, 3H), 2.24-2.34 (m, 1 H), 2.55-2.65 (m, 1H), 2.94-3.06 (m, 2H), 3.57-3.67 (m, 1 H), 3.93-4.01 (m, 1H), 3.95 (s, 3H), 4.2-4.43 (m, 1 H), 4.44-4.53 (m, 2H), 4.94 (d, 1H), 5.06 (d, 1 H), 5.22-5.33 (m, 1 H), 7.53 (s, 1 H), 7.66 (s, 1 H), 7.71 (s, 2H), 7.78 (s, 1 H), 7.88 (s, 1 H), 8.44 (s, 2H). ESI-MS m/z: 738 [M+1]+, Retention time 1.96 min (condition A).\n\n\n \n\n\nExample 33: Synthesis of 1-[4-((2S,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-methoxymethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 5 ml test tube for microwave reactor is charged with ethyl piperidine 4-carboxylate (202 mg, 1.28 mmol), (3,5-bis-trifluoromethyl-benzyl)-[(3S,5S)-1-(2,5-dichloro-pyrimidin-4-yl)-5-methoxymethyl-pyrrolidin-3-yl]-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine (170 mg, 0.26 mmol) and isopropanol (1.5 ml). Then, the test tube is set into microwave reactor at 95 degree for 2 hours. After cooling to rt, reaction mixture is transferred into a 25 ml round-bottom flask and solvent is removed under reduced pressure. Then, into the flask is added 1N NaOH (1.28 ml, 1.28 mmol). The mixture is stirred for 1 hour, and pH is adjusted to 6-7 using 1.5 N HCl. The resulted solution is extracted with EtOAc and the organic layer is dried over MgSO\n4\n. The solvent is removed under reduced pressure, and the obtained residue is purified with reverse phase column to give 1-[4-((2S,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-methoxymethyl-pyrrolidin-1-yl)-5-chloro-pyrimidin-2-yl]-piperidine-4-carboxylic acid (78 mg, 0.74 mmol, 58% for 2 steps).\n\n1H NMR (400 MHz, chloroform-d)  ppm 1.73-1.79 (m, 2H), 1.96-2.06 (m, 2H), 2.13-2.21 (m, 1 H), 2.25-2.31 (m, 1 H), 2.61-2.66 (m, 1H), 3.14-3.19 (m, 2H), 3.31 (s, 3H), 3.53-3.62 (m, 3H), 3.95 (s, 3H), 4.20-4.25 (m, 1 H), 4.43-4.49 (m, 2H), 4.70 (bs, 1 H), 4.95 (d, 1 H), 5.09 (d, 1 H), 5.34-5.38 (m, 1 H), 7.54 (s, 1 H), 7.66 (s, 1 H), 7.70 (s, 2H), 7.77 (s, 1 H), 7.90 (s, 1 H), 8.44 (s, 2H). ESI-MS m/z: 755 [M+1]+, Retention time 1.90 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of Example 33 using corresponding amine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n33-1\n \n \n \n \n \n \n663\n \n1.91 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n33-2\n \n \n \n \n \n \n744\n \n1.99 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n33-3\n \n \n \n \n \n \n717\n \n1.90 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 34: Synthesis of (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(2-methoxycarbonyl-ethyl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n(2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-((E)-2-methoxycarbonyl-vinyl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (200 mg, 0.33 mmol) is dissolved in EtOH (5 mL) and hydrogenation reaction with 10% Pd/C. The residue is purified by column chromatography on silica gel (eluent: n-hexane/EtOAc) to give (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(2-methoxycarbonyl-ethyl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (198 mg, 99%).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.80 (t, 3H), 1.44-1.49 (m, 1H), 1.60-1.68 (m, 1H), 1.90 (bs, 1H), 2.25-2.28 (m, 1H), 2.58 (t, 2H), 2.79 (t, 2H), 3.05 (t, 1H), 3.67 (s, 3H), 3.72-3.90 (m, 2H), 4.88 (s, 2H), 5.17-5.21 (1H), 7.63 (s, 2H), 7.74 (s, 1H), 8.20 (s, 2H). ESI-MS m/z: 605 [M+1]+, Retention time 2.47 min (condition A).\n\n\n \n\n\nExample 35: Synthesis of (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-hydroxy-propyl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n1.0M solution of LAH (1.7 ml, 1.7 mmol) in diethylether solution is added to (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(2-methoxycarbonyl-ethyl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (350 mg, 0.58 mmol) in diethylether (8 ml) at 0C, and this mixture is stirred for 0.5 hour at the same temperature. The reaction mixture is quenched with saturated ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with 1N HCl, sat NaHCO\n3\n aq. and brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: \nn\n-hexane/EtOAc) to give (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-hydroxy-propyl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (0.25 g, 74%).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.81 (t, 3H), 1.30 (t, 1H), 1.44-1.49 (m, 1H), 1.60-1.66 (m, 1H), 1.79-1.86 (m, 2H), 2.24-2.29 (m, 1H), 2.57 (t, 2H), 3.06 (t, 1H), 3.66-3.71 (m, 2H), 3.74-3.85 (m, 2H), 4.88 (s, 2H), 5.15-5.23 (m, 1H), 7.64 (s, 2H), 7.74 (s, 1 H), 8.20 (s, 2H). ESI-MS m/z: 577 [M+1]+, Retention time 2.33 min (condition A).\n\n\n \n\n\nExample 36: Synthesis of (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2R,4S)-4-amino-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (150 mg, 0.7 mmol) in methanol (2 mL) is added to 3,5-bis-trifluoromethyl-benzaldehyde (340 mg, 1.4 mmol), and the reaction mixture is stirred at room temperature. After stirring for overnight, sodium borohydride (53 mg, 1.4 mmol) is added. After stirring for additional 1 hour, The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure to give crude (2R,4S)-4-(3,5-bis-trifluoromethyl-benzylamino)-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (250 mg).\n\n\n \n \n \n \nA solution of the crude product (82 mg 0.18 mmol), bromonitrile (60 mg, 0.56 mmol) and sodium carbonate (59 mg, 0.56 mmol) in methanol (2 mL) is stirred at room temperature for 1 hour. The reaction mixture is quenched with saturated ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is passed through silica pad (eluent: \nn-\nhexane / EtOAc) to give crude (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-cyano-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butylester (52 mg).\n\n\n \n \n \n \nA solution of the crude (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-cyano-amino]-2-ethylpyrrolidine-1-carboxylic acid tert-butylester (52 mg, 0.11 mmol), sodium azide (72 mg, 1.11 mmol) ammmonium chloride (60 mg, 1.11 mmol) in DMF (2 mL) is stirred at 90 C for 12 hours. The reaction mixture is diluted with water after letting it cool to room temperature. The product is extracted twice with EtOAc. The combined organic layer is washed with water and brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is passed through silica pad (eluent: \nn-\nhexane / EtOAc) to give crude (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(2H-tetrazol-5-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (52 mg).\n\n\n \n \n \n \nA solution of the crude (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(2H-tetrazol-5-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (52 mg, 0.10 mmol), methyl iodide (90 mg, 0.51 mmol) and potassium carbonate (28 mg, 0.20 mmol) in DMF (1.3 mL) is stirred at 50 C for 2 hours. The reaction mixture is quenched with saturated ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: \nn-\nhexane/EtOAc) to give (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (45 mg, 44% overall yield in 4 steps).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.83 (t, 3H), 1.44 (s, 9H), 1.47-1.53 (m, 1H), 1.75-1.83 (m, 1 H), 1.95 (bs, 1 H), 2.27-2.34 (m, 1 H), 3.19 (t, 1 H), 3.73-3.75 (m, 1 H), 3.89 (bs, 1 H), 4.16 (s, 3H), 4.48-4.53 (m, 1H), 4.74 (t, 2H), 7.70 (s, 2H), 7.78 (s, 1H). ESI-MS m/z: 523 [M+1]+, Retention time 2.26 min (condition A).\n\n\n \n\n\nExample 37: Synthesis of (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-((E)-2methoxycarbonyl-vinyl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n(2R,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (300 mg, 0.5 mmol), palladium(II) acetate (15 mg,0.05 mmol), tri(o-tolyl)phosphine (36 mg, 0.1 mmol), triethylamine(0.2 mL, 1.5 mmol), and methyl acrylate (0.15 mL, 1.5 mmol) are dissolved in DMF (5 mL) and heated in a microwave at 150 C for 30 minutes. The reaction mixture is filtered through Celite with EtOAc and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: \nn-\nhexane/EtOAc) to give (2R,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-((E)-2methoxycarbonyl-vinyl)-pyrimidin-2-yl]-amino}-2-ethylpyrrolidine-1-carboxylic acid tert-butyl ester (225 mg, 75%).\n\n1H NMR (400 MHz, chloroform-d)  ppm 0.81 (t, 3H), 1.44-1.51 (m, 1H), 1.64-1.67 (m, 1H), 1.94 (bs, 1 H), 2.26-2.32 (m, 1 H), 3.10 (t, 1 H), 3.73-3.86 (m, 2H), 3.84 (s, 3H), 4.94 (t, 2H), 5.20-5.26 (m, 1 H), 6.34 (d, 1 H), 7.52 (d, 1 H), 7.62 (s, 2H), 7.77 (s, 1 H), 8.50 (s, 2H). ESI-MS m/z: 603 [M+1]+, Retention time 2.51 min (condition A).\n\n\n \n\n\nPreparation of the starting materials can be done as follows.\n\n\n\n\n\n\nExample 38: Synthesis of (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-(3,5-bis-trifluoromethyl-benzylamino)-5-ethyl-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution (2\nS\n,5\nR\n)-2-benzyl-5-ethyl-3-oxo-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (0.038 mmol; 25.1 mg) and 3,5-bis(trifluoromethyl)benzylamine (0.166 mmol; 40.4 mg) in MeOH (0.4 mL) is added titanium(IV) isopropoxide (0.1 mmol; 28.4 mg). After stirring for 6 hours, NaBH\n4\n (0.125 mmol; 4.8 mg) is added to the reaction mixture at 0 C. After stirring for 1.5 hours at room temperature, another NaBH\n4\n (0.041 mmol; 1.6 mg) is added to the mixture at the same temperature. After stirring for additional 45 minutes, H\n2\nO is added to the mixture. The mixture is filtered and concentrated under reduced pressure. Water and dichloromethane are added to the residue. The organic layer after dried is separated, concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent: \nn-\nhexane/EtOAc) to give (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-(3,5-bis-trifluoromethyl-benzylamino)-5-ethyl-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester (25.8 mg, 59%); ESI-MS \nm\n/\nz\n: 531 [M+1]\n+\n, Retention time 4.55 min (condition B).\n\n\n \n\n\nExample 39: Synthesis of (2\nS\n,3\nS\n,5\nR\n)- 2-benzyl-3-(5-bromo-pyrimidin-2-ylamino)-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of a diastereomeric mixture of (2\nS\n)-2-benzyl-5-ethyl-3-oxo-pyrrolidine-1-carboxylic acid isopropyl ester (0.29 mmol; 84 mg) and benzylamine (0.58 mmol; 62.1 mg) in MeOH (1.5 mL) is added titanium(IV) isopropoxide (0.58 mmol; 165 mg) at room temperature under nitrogen. After stirring for 5 hours, NaBH\n4\n (0.58 mmol; 22 mg) is added to the mixture at 0 C. The mixture is stirred for 2 hours at room temperature and then diluted with water and aqueous 0.1 M NaOH solution. The solution is filtered and concentrated under reduced pressure. To the residue is added water and dichloromethane. The product is extracted twice with dichloromethane. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (\nn-\nhexane/EtOAc) to give (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-benzylamino-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (61 mg, 55%); ESI-MS \nm\n/\nz\n: 381 [M\n+\n +1], Retention time 1.77 min (condition A).\n\n\n \n \n \n \nA solution of (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-benzylamino-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (0.16 mmol; 61 mg) in ethanol (5 mL) is hydrogenated over 10% palladium on carbon (6 mg) at 50 C and atmospheric pressure. After 9.5 hours, the suspension is cooled to ambient temperature and purged with nitrogen. The reaction mixture is filtered and concentrated under reduced pressure. A mixture of the obtained material (46 mg), 5-bromo-2-chloropyrimidine (0.18 mmol; 34.8 mg) and DIPEA (0.32 mmol; 41.4 mg) in DMF (0.8 mL) is stirred at 100 C for 4 hours and then at 120 C for 8.5 hours, and cooled to ambient temperature. The solution is diluted with brine and EtOAc. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (\nn-\nhexane/EtOAc) to give (2\nS\n,3\nS\n,5\nR\n)- 2-benzyl-3-(5-bromo-pyrimidin-2-ylamino)-5-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester (28.6 mg, 40% in 2 steps); ESI-MS \nm\n/\nz\n: 447 [M\n+\n +1], Retention time 2.36 min (condition A).\n\n\n \n\n\nExample 40: Synthesis of (2\nS\n,5\nR\n)-2-benzyl-5-ethyl-3-oxo-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of ((\nR\n)-2-cyano-1-ethyl-ethyl)-carbamic acid \ntert\n-butyl ester (10 mmol; 1.98 g) in Et\n2\nO (50 mL) is slowly added a 0.97 M \nn-\nhexane solution (40 mmol; 41 mL) of DIBAL under nitrogen at -78 C. The reaction mixture is warmed to -40 C and stirred for an additional 3.5 hours. Another 1.00 M \nn\n-hexane solution (30 mmol; 30 mL) of DIBAL is added to the suspension at the same temperature. After stirring for additional 1.5 hours, the solution is quenched by careful addition of 1 ml of MeOH then immediately poured into 25 ml of saturated aqueous ammonium chloride solution in a separatory funnel. Shake mixture and leave until it reaches room temperature. Aqueous 1M HCl is added to reach a pH of 3-4. The solution is extracted three times with EtOAc and the combined organic layer is washed with an aqueous 1M HCl/brine (1:1) solution and twice with a saturated aqueous NaHCO3/brine (1:1) solution, dried over Na\n2\nSO\n4\n, filtered and concentrated under reduced pressure and purified by column chromatography on silica gel (eluent; \nn-\nhexane/EtOAc) to give ((\nR\n)-1-ethyl-3-oxo-propyl)-carbamic acid \ntert\n-butyl ester (590mg, 29%); ESI-MS \nm\n/\nz\n: 146 [M\n+\n -tBu+2], Retention time 2.17 min (condition A).\n\n\n \n \n \n \nTo a solution of ((\nR\n)-1-ethyl-3-oxo-propyl)carbamic acid \ntert\n-butyl ester (2.9 mmol; 584 mg) in THF (20 mL) is added a 1.44 M THF solution (11.6 mmol; 8.1 mL) of vinylmagnesium chloride under nitrogen at -78 C. After stirring for 30 minutes, the reaction mixture is warmed to room temperature and stirred for an additional 1.5 hours. Another 1.44 M THF solution (2.9 mmol; 2 mL) of vinylmagnesium chloride is added to the reaction mixture at room temperature. After stirring for additional 15 minutes, the solution is quenched by saturated aqueous ammonium chloride solution and extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent; \nn-\nhexane/EtOAc) to give ((1\nR\n,3\nS\n)-1-ethyl-3-hydroxy-pent-4-enyl)-carbamic acid \ntert-\nbutyl ester (130mg, 20%); ESI-MS \nm\n/\nz\n: 174 [M\n+\n -tBu+2], Retention time 4.13 min (condition B).\n\n\n \n \n \n \nTo a solution of ((1\nR\n,3\nS\n)-1-ethyl-3-hydroxy-pent-4-enyl)-carbamic acid \ntert\n-butyl ester (0.541 mmol; 124 mg) and imidazole (2.164 mmol; 147 mg) in DMF (1.8 mL) is added \ntert\nbutyldimethylsilyl chloride (1.623 mmol; 245 mg) at room temperature under N\n2\n. After 12hours, the reaction mixture is quenched with water, extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent; \nn-\nhexane/EtOAc) to give [(1\nR\n,3\nS\n)-3-(\ntert-\nbutyl-dimethyl-silanyloxy)-1-ethyl-pent-4-enyl]-carbamic acid \ntert\n-butyl ester (160 mg, 86%); ESI-MS \nm\n/\nz\n: 288 [M\n+\n -tBu+2], Retention time 5.77 min (condition B).\n\n\n \n \n \n \ngive [(1\nR\n,3\nS\n)-3-(\ntert-\nbutyl-dimethyl-silanyloxy)-1-ethyl-pent-4-enyl]-carbamic acid \ntert-\nbutyl ester (0.38 mmol; 138 mg), palladium(II) acetate (0.038 mmol; 8.5 mg), (Oxidi-2,1-phenylene)bis(diphenylphosphine) (0.076 mmol; 41 mg), bromobenzene (0.57 mmol; 89 mg), and Cs\n2\nCO\n3\n (1.14 mmol; 371 mg) are dissolved in 1,4-dioxane (1.9 mL) at room temperature. The mixture is stirred at 100 C for 15 hours, and cooled to room temperature. To the mixture is added saturated aqueous ammonium chloride solution and the solution is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography to give (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-(\ntert-\nbutyldimethyl-silanyloxy)-5-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (102 mg, 64%); ESI-MS \nm\n/\nz\n: 364 [M\n+\n -tBu+2] Retention time 6.22 min (condition B).\n\n\n \n \n \n \nTo a solution of (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-3-(\ntert-\nbutyl-dimethyl-silanyloxy)-5-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (0.243 mmol; 102 mg) in THF is added 1.0 M THF solution (0.36 mL) of tetra-\nn-\nbutylammonium fluoride under nitrogen at room temperature. After 3 hours, The reaction mixture is quenched with saturated aqueous ammonium chloride solution, extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent; \nn-\nhexane/EtOAc) to give (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-5-ethyl-3-hydroxy-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (74.4 mg, 99%); ESI-MS \nm\n/\nz\n: 250 [M\n+\n -tBu+2], Retention time 2.34 min (condition A).\n\n\n \n \n \n \nTo a solution of (2\nS\n,3\nS\n,5\nR\n)-2-benzyl-5-ethyl-3-hydroxy-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester (0.138 mmol; 42 mg) in dichloromethane (1.4 mL) is added Dess-Martin periodinane (0.166 mmol; 70.4 mg) at 0 C. The mixture is stirred at the same temperature for 1.5 hours. To the mixture, brine and EtOAc are added. The organic layer is separated, washed with saturated aqueous Na\n2\nS\n2\nO\n3\n solution, dried over Na\n2\nSO\n4\n, filtered, concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (eluent; \nn-\nhexane/EtOAc) to give (2\nS\n,5\nR\n)-2-benzyl-5-ethyl-3-oxo-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (29.8 mg, 71%); ESI-MS \nm\n/\nz\n: 248 [M\n+\n -tBu+2], Retention time 2.49 min (condition A).\n\n\n \n\n\nExample 41: Synthesis of diastereomers of (2\nS\n)-2-benzyl-5-ethyl-3-oxo-pyrrolidine-1-carboxylic acid isopropyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (\nR\n)-2-cyano-1-ethylethylammonium methanesulfonate (50 mmol; 9.72 g) and DIPEA (105 mmol; 13.6 g) in dichloromethane (100 mL) is added isopropyl chloroformate (52.5 mmol; 6.43 g) at 0 C. The solution is warmed to room temperature and stirred for 4 hours. The reaction mixture is quenched with brine and extracted with dichloromethane. The organic layer is washed with aqueous 0.1 M HCl, saturated aqueous NaHCO\n3\n solution and then brine, dried over MgSO\n4\n, filtered concentrated under reduced pressure to give ((\nR\n)-2-cyano-1-ethyl-ethyl)-carbamic acid isopropyl ester (8.75 g, 95%); ESI-MS \nm\n/\nz\n: 185 [M\n+\n +1], Retention time 1.60 min (condition A).\n\n\n \n \n \n \nTo a suspension of ((\nR\n)-2-cyano-1-ethyl-ethyl)-carbamic acid isopropyl ester (20 mmol; 3.68 g) and sodium hydride (60% dispersion in mineral oil, 40 mmol; 1.60g) in THF (80 mL) is added chloromethyl methyl ether at 0 C. The reaction mixture is stirred at room temperature for 15 hours. The reaction mixture is quenched with brine and saturated aqueous ammonium chloride solution, and extracted three times with Et\n2\nO. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, concentrated under reduced pressure. To a solution of the obtained residue (5.75 g) in Et\n2\nO (200 ml) is added 1.0 M \nn-\nhexane solution of DIBAL (25 mmol; 25 ml) dropwise over 10 minutes at -78 C under N\n2\n. The solution is stirred for 1 hour at the same temperature, then warmed to -60 C for 3 hours. Another 15 mL of DIBAL (1.0 M in \nn-\nhexane) is added after 18.5 hours. After stirring for additional 2 hours, the reaction mixture is quenched by careful addition of 2 ml of MeOH then immediately poured on saturated aqueous ammonium chloride solution in a separatory funnel. Shake the mixture and leave until it reaches room temperature. Aqueous 1M HCl is added to reach a pH of 2. The solution is extracted three times with Et\n2\nO and the combined organic layer is washed with aqueous 1M HCl/brine (1:1) solution and saturated aqueous NaHCO\n3\n/brine (1:1) solution, dried over Na\n2\nSO\n4\n, filtered and concentrated under reduced pressure. To a solution of the obtained residue (4.27 g) in THF (87 ml) is added 1.44 M THF solution (19 mmol; 13.2 mL) of vinylmagnesium chloride under N\n2\n at -78 C. After stirring for 1.5 hours, another 1.44 M THF solution (38 mmol; 26.4 ml) of vinylmagnesium chloride is added in 1.5 hours to the reaction mixture at the same temperature. After stirring for additional 1 hour, another 1.44 M THF solution (19 mmol; 13.2 mL) of vinylmagnesium chloride is added to the reaction mixture at room temperature. The solution is quenched by water, saturated aqueous ammonium chloride solution, aqueous 0.1 M HCl and then aqueous 1 M HCl, and extracted twice with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. To a solution of the obtained residue (4.44 g) and imidazole (42.5 mmol; 2.89 g) in DMF (50 mL) is added chloro \ntert\n-butyldiphenylchlorosilane (34 mmol; 9.35 g) at room temperature under nitrogen. After stirring for 2 hours at 60 C, the reaction is cooled down to ambient temperature, then quenched with saturated aqueous ammonium chloride solution and extracted twice with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. A mixture of the obtained residue (13.4 g), acetic acid (100 mL) and water (20 mL) is stirred at 60 C for 3 hours. The mixture is concentrated under reduced pressure and then diluted with Et\n2\nO and aqueous sodium hydroxide solution. The product is extracted three times with Et2O. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (\nn-\nhexane/EtOAc) to give [(1\nR\n)-3-(\ntert\n-butyl-diphenyl-silanyloxy)-1-ethyl-pent-4-enyl]-carbamic acid isopropyl ester (3.43 g, 42% in 5 steps) as a diastereomeric mixture; ESI-MS \nm\n/\nz\n: 454 [M\n+\n +1], Retention time 5.51 min (condition C).\n\n\n \n \n \n \nDiastereomeric mixture of [(1\nR\n)-3-(\ntert-\nbutyl-diphenyl-silanyloxy)-1-ethyl-pent-4-enyl]-carbamic acid isopropyl ester (1.54 mmol; 840 mg), palladium(II) acetate (0.154 mmol; 34.5 mg), 1,4-bis(diphenylphosphino)butane (0.308 mmol; 131 mg), bromobenzene (2.31 mmol; 363 mg), Cs\n2\nCO\n3\n (4.62 mmol; 1.51 g) are dissolved in 1,4-dioxane (7.7 ml) at room temperature. The mixture is stirred at 100 C for 28 hours, and cooled to ambient temperature. To the mixture is added water and the product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (\nn-\nhexane/EtOAc) to give the desired product. To a solution of the obtained product in THF (15 mL) is added a 1.0 M THF solution of tetrabutylammonium fluoride (1.5 mL) under N\n2\n. The mixture is stirred for 13 hours at room temperature and quenched with saturated aqueous ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. To a solution of the residue in dichloromethane (15 mL) is added Dess-Martin periodinane (1.54 mmol; 653 mg) at 0 C. After stirring for 1 hour at the same temperature, the reaction mixture is stirred at room temperature for 1 hour. To the mixture, another portion of Dess-Martin periodinane (3.08 mmol; 1.31 g) is added in 2 hours. The mixture is stirred for additional 2 hours, and then quenched with brine. The product is extracted twice with EtOAc. The combined organic layer is washed with saturated aqueous Na\n2\nS\n2\nO\n3\n solution and brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (\nn-\nhexane/EtOAc). The product fractions are collected and washed with saturated aqueous Na\n2\nS\n2\nO\n3\n solution, saturated aqueous NaHCO\n3\n solution and brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure to give (2\nS\n)-2-benzyl-5-ethyl-3-oxo-pyrrolidine-1-carboxylic acid isopropyl ester (84 mg, 19% in 3 steps) as a diastereomeric mixture (cis/trans = 71:29); ESI-MS \nm\n/\nz\n: 290 [M\n+\n +1], Retention time 2.12 min (condition A).\n\n\n \n\n\nExample 42:\n\n\n\n\n \n \n \nThe following compounds are prepared following the procedure of \nExample 7.\n\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nAlcohol\n \nStarting Material\n \n \n \n \n42-1\n \n \n \n \n \n \n683\n \n2.26 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 43\n\n\n\n\n \n \n \nThe following compounds are prepared following the procedure of Example 16 using corresponding amines.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nAmine\n \nStarting Material\n \n \n \n \n43-1\n \n \n \n \n \n \n628\n \n4.17 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n43-2\n \n \n \n \n \n \n696\n \n4.22 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n43-3\n \n \n \n \n \n \n640\n \n2.01 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 44: Synthesis of (3,5-bis-trifluoromethyl-benzyl)-((3\nS\n,5\nR\n)-5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nR\n,4\nS\n)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester (1.2 g, 2 mmol) in CH\n2\nCl\n2\n (20 mL) is added trifluoroacetic acid (7 mL) at room temperature. The reaction mixture is stirred at room temperature for 1.5 hours. The mixture is quenched with saturated aqueous NaHCO\n3\n solution, then extracted with CH\n2\nCl\n2\n. The combined organic layer is washed by saturated aqueous NaHCO\n3\n solution, then dried over Na\n2\nSO\n4\n and concentrated under reduced pressure to give (3,5-bis-trifluoromethyl-benzyl)-((3\nS\n,5\nR\n)-5-ethyl-pyrrolidin-3-yl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine as a yellow oil (1.01 g, quant.). ESI-MS m/z: 499 [M+1]+, Retention time 1.84 min (condition A).\n\n\n \n\n\nExample 45: Synthesis of (2\nR\n,4\nS\n)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of (2\nS\n,4\nR\n)-4-benzyloxy-pyrrolidine-1,2-dicarboxylic acid 1-\ntert\n-butyl ester (77.8 mmol; 25.0 g) in THF (135 mL) is added 0.93 M THF solution of borane THF complex (116.7 mmol; 125 mL) at 0 C under nitrogen. The solution is stirred for 1.5 hours at room temperature, quenched by dropwise addition of 40 ml of MeOH. After concentrating, the mixture is diluted with 400 ml of dichloromethane and 250 ml of saturated aqueous ammonium chloride solution. The product is extracted twice with 100 ml of dichloromethane. The combined organic layer is washed with 250 ml of brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure to give the crude product (24.3 g).\n\n\n \n \n \n \nTo a solution of the crude product (24.3 g) and triethylamine (97.3 mmol; 9.85 g) in Et\n2\nO (260 ml) is added MsCl (85.6 mmol; 9.81 g) at 0 C under nitrogen. The reaction mixture is stirred for 13 hours and filtered. The filter cake is washed with additional Et\n2\nO (250 mL). The filtrate is washed with 200ml of a saturated aqueous ammonium chloride solution and 100 ml of brine, dried over MgSO\n4\n, filtered, and concentrated under reduced pressure to give the crude product (29.8 g).\n\n\n \n \n \n \nTo a suspension of Cu (163 mmol; 31.0 g) in Et\n2\nO (100 mL) is slowly added 1.09 M Et\n2\nO solution of MeLi (300 mL) at 0 C under nitrogen to give a clear solution. After stirring for 30 minutes, to the clear solution is slowly added a solution of the crude product (29.8 g) in Et\n2\nO (100 mL) at 0 C. The reaction mixture is stirred for 3 hours at the same temperature, quenched with 800 mL of a saturated ammonium chloride solution. The product is extracted twice with 500 ml of Et\n2\nO. The combined organic layer is washed with 400 ml of brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn-\nhexane / EtOAc) to give (2\nR\n,4\nR\n)-4-benzyloxy-2-ethyl-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester (8.91 g, 37 % in 3 steps).\n\n\n \n \n \n \nIn a flask purged with ammonia gas, about 150 mL of liquid ammonia is collected with ammonia condenser at -78 C. To the liquid ammonia is added portion wise lithium metal (116 mmol; 805 mg) at the same temperature. To the deep blue solution is added a solution of (2\nR\n,4\nR\n)-4-benzyloxy-2-ethyl-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester (29.1 mmol; 8.90 g) and \ntert\n-butanol (58.2 mmol; 4.31 g) in THF (30 mL). After stirring for 2 hours, the reaction mixture is quenched with MeOH, and then warmed to ambient temperature. The mixture is diluted with water, then aqueous 1M HCl is added to reach pH 8-9. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure to give (2\nR\n,4\nR\n)-4-hydroxy-2-ethylpyrrolidine-1-carboxylic acid \ntert-\nbutyl ester (6.25 g, 99.8%).\n\n\n \n \n \n \nTo a solution of (2\nR\n,4\nR\n)-4-hydroxy-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (21.5 mmol; 4.63 g) and Et\n3\nN (32.3 mmol; 3.27 g) in dichloromethane (86 mL) is added MsCl (30.1 mmol; 3.45 g) at room temperature. The reaction mixture is stirred for 4 hours, and then quenched with saturated aqueous NaHCO\n3\n solution. The product is extracted three times with dichloromethane. The combined organic layer is washed with saturated aqueous ammonium chloride and then brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure to give the crude product.\n\n\n \n \n \n \nTo a solution of the crude product in DMF (86 ml) is added sodium azide (30.1 mmol; 1.96 g) under nitrogen at room temperature. After stirring for 6 hours at 90 C, the reaction mixture is cooled to ambient temperature, then quenched with saturated ammonium chloride solution. The product is extracted twice with EtOAc. The combined organic layer is washed twice with aqueous 0.1 M HCl and then once with brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure to give the crude product.\n\n\n \n \n \n \nA suspension of the crude product and magnesium metal (107.5 mmol; 2.61 g) in MeOH (43 mL) is stirred for 7 hours. The suspension is filtered and concentrated. To the residue are added EtOAc and brine. The product is extracted twice with EtOAc. The combined organic layer is washed with brine, dried over K\n2\nCO\n3\n, filtered, concentrated under reduced pressure to give the crude product.\n\n\n \n \n \n \nA solution of the crude product, 5-bromo-2-chloropyrimidine (25.8 mmol; 4.99 g) and N,N-diisopropylethylamine (43.0 mmol; 5.56 g) in DMF (72 mL) is stirred at 120 C for 2 hours. The reaction mixture is cooled to ambient temperature, and then quenched with saturated ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn-\nhexane / EtOAc) to give (2\nR\n,4\nS\n)-4-(5-bromo-pyrimidin-2-ylamino)-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (5.56 g, 70 % in 4 steps).\n\n\n \n \n \n \nA mixture of (2\nR\n,4\nS\n)-4-(5-bromo-pyrimidin-2-ylamino)-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (13.0 mmol; 4.84 g), 3,5-bis(trifluoromethyl)benzyl bromide (26.0 mmol; 7.98 g) and sodium hydride (60% dispersion in mineral oil, 39.0 mmol; 1.56 g) in DMF (52 mL) is stirred for 1.5 hours at room temperature under nitrogen. The reaction mixture is quenched with water then saturated ammonium chloride solution. The product is extracted twice with EtOAc. The combined organic layer is washed with brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn-\nhexane / EtOAc) to give (2\nR\n,4\nS\n)-4-[(3,5-bis-trifluoromethyl -benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (5.57 g, 72%).\n\n\n \n\n\nExample 46:\n\n\n\n\n \n \n \nThe following compounds are prepared following the procedure of \nExample 6\n using corresponding chloroformates.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n46-1\n \n \n \n \n \n \n664\n \n5.07 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 47\n\n\n\n\nPreparation of amines (for Example 16 and 43) and alcohols (for Example 7 and 9)\n\n\n\n\nExample 47-1: 4-Hydroxy-2,2-dimethylbutyric acid ethyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA mixture of dihydro-3,3-dimethyl-2(3\nH\n)-furanone (10 mmol; 1.14 g), aqueous 1 M KOH solution (10 mmol) and one drop of phenolphthalein indicator (0.5% w/v in EtOH/water (1:1)) is stirred at 105 C for 3.5 hours. The mixture is cooled to ambient temperature and concentration under reduced pressure. To the residue is added 10 mL of EtOH. To the solution is added 50 ml of Et\n2\nO, and the solid isolated by filtration and dried under 100 mbar at 50 C to give potassium 4-hydroxy-2,2-dimethylbutyrate (1.21 g, 71 %).\n\n\n1\nH NMR (400 MHz, \nd\n6\n \n DMSO)  ppm 0.96 (s, 6 H), 1.47 (t, \nJ =\n 5.54 Hz, 2 H), 3.43 (t, \nJ =\n 5.54 Hz, 2 H)\n\n\n \n \n \n \nTo a solution of potassium 4-hydroxy-2,2-dimethylbutyrate (1.92 mmol; 327 mg) in DMF (6 mL) is added ethyl iodide (2.30 mmol; 359 mg). The reaction mixture is stirred for 2 hours, and quenched with saturated ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with aqueous 0.1 M HCl then brine, dried over Na\n2\nSO4, filtered, concentrated under reduced pressure to give 4-Hydroxy-2,2-dimethylbutyric acid ethyl ester (520 mg) contaminated with DMF.\n\n1H NMR (400 MHz, CHLOROFORM-d)  ppm 1.22 (s, 6 H) 1.26 (t, \nJ\n = 7.06 Hz, 3 H) 1.82-1.85 (m, 2 H) 1.91 (brs, 1 H) 3.69 (t, \nJ\n = 6.55 Hz, 2 H) 4.13 (q, \nJ\n = 7.06 Hz, 2 H)\n\n\n \n\n\nExample 47-2: \ntrans\n-3-hydroxy-cyclobutanecarboxylic acid methyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of cis-trans mixture of 3-hydroxy-cyclobutanecarboxylic acid methyl ester (1.30 g, 10 mmol) in DMF 13 mL is added NaH (50% in oil, 720 mg, 15 mmol) at 0 C. After stirring at 0 C for 15 minutes, benzyl bromide (1.43 ml, 12 mmol) is added at 0 C. The mixture is stirred at room temperature for 2 hours and quenched with H2O. The solution is extracted with EtOAc. The organic layer is washed with H2O and brine, dried over MgSO4 and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (eluent; hexane / EtOAc) to give trans-3-benzyloxy-cyclobutanecarboxylic acid methyl ester (340 mg, 15.4%). TLC (hexane/EtOAc, 5:1) Rf 0.40. 1 H NMR (400 MHz, chloroform-d)  ppm 2.26-2.34 (m, 2H), 2.48-2.52 (m, 2H), 3.02-3.06 (m, 1 H), 3.69 (s, 3H), 4.26-4.33 (m, 1 H), 4.42 (s, 2H), 7.27-7.35 (m, 5H).\n\n\n \n \n \n \nA solution of \ntrans-\n3-benzyloxy-cyclobutanecarboxylic acid methyl ester (680 mg, 3.09 mmol) as 0.05 M solution in MeOH is pumped through the H-Cube\n\n flow hydrogenator fitted with a 10 mol% Pd/C catalyst cartridge heated to 40 C at 10 bar. The flow rate is set at 1 ml/min. The solvent is removed under reduced pressure to give trans-3-hydroxy-cyclobutanecarboxylic acid methyl ester (380 mg, 94.5%); TLC (hexane/EtOAc, 1:1) Rf 0.38. 1H NMR (400 MHz, chloroform-d)  ppm 2.18-2.25 (m, 2H), 2.55-2.61 (m, 2H), 3.01-3.08 (m, 1H), 3.70 (s, 3H), 4.53-4.61 (m, 1 H).\n\n\n \n\n\nExample 47-3: \ntrans\n-3-hydroxy-cyclobutanecarboxylic acid methyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of cis-trans mixture of 3-hydroxy-cyclobutanecarboxylic acid methyl ester (1.30 g, 10 mmol) in DMF (13 mL) is added 50% NaH (720 mg, 15 mmol) at 0 C. After stirring at 0 C for 15 min, benzyl bromide (1.43 ml, 12 mmol) is added at 0 C. The mixture is stirred at room temperature for 2 hours, and quenched with H\n2\nO. The solution is extracted with EtOAc. The organic layer is washed with H\n2\nO and brine, dried over MgSO\n4\n and concentrated under reduced pressure. The residue is purified by silica gel column chromatography to give \ntrans-\n3-benzyloxy-cyclobutanecarboxylic acid methyl ester (750 mg, 34.1 %); TLC (hexane/EtOAc, 5:1) R\nf\n 0.35.\n\n1H NMR (400 MHz, chloroform-d)  ppm 2.22-2.30 (m, 2H), 2.45-2.52 (m, 2H), 2.58-2.67 (m, 1 H), 3.68 (s, 3H), 3.92-3.99 (m, 1 H), 4.43 (s, 2H), 7.26-7.36 (m, 5H).\n\n\n \n \n \n \nA solution of \ntrans-\n3-benzyloxy-cyclobutanecarboxylic acid methyl ester (730 mg, 3.32 mmol) as a 0.05 M solution in MeOH is pumped through the H-Cube flow hydrogenator fitted with a 10 mol% Pd/C catalyst cartridge heated to 40 C at 10 bar. The flow rate was set at 1 ml/min. The solvent is removed under reduced pressure to give trans 3-hydroxy-cyclobutanecarboxylic acid methyl ester (400 mg, 92.7%); TLC (hexane/AcOEt, 1:1) R\nf\n 0.38. 1H NMR (400 MHz, chloroform-d)  ppm 2.14-2.22 (m, 2H), 2.56-2.64 (m, 3H), 3.69 (s, 3H), 4.16-4.23 (m, 1 H).\n\n\n \n\n\nExample 47-4: 4-Hydroxymethyl-cyclohexanecarboxylic acid methyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a slurry of NaH (440 mg, 11 mmol) in THF(22 mL) is added \ntrans-\n1,4-cyclohexanedimethanol (1.44 g, 10 mmol) at 0C, and the mixture is stirred for 1h while warming to room temperature. Benzyl bromide (1.2 mL, 10 mmol) is added dropwise followed by tetrabutylammonium iodide (185 mg, 0.5 mmol). The reaction is heated to 60C for 15hours. After cooling to room temperature, H\n2\nO is added and the aqueous layer is extracted with EtOAc. The combined organic layer (dried with MgSO\n4\n) is concentrated. The desired product, (4-benzyloxymethyl-cyclohexyl)-methanol, is obtained (1.40g, 60%) after purification using silica gel column chromatography (eluent: EtOAc / hexane).\n\n\n \n \n \n \nTo a mixture of (4-benzyloxymethyl-cyclohexyl)-methanol (1.40 g, 6 mmol) in dichloromethane (28 mL) is added Dess-Marin reagent (2.53 g, 6 mmol) at 0C, and the mixture is stirred for 0.5 hour while warming to room temperature. After addition of saturated aqueous NaHCO\n3\n, the aqueous layer is extracted with EtOAc. The combined organic layer (dried with MgSO\n4\n) is concentrated. The desired product, 4-benzyloxymethyl-cyclohexanecarbaldehyde, is obtained (1.07 g, 79%) after purification using silica gel column chromatography (eluent: EtOAc / hexane).\n\n\n \n \n \n \n4-Benzyloxymethyl-cyclohexanecarbaldehyde (1.70 g, 2.0 mmol) is dissolved in acetic acid (0.24 mL) and 2 mL of MeOH. The reaction mixture is cooled to 0-5C and stirred while 10% NaOCl solution (2.5 mL, 4 mmol) is added dropwise over 20 minutes. The cooling bath is removed and the mixture is allowed to come to room temperature. After addition of saturated aqueous NaHCO\n3\n, the aqueous layer is extracted with EtOAc. The combined organic layer (dried with MgSO\n4\n) is concentrated. The desired product, 4-benzyloxymethyl-cyclohexanecarboxylic acid methyl ester, is obtained (343 mg, 65%) after purification using silicagel column chromatography (eluent: EtOAc / hexane).\n\n\n \n \n \n \n4-Benzyloxymethyl-cyclohexanecarboxylic acid methyl ester (340 mg, 1.30 mmol) is dissolved in MeOH (15 mL). In the presence of catalytic amount of 10% Pd/C, the reaction mixture is stirred for 3 hours under H\n2\n (10 bar). After removal of 10% Pd/C, solvent is evaporated. The desired product, 4-hydroxymethyl-cyclohexanecarboxylic acid methyl ester, is obtained (160 mg, 72%) after purification using silica gel column chromatography (eluent: EtOAc / hexane).\n\n\n1\nH-NMR (400MHz, CDCl\n3\n),  (ppm): 0.99 (m, 2H), 1.47 (m, 3H), 1.88 (m, 2H), 2.02 (m, 2H), 2.23 (m, 1H), 3.46 (d, 2H), 3.66 (s, 3H).\n\n\n \n\n\nExample 47-5: 1-Hydroxymethyl-cyclopentanecarboxylic acid methyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of malonic acid dimethyl ester (5.28 g, 40 mmol) in DMF (100 mL), 1,4-dibromo-butane (5.26 mL, 44 mmol), K\n2\nCO\n3\n (13.8 g, 100 mmol), 1-butyl-3-methylimidazolium tetrafluoroborate (0.904 g, 4.0 mmol) are added at room temperature. The mixture is stirred at room temperature for 15 hours. To the mixture, water is added and the solution is extracted with EtOAc. The organic layer is washed with H\n2\nO and brine, dried over MgSO\n4\n, and concentrated under reduced pressure. The residue is purified by silica gel column chromatography to give cyclopentane-1,1-dicarboxylic acid dimethyl ester (6.13 g, 82%); TLC (hexane/AcOEt, 5:1) Rf 0.48.\n\n1H NMR (400 MHz, chloroform-d)  ppm 1.67-1.71 (m, 4H), 2.17-2.21 (m, 4H), 3.72 (s, 6H).\n\n\n \n \n \n \nTo a solution of cyclopentane-1,1-dicarboxylic acid dimethyl ester (4.0 g, 21.5 mmol) in MeOH (25 mL) is added potassium hydroxide (1.32 g, 23.7 mmol). The mixture is stirred at room temperature for 15 hours and concentrated under reduced pressure. To the obtained residue, aqueous 1 M HCl (50 mL) is added and the solution is extracted with EtOAc. The organic layer is washed with H2O, dried over Na2SO4, and concentrated under reduced pressure to give cyclopentane-1,1-dicarboxylic acid methyl ester (3.72 g, quant.); TLC (dichloromethane / MeOH, 10:1) Rf 0.25.\n\n1 H NMR (400 MHz, chloroform-d)  ppm 1.67-1.74 (m, 4H), 2.17-2.25 (m, 4H), 3.75 (s, 3H).\n\n\n \n \n \n \nTo a solution of cyclopentane-1,1- dicarboxylic acid methyl ester (1.00 g, 5.81 mmol) and triethylamine (808 uL, 5.81 mmol) in THF (15 mL) is added isobutyl chloroformate (750 uL, 5.81 mmol) at 0 C. The mixture is stirred at 0 C for 20 minutes. The mixture is filtrated, and the filtrate is added to a suspension of NaBH4 (242 mg) in THF (15 mL) at 0 C. The mixture is stirred at 0 C for 3 hours and at room temperature for 12 hours. To the mixture, H2O is added and the mixture is extracted with EtOAc. The organic layer is dried over MgSO4, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography to give 1-hydroxymethyl-cyclopentanecarboxylic acid methyl ester (433 mg, 47%); TLC (hexane / EtOAc, 1:1) Rf 0.43.\n\n1H NMR (400 MHz, chloroform-d)  ppm 1.61-1.77 (m, 6H), 1.93-2.00 (m, 2H), 2.53 (m, 1H), 3.57 (d, 2H), 3.72 (s, 3H).\n\n\n \n\n\nExample 47-6: \ntrans\n-4-(aminomethyl)cyclohexanecarboxylic acid methyl ester hydrochloride\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of \ntrans-\n4-aminomethyl-1-cyclohexanecarboxylic acid (10 mmol, 1.57 g) in methanol (10 mL) is added of thionyl chloride (12 mmol, 0.88 mL) at 0C. The mixture is stirred at room temperature for 24 hours and then concentrated under reduced pressure. The residue is washed with hexane to obtain 1.9 g (92%) of \ntrans\n-4-(aminomethyl) cyclohexanecarboxylic acid methyl ester hydrochloride as white solid. ESI-MS m/z: 172 [M+1]\n+\n, Retention time 2.12 min (condition B).\n\n\n \n\n\nExample 47-7: (\nS\n)-Piperidine-2-carboxylic acid methyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a mixture of (\nS\n)-piperidine-2-carboxylic acid (10 mmol, 1.29 g) in MeOH (20 mL) is dropwise added thionyl chloride (30 mmol, 2.17 mL) at room temperature. The mixture is stirred at 2 hours, and then concentrated under reduced pressure. To the residue is added water (5 mL) and basified with potassium carbonate. The mixture is extracted with CH\n2\nCl\n2\n. The combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure to give (\nS\n)-piperidine-2-carboxylic acid methyl ester as a pale brown oil (800 mg, 56%).\n\n1 H NMR (400 MHz, CHLOROFORM\n-d\n)  ppm 1.40 - 1.61 (m, 4 H) 1.74 - 1.85 (m, 1 H) 1.92 - 2.01 (m, 1 H) 2.62 - 2.71 (m, 1 H) 3.05 - 3.11 (m, 1 H) 3.37 (dd, \nJ=\n9.73, 3.16 Hz, 1 H) 3.64 (s, 1 H) 3.72 (s, 3 H).\n\n\n \n\n\nExample 47-8: \ntrans\n-4-aminocyclohexanecarboxylic acid methyl ester hydrochloride\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of \ntrans-\n4-aminocyclohexanecarboxylic acid (20 mmol, 2.86 g) in methanol (20 mL) is added thionyl chloride (24 mmol, 1.76 mL) at 0C. The mixture is stirred at room temperature for 12 hours then concentrated under reduced pressure. The residue is washed with hexane to obtain 3.5 g (90%) of \ntrans-\n4-aminocyclohexanecarboxylic acid methyl ester hydrochloride as white solid. ESI-MS m/z: 157 [M+1]\n+\n, Retention time 0.77 min (condition B).\n\n\n \n\n\nExample 47-9: \ntrans\n-4-(methylamino)cyclohexanecarboxylic acid methyl ester hydrochloride\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of \ntrans-\n4-aminocyclohexanecarboxylic acid methyl ester hydrochloride (10 mmol, 1.94 g) in THF (30 mL) are added triethylamine (22 mmol, 3.1 mL) and di-\ntert-\nbutyl dicarbonate (11 mmol, 2.4 g) at room temperature. The mixture is stirred at room temperature for 5 hours, poured into a saturated aqueous ammonium chloride, then extracted with ethyl acetate. The combined organic phase is washed with water and brine, dried over anhydrous Na\n2\nSO\n4\n and concentrated under reduced pressure to obtain 2.6 g (quantitative) of \ntrans-\n4-(\ntert-\nbutoxycarbonylamino)cyclohexanecarboxylic acid methyl ester as white solid. ESI-MS m/z: 258 [M+1]\n+\n, Retention time 3.16 min (condition B).\n\n\n \n \n \n \nTo a solution of \ntrans\n-4-(\ntert\n-butoxycarbonylamino)cyclohexane carboxylic acid methyl ester (5 mmol, 1.3 g) in dimethylformamide (15 mL) is cooled to 0C and treated with of sodium hydride (60% in oil, 6 mmol, 240mg) over 30 minutes. The mixture is stirred at room temperature for 1 hour, then cooled to 0C and treated with iodomethane (6 mmol, 0.38 mL). After stirring overnight at room temperature, the mixture is poured into a saturated aqueous ammonium chloride and extracted with ethyl acetate. The combined organic phase is washed with water and brine, dried over anhydrous Na\n2\nSO\n4\n and concentrated under reduced pressure. The obtained residue is purified by column chromatography on silica gel (eluent: n-hexane-ethyl acetate 10:1) to obtain 1.3 g (96%) of \ntrans\n-4-[(\ntert-\nButoxycarbonyl)(methyl)amino]cyclohexane carboxylic acid methyl ester as colorless oil. ESI-MS m/z: 272 [M+1]\n+\n, Retention time 3.57 min (condition B).\n\n\n \n \n \n \nA solution of \ntrans-\n4-[(tert-Butoxycarbonyl)(methyl)amino] cyclohexanecarboxylic acid methyl ester (3.69 mmol, 1.0 g) is dissolved in EtOAc (5 mL), cooled to 0C and treated with 4M HCl in ethyl acetate (5 mL). The mixture is stirred at room temperature for 5 hours. After the mixture is concentrated under reduced pressure, 100 mL of ethyl ether is added. The solid precipitate is filtrated, washed with ethyl ether and dried under reduced pressure to obtain 700 mg (91 %) of \ntrans-\n4-(methylamino)cyclohexanecarboxylic acid methyl ester hydrochloride as white solid. ESI-MS m/z: 171 [M+1]\n+\n, Retention time 1.00 min (condition B).\n\n\n \n\n\nExample 47-10: \ntrans-\n4-(ethylamino)-1-cyclohexanecarboxylic acid methyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of \ntrans-\n4-(aminomethyl)cyclohexanecarboxylic acid methyl ester hydrochloride (1.5mmol, 310 mg) in pyridine (2 mL) is added acetic anhydride (1.8mmol, 0.31 mL) at room temperature. The mixture is stirred at room temperature for 4 hours, poured into 1 M HCl and ice-water, and then extracted with ethyl acetate. The combined organic phase is washed with water and brine, dried over anhydrous Na\n2\nSO\n4\n and concentrated under reduced pressure to obtain \ntrans-\n4-(acetamidomethyl)-1-cyclohexanecarboxylic acid methyl ester (330mg) as colorless oil. ESI-MS m/z: 214 [M+1]\n+\n, Retention time 1.97 min (condition B).\n\n\n \n \n \n \nTo a solution of \ntrans-\n4-(acetamidomethyl)-1- cyclohexanecarboxylic acid methyl ester (1.5 mmol, 330 mg) and acetic acid (17.5 mmol, 1 mL) in THF (10 mL) is added sodium borohydride (7.5 mmol, 284 mg) at room temperature. The mixture is stirred at 75C for 4 hours, poured into ice-water, and extracted with ethyl acetate. The combined organic phase is washed with 1M NaOH aqueous solution, water, and brine, dried over anhydrous Na\n2\nSO\n4\n and concentrated under reduced pressure to obtain 200mg (67%) of \ntrans-\n4-(ethylamino)-1-cyclohexanecarboxylic acid methyl ester as colorless oil. ESI-MS m/z: 200 [M+1]\n+\n, Retention time 1.57 min (condition B).\n\n\n \n\n\nExample 47-11: \ntrans-\n(4-Hydroxymethylcyclohexyl)-acetic acid ethyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \ncis\n/\ntrans\n mixture of 4-ethoxycarbonylmethyl-cyclohexanecarboxylic acid (112 g) is filtered to collect the solids. After washing with \nn-\nhexane, a suspension of the solids (27.2 g) in \nn-\nhexane (500 mL) is heated at 90 C to be homogeneous solution. The solution is stirred for 30 min. and cooled to -25 C for 1.5 hours. The solids are isolated by filtration, washed twice with 100 ml of \nn-\nhexane, and dried under reduced pressure to provide \ntrans\n-4-ethoxycarbonylmethyl-cyclohexanecarboxylic acid (19.4 g, \ncis\n/\ntrans\n = 2: >98 determined by \n1\nH NMR).\n\n1H NMR (400 MHz, CHLOROFORM\n-d\n)  ppm 0.98-1.08 (m, 2 H), 1.26 (t, \nJ\n = 7.05 Hz, 3 H), 1.42-1.53 (m, 2 H), 1.74-1.87 (m, 3 H), 2.00-2.05 (m, 2 H), 2.20 (d, \nJ\n = 6.56 Hz, 2 H), 2.26 (tt, \nJ\n = 3.52, 12.1 Hz, 1H), 1.91 (brs, 1 H) 3.69 (t, \nJ\n = 6.55 Hz, 2 H) 4.13 (q, \nJ\n = 7.05 Hz, 2 H).\n\n\n \n \n \n \nTo a solution of \ntrans-\n4-ethoxycarbonylmethyl-cyclohexanecarboxylic acid (1 mmol; 214 mg) in THF (3 mL) is added 1.0 M THF solution of borane THF complex (2 mmol; 2 mL) at 0 C under nitrogen. The solution is stirred for 1.5 hours at room temperature, quenched by dropwise addition of 1 mL of MeOH. The mixture after concentration is diluted with dichloromethane and saturated aqueous ammonium chloride solution. The product is extracted with 100 ml of dichloromethane. The organic layer after dried is separated, concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (\nn-\nhexane/EtOAc) to give \ntrans\n-(4-hydroxymethylcyclohexyl)-acetic acid ethyl ester (166 mg, 83%); ESI-MS \nm\n/\nz\n: 201 [M\n+\n +1], Retention time 1.67 min (condition A).\n\n\n \n\n\nExample 48: (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-methyl-2-oxo-imidazolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid \ntert-\nbutyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nIn a 2 mL glass microwave reaction vessel are placed in (2\nR\n,4\nS\n)-4-[(3,5-bis-trifluoromethylbenzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (200 mg, 0.32 mmol), 1-Methyl-imidazolidin-2-one (35 mg, 0.35 mmol), Cul (123.4 mg, 0.35 mmol), \ntrans-\n1,2-cyclohexane (0.005 mL, 0.35 mmol), K\n2\nCO\n3\n (88 mg, 0.64 mmol) in dry dioxane (2 mL). The reaction vessel is sealed and heated under microwave irradiation at 180 C for 20 min. After completion of the reaction, the solvent is diluted with EtOAc and washed with sat. NH\n3\n(aq.), water, dried (Na\n2\nSO\n4\n), and concentrated under reduced pressure. The residue is purified by flash chromatography on silica gel to give (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-methyl-2-oxo-imidazolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (120 mg, 61 %).\n\n\n1\nH NMR (400 MHz, chloroform-d)  ppm 0.81 (t, 3H), 1.44 (s, 9H), 1.43-1.73 (m, 3H), 2.20-2.34 (m, 1 H), 2.89 (s, 3H), 3.07 (brt, 2H), 3.51 (dd, 2H), 3.74 (dd, 2H), 3.80-3.90 (m, 1 H). 4.88 (brs, 2H), 5.10-5.23 (m, 1H), 7,64 (brs, 2H), 7.74 (brs, 1H), 8.55 (s, 2H); ESI-MS m/z: 617 [M+1]+, Retention time 4.82 min (condition A).\n\n\n \n \n \n \nTo a mixture of (2\nR\n,4\nS\n)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(3-methyl-2-oxo-imidazolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid \ntert\n-butyl ester (150 mg, 0.24 mmol) in EtOAc (1 mL) is added 4N HCl/EtOAc (2.4 mL, 2.44 mmol). After removal of solvent, the mixture is used without further purification. (2R,4\nS\n)-4-{(3,5-Bis-trifluoromethylbenzyl)-[5-(3-methyl-2-oxo-imidazolidin-1-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine is treated with 2,4,5-trichloro-pyrimide (67.1 mg, 0.37 mmol) and Et\n3\nN (0.07mL, 0.49 mmol) in CH\n2\nCl\n2\n (1 mL) at RT for 12 hours. After adding sat. NaHCO\n3\n(aq.), the mixture is extracted with CH\n2\nCl\n2\n, washed with brine and dried (MgSO\n4\n). Concentration under vacuum and purification with silica gel column chromatography (eluent: \nn-\nhexane : EtOAc = 1:1) gives 1-[2-((3,5-Bis-trifluoromethyl-benzyl)-{(3\nS\n,5\nR\n)-1-[5-chloro-2-(4-hydroxy-piperidin-1-yl)-pyrimidin-4-yl]-5-ethyl-pyrrolidin-3-yl}-amino)-pyrimidin-5-yl]-3-methyl-imidazolidin-2-one (110 mg, 68%)\n\n\n1\nH NMR (400 MHz, chloroform-d)  ppm 0.85 (t, 3H), 1.79-1.97 (m, 1H), 2.27 (dt, 1H), 2.89 (s, 3H), 3.51 (dd, 2H), 3.67 (t, 3H), 3.75 (dd, 2H), 4.05-4.15 (m, 2H), 4.40-4.48 (m, 1 H), 4.88 (d, 1 H), 5.05 (d, 1 H), 7.69 (brs, 2H), 7.78 (brs, 1 H), 8.04 (brs, 1 H), 8.56 (s, 2H); ESI-MS m/z: 663 [M]+, Retention time 4.90 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of \nExample 48\n using corresponding amine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n48-1\n \n \n \n \n \n \n650\n \n4.82 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n48-2\n \n \n \n \n \n \n648\n \n4.66 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 49:\n\n\n\n\n \n \n \nThe following compounds are prepared following the procedure of Example 23 using corresponding amine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n49-1\n \n \n \n \n \n \n783\n \n4.12 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n49-2\n \n \n \n \n \n \n770\n \n3.94 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n49-3\n \n \n \n \n \n \n771\n \n4.05 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 50: Synthesis of (3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-[(3S,5R)-1-(2,5-dichloro-pyrimidin-4-yl)-5-ethyl-pyrrolidin-3-yl]-amine\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 50 ml round-bottom flask is charged with (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (1.8 g, 3 mmol) and a stirbar under N\n2\n. HCl/EtOAc (4 N, 7.5 ml) is added with stirring. TLC monitor showed that reaction completed after 30 minutes. Sat. Na\n2\nCO\n3\n was added and extracted with dichloromethane. Filter through phase separator, removal of solvent give the BoC deprotected pyrrolidine which is used without further purification.\n\n\n \n \n \n \nA 100 ml round-bottom flask is charged with the pyrrolidine (3 mmol), trichloropyrimidine (753 ul, 6 mmol), triethylamine (831 ul, 6 mmol) and a stirbar under N\n2\n. 1,4-dixoane (20 ml) is added with stirring. The resulted pale yellow solution is then heated to 60 degree for 2 hours. After removal of solvent via evaporation, H\n2\nO and dichloromethane is added and organic layer is collected filtering through phase separator. Removal of solvent and subsequent purification with Hex/EtOAc on column give (3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-[(3S,5R)-1-(2,5-dichloro-pyrimidin-4-yl)-5-ethyl-pyrrolidin-3-yl]-amine (1.63 g, 90% for 2 steps). ESI-MS m/z: 645 [M]+, Retention time 2.65 min (condition A).\n\n\n \n \n \n \nThe following compounds are prepared following the procedure of Example 50 using corresponding pyrimidine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n50-1\n \n \n \n \n \n \n768\n \n2.65 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-2\n \n \n \n \n \n \n631\n \n2.07 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-3\n \n \n \n \n \n \n650\n \n4.71 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-4\n \n \n \n \n \n \n624\n \n2.39 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-5\n \n \n \n \n \n \n646\n \n2.44 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-6\n \n \n \n \n \n \n670\n \n2.24 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-7\n \n \n \n \n \n \n651\n \n2.30 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-8\n \n \n \n \n \n \n570\n \n2.41 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-9\n \n \n \n \n \n \n662\n \n2.38 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-10\n \n \n \n \n \n \n618\n \n2.31 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-11\n \n \n \n \n \n \n670\n \n2.36 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n50-12\n \n \n \n \n \n \n682\n \n4.28 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 51:\n\n\n\n\n \n \n \nThe following compound is prepared following the procedure of Example 11 using corresponding amine.\n\n \n \n \n \n \nNo\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n1\n \n \n \n \n \n \n650\n \n4.71 (condition B)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 52:\n\n\n\n\n \n \n \nThe following compounds are prepared following the procedure of Example 12 using corresponding amine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n52-1\n \n \n \n \n \n \n722\n \n2.63 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 53: Synthesis of benzoic acid piperidin-4-yl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 25 ml round-bottom flask is charged with 4-OH piperidine (303 mg, 3 mmol), TEA (500 ul, 3.6 mmol and CH\n2\nCl\n2\n (6 ml), then ice-cooled. BoC anhydride (786 mg, 3.6 mmol) is added slowly, and after removal of the ice bath, the mixture is stirred at rt for 1 hour. H\n2\nO and CH\n2\nCl\n2\n are added and organic layer is collected with phase separator. Removal of solvent under reduced pressure give a colorless oil which is used for the next step without further purification.\n\n\n \n \n \n \nA 50 ml round-bottom flask is charged with the crude N-Boc-4-OH-piperidine (3 mmol), benzoyl chloride (495 ul, 3.9 mmol), TEA (540 ul, 3.9 mmol), DMAP (96 mg, 0.78 mmol), CH\n2\nCl\n2\n (9 ml), then ice-cooled. After removal of the ice bath, the mixture is stirred at rt for 4 hours. H\n2\nO and CH\n2\nCl\n2\n are added and organic layer was collected with phase separator. Removal of solvent under reduced pressure give a colorless oil which is purified with silica gel column to give 4-O-benzoyl N-BoC piperidine (700 mg, 0.23 mmol). ESI-MS m/z: 306 [M]+, Retention time 2.12 min (condition A).\n\n\n \n \n \n \nA 25 ml round-bottom flask is charged with 4-O-Benzoyl N-BoC (700 mg, 0.23 mmol) under N\n2\n. HCl/EtOAc (4 N, 0.6 ml) is added while stirring for 30 minutes. Saturated Na\n2\nCO\n3\n is added and extracted with dichloromethane. Filter through phase separator, removal of solvent under reduced pressure give 4-O-benzoyl piperidine which is used without further purification.\n\n\n \n\n\nExample 54: Synthesis of (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-imidazol-1-yl-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA 25 ml round-bottom tube is charged with (2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (480 mg, 0.8 mmol), imidazole (82 mg, 1.2 mmol), Cul (152 mg, 0.8 mmol), K\n2\nCO\n3\n (221 mg, 1.3 mmol), N,N-dimethyl glycine (82 mg, 0.8 mmol), and DMSO (4 ml). Then the tube is sealed and heated to 110 degree for 18 hours. After cooling to rt, saturated NH\n3\n/H\n2\nO and EtOAc are added and then filtered through Celite pad. The solution is extracted with EtOAc and organic layer is dried over MgSO\n4\n. Removal of solvent under reduced pressure and purification with reverse phase column give product (163 mg, 0.27 mmol, 35%). ESI-MS m/z: 585 [M]+, Retention time 2.07 min (condition A).\n\n\n \n\n\nExample 55:\n\n\n\n\n \n \n \nThe following compounds are prepared following the procedure of \nExample 30\n using corresponding amine.\n\n \n \n \n \n \nNo.\n \nProduct\n \nESI-MS m/z [M+1]\n+\n \n \nRetention time (min)\n \nStarting Material\n \nStarting Material\n \n \n \n \n55-1\n \n \n \n \n \n \n671\n \n2.38 (condition A)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n\n\nExample 56: Synthesis of (2S,4R)-4-benzyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \n \n \n \n\nTo a solution of (2\nS\n,4\nR\n)-4-benzyloxy-pyrrolidine-1,2-dicarboxylic acid 1-\ntert\n-butyl ester (15.5 mmol; 5.0 g) in THF (135 mL) is added 1 M THF solution of borane THF complex (31 mmol; 31 mL) at 0 C under nitrogen. The solution is stirred for 1 hour at room temperature, quenched by dropwise addition of 15 ml of MeOH. After concentrating, the mixture is diluted with dichloromethane and saturated aqueous ammonium chloride solution. The product is extracted twice with dichloromethane. The combined organic layer is washed with brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure to give the crude product. To a solution of crude material in MeCN (20 mL) were added Ag2O (46.5 mmol; 8.9 g) and Mel (155 mmol; 21.8 g) at room temperature, heated and stirred under reflux condition for 3 hours. After filteration and concentration, the resulting mixture is diluted with dichloromethane and saturated aqueous ammonium chloride solution. The product is extracted twice with dichloromethane. The combined organic layer is washed with brine, dried over MgSO\n4\n, filtered, concentrated under reduced pressure to give the crude (2S,4R)-4-benzyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (3.1 g).\n\n\n \n\n\nExample 57: Synthesis of (2S,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \nThe following compound is prepared following the procedures of \nExample 3\n and \n45\n\n\n \n \n \n\n\n \n \n \n \nIn a flask purged with ammonia gas, about 40 mL of liquid ammonia is collected with ammonia condenser at -78 C. To the liquid ammonia is added portionwise lithium metal (46 mmol; 320 mg) at the same temperature. To the deep blue solution is added a solution of (2S,4R)-4-benzyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (9.2 mmol; 3.1 g) and \ntert-\nbutanol (18.4 mmol; 1.36 g) in THF (15 mL). After stirring for 2 hours, the reaction mixture is quenched with MeOH, and then warmed to ambient temperature. The mixture is diluted with water, and then aqueous 1M HCl is added to reach pH 8-9. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over MgSO\n4\n, filtered, and concentrated under reduced pressure to give (2S,4R)-4-hydroxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (2.2 g).\n\n\n \n \n \n \nTo a solution of (2S,4R)-4-hydroxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (8.9 mmol; 2.2 g) and Et\n3\nN (11.6 mmol; 1.6 mL) in diethylether (22 mL) is added MsCl (11.6 mmol; 0.90 mL) at room temperature. The reaction mixture is stirred for 4 hours, and then quenched with saturated aqueous NaHCO\n3\n solution. The product is extracted three times with dichloromethane. The combined organic layer is washed with saturated aqueous ammonium chloride and then brine, dried over MgSO\n4\n, filtered, and concentrated under reduced pressure to give the crude product.\n\n\n \n \n \n \nTo a solution of the crude product in DMF (22 ml) is added sodium azide (14.3 mmol; 925 mg) under nitrogen at room temperature. After stirring for 8 hours at 90 C, the reaction mixture is cooled to ambient temperature, and then quenched with saturated ammonium chloride solution. The product is extracted twice with EtOAc. The combined organic layer is washed twice with aqueous 0.1 M HCl and then once with brine, dried over MgSO\n4\n, filtered, and concentrated under reduced pressure to give the crude product.\n\n\n \n \n \n \nA suspension of the crude product and magnesium metal (18 mmol; 1.1 g) in MeOH (18 mL) is stirred for 3 hours. The suspension is filtered and concentrated. To the residue are added EtOAc and brine. The product is extracted twice with EtOAc. The combined organic layer is washed with brine, dried over K\n2\nCO\n3\n, filtered, and concentrated under reduced pressure to give the crude product.\n\n\n \n \n \n \nA solution of the crude product, 5-bromo-2-chloropyrimidine (14.3 mmol; 2.6 g) and \nN,N-\ndiisopropylethylamine (17.8 mmol; 3.1 mL) in DMF (18 mL) is stirred at 120 C for 3 hours. The reaction mixture is cooled to ambient temperature, and then quenched with saturated ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is passed through silica pad (eluent: \nn-\nhexane / EtOAc) to give (2S,4S)-4-(5-bromo-pyrimidin-2-ylamino)-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (1.8 g).\n\n\n \n \n \n \nA mixture of ((2S,4S)-4-(5-bromo-pyrimidin-2-ylamino)-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (2.84 mmol; 1.1 g), 3,5-bis(trifluoromethyl)benzyl bromide (4.3 mmol; 0.78 mL) and sodium hydride (60% dispersion in mineral oil, 4.3 mmol; 0.17 g) in DMF (9 mL) is stirred for 1 hour at room temperature under nitrogen. The reaction mixture is quenched with water then saturated ammonium chloride solution. The product is extracted twice with EtOAc. The combined organic layer is washed with brine, dried over MgSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is passed though silica pad (eluent: \nn-\nhexane / EtOAc) to give (2S,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester.\n\n\n \n \n \n \nTo a mixture of (2S,4S)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester, 1-methylpyrazol-3-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (7.1 mmol, 1.48 g), tetrakis(triphenylphosphine)palladium(0) (0.43 mmol, 490 mg) and 2M aqueous sodium hydrogen carbonate (3.6 mL) in 1,2-dimethoxy-ethane (4 mL) is allowed to warm to 95 C and stirred for 3 hours. The mixture is cooled to room temperature and then added water. The mixture is extracted with CH\n2\nCl\n2\n, and the combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give (2S,4S)-4-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (1.3 g, 74% overall yield for 2 steps); ESI-MS m/z: 615 [M+1]\n+\n, Retention time 2.12 min (condition A).\n\n\n \n\n\nExample 58: Synthesis of (S)-3-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-pyrrolidine-1-carboxylic acid tert-butyl ester\n\n\n\n\n \n \n \nThe following compound is prepared following the procedures of \nExample 2, 3\n and \n39\n\n\n \n \n \n\n\n \n \n \n \nA solution of (S)-3-amino-pyrrolidine-1-carboxylicacid tert-butyl ester(10.7 mmol; 2.0 g), 5-bromo-2-chloropyrimidine (12.8 mmol; 2.4 g) and \nN,N\n-diisopropylethylamine (21.4 mmol; 2.98 g) in DMF (25 mL) is stirred at 120 C for 2 hours. The reaction mixture is cooled to ambient temperature, and then quenched with saturated ammonium chloride solution. The product is extracted three times with EtOAc. The combined organic layer is washed with brine, dried over Na\n2\nSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is passed through silica pad (eluent: \nn-\nhexane / EtOAc) to give crude product.\n\n\n \n \n \n \nA mixture of the resulting crude product, 3,5-bis(trifluoromethyl)benzyl bromide (12 mmol; 4.0 g) and sodium hydride (60% dispersion in mineral oil, 18 mmol; 0.72 g) in DMF (25 mL) is stirred for 1 hours at room temperature under nitrogen. The reaction mixture is quenched with water then saturated ammonium chloride solution. The product is extracted twice with EtOAc. The combined organic layer is washed with brine, dried over MgSO\n4\n, filtered, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: \nn-\nhexane / EtOAc) to give (S)-3-[(3,5-bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-pyrrolidine-1-carboxylic acid tert-butyl ester (4.14g, 68% for 2 steps). ESI-MS m/z: 570 [M+1]\n+\n, Retention time 2.48 min (condition A).\n\n\n \n \n \n \nTo a mixture of (S)-3-[(3,5-Bis-trifluoromethyl-benzyl)-(5-bromo-pyrimidin-2-yl)-amino]-pyrrolidine-1-carboxylic acid tert-butyl ester (2.2 mmol, 1.28 g), 1-methylpyrazol-3-yl-4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolane (2.7 mmol, 0.72 g), tetrakis(triphenylphosphine)palladium(0) (0.22 mmol, 260 mg) and 2M aqueous sodium hydrogen carbonate (3.2 mL) in 1,2-dimethoxy-ethane (15 mL) is allowed to warm to 95 C and stirred for 3 hours. The mixture is cooled to room temperature and then added water. The mixture is extracted with CH\n2\nCl\n2\n. The combined organic layer is dried over Na\n2\nSO\n4\n, filtrated, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n-hexane / EtOAc) to give (S)-3-{(3,5-bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-pyrrolidine-1-carboxylic acid tert-butyl ester 766 mg, 61%). ESI-MS m/z: 571 [M+1]\n+\n, Retention time 2.25 min (condition A).\n\n\n \n\n\nExample 59: Synthesis of 2,4-dichloro-pyrimidine-5-carboxylic acid dimethylamide\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of 2,4-dichloro-pyrimidine-5-carbonyl chloride (197.7 mg, 0.94 mmol) in CH\n2\nCl\n2\n (9.4 mL) at RT is added Me\n2\nNH (2.0 \nM\n THF solution, 390 L, 0.78 mmol) and Et\n3\nN (108.6 L, 0.78 mmol) at 0 C. The reaction mixture is stirred overnight at RT. After adding water, the mixture is extracted with CH\n2\nCl\n2\n. The organic layer is dried and concentration under reduce pressure give 2,4-dichloro-pyrimidine-5-carboxylic acid dimethylamide (272.5 mg, quant). ESI-MS m/z: 221 [M+1]\n+\n, Retantion time 1.94 min (condition B)."
  },
  {
    "id": "EP2377850A1",
    "text": "TRPV1 vanilloid receptor antagonists with a bicyclic portion AbstractThe invention discloses compounds of formula Iwherein Y s selected from a group of formulaand W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description.The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1. Claims (\n9\n)\n\n\n\n\n \n\n\nCompounds of formula (\nI\n)\n\n \n \n\nwherein:\n\nY is a group of formula:\n\n \n \n\n\n \n \n \n\nin which:\n\nJ is NH, O or a bond;\n\n\nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero;\n\n\nK is NH, O or CH\n2;\n \n\n\nW is NH, O, a bond or CH\n2\n;\n\n\nQ is NH, O, a bond or CH\n2\n;\n\n\nn is 0 or 1;\n\n\nU1, U2, U3, U4 and U5 form an aromatic ring and are independently CH, N, O, S, or one of them may be absent;\n\n\nR1 and R2 are independently selected from hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkoxy, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O;\n\n\nR3 is hydrogen or with n = 1 is CH2 and forms a cycle with R1 = CH2 or = CH2-CH2.\n \n\n\n\n\n \n \n\n\nCompounds according to claim 1 of formula (IA) wherein Y is A or C and W and Q are NH\n\n \n \n\nand\n\nJ is NH, O or a bond;\n\nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero; K is NH, O or CH\n2\n;\n\nn is 0 or 1;\n\nU1, U2, U3, U4 and U5 form an aromatic ring and are independently CH, N, O, S, or one of them may be absent;\n\nR1 is hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, heterocycle, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O;\n\nR2 is halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O;\n\nR3 is hydrogen or when n = 1 is CH\n2\n and forms a cycle with R1 = CH2.\n\n\n\n\n \n \n\n\nCompounds according to claim 2 wherein R1 and R2 are independently pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n\n\n \n \n\n\nCompounds according to claim 1 of formula (IB) wherein Y is C, W is NH, Q is a bond and R3 is hydrogen\n\n \n \n\nand\n\nJ is NH, O or a bond;\n\nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero; K is NH, O or CH\n2\n;\n\nn is 0 or 1;\n\nR1 is hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O;\n\nR2 is halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O.\n\n\n\n\n \n \n\n\nCompounds according to claim 4 wherein R1 and R2 are independently pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n\n\n \n \n\n\nCompounds according to claim 1 of formula (IC) wherein Y is C, Q is NH and R3 is hydrogen\n\n \n \n\nand\n\nJ is NH, O or a bond;\n\nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero; K is NH, O or CH\n2\n;\n\nW is O or a bond;\n\nn is 0 or 1;\n\nR1 is hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O;\n\nR2 is halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O.\n\n\n\n\n \n \n\n\nCompounds according to claim 6 wherein R1 and R2 are independently pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n\n\n \n \n\n\nPharmaceutical compositions comprising one or more compounds of claims 1- 7 as the active ingredient.\n\n\n\n\n \n \n\n\nThe compounds of claims 1- 7 for use as TRPV1 antagonists. Description\n\n\n\n\n\n\n\n\nField of the invention\n\n\n\n\n\n\n \n \n \nThe present invention concerns TRPV1 antagonists characterized by a bicyclic portion and, when possible, pharmaceutically acceptable salts thereof along with the formulations containing them. The pharmaceutical compositions of the invention are useful in the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV 1.\n\n\n \n\n\n\n\nBackground\n\n\n\n\n\n\n \n \n \nThe transient receptor potential vanilloid 1 (TRPV1) is a member of ion channels mainly localized on primary afferent neurons. Activation of TRPV1 on sensory neurons by chemical stimulants including capsaicin and resiniferatoxin, as well as low pH (<6), heat (>42C), and nucleosides such as ATP, leads to an influx of Ca2+ and Na+ ions through the channel, causing depolarization of the cell and transmission of painful stimuli. Unlike traditional analgesic drugs that either suppress inflammation (e.g. NSAIDs and COX-2 inhibitors) or block pain transmission (e.g. opiates), TRPV1 channel inhibitors aim to prevent pain by blocking a receptor where pain is generated. In patients, the expression of TRPV 1 is up-regulated in a number of painful inflammatory disorders. TRPV1 as a pain target has been validated by genetic deletion and pharmacological inhibition experiments. The pungency of capsaicin and many other agonists at the vanilloid receptor clearly define TRPV1 as a key transducer in the pain pathway. Characterization of TRPV1 mice, which lack both copies of the TRPV1 gene, shows a complete absence of thermal hyperalgesia associated with inflammation demonstrating the key role of TRPV1 in disease and providing impetus to develop selective TRPV1 antagonists as a novel pain therapy with the potential for an improved side effect profile compared to existing therapies. Some 10 years post cloning and many novel selective and chemically distinct TRPV1 antagonists have now been identified and a number of these have been assessed in preclinical models of pain. Some of them reverse mechanical hyperalgesia in the Freund's complete adjuvant model of inflammatory pain in rodents. Others show efficacy in neuropathic pain models, in post-operative pain and in cancer pain. These data provide robust validation of this approach for the treatment of a broad range of pain conditions in humans.\n\n\n \n \n \n \nIn the bladder, the presence of TRPV1 was demonstrated in various cell types, including urothelium, detrusor muscle and fibroblasts. There is good evidence that TRPV1 in urothelium is functional. Capsaicin evokes an inward current similar to that seen in DRG neurons in patch-clamped human urothelial cells. Furthermore capsaicin induces calcium uptake in human urothelial cells culture which is blocked by the TRPV1 antagonists implying that the regulation of TRPV1 is similar in sensory neurons and urothelial cells. Overactive bladder (OAB) is a syndrome characterised by urgency (with or without urge incontinence), usually with frequency and nocturia, in the absence of other pathologic or metabolic conditions that might explain the symptoms. Differently from antimuscarinic compounds dominating the market of OAB that only act on the efferent components, TRPV1 antagonists, acting on sensory nerves or on urothelium, are effective in diverse experimental models of cystitis/overactive bladder without interfere with the physiological volume-induced avoiding contractions (VIVC) and distention of the urinary bladder in healthy animals.\n\n\n \n \n \n \nThe documented ability of citric acid as well as pungent compounds such as capsaicin to induce cough when delivered to the lungs of experimental animals and humans, combined with the contribution of TRPV1-sensitive nerves to airway hyper responsiveness and bronco constriction has led to a large degree of interest in the potential for targeting TRPV1 for the treatment of a range of respiratory diseases. These effects are thought to derive from the key contribution of TRPV1 which is highly expressed by sensory neurons and vagal afferents that innervate the airways, to the cough reflex. Preclinical studies have now demonstrated antitussive efficacy of a range of TRPV1 antagonists in rodent models.\n\n\n \n\n\n\n\nDescription of the invention\n\n\n\n\n\n\n \n \n \nThe present invention relates to TRPV1 inhibitors of formula \n(I)\n\n\n \n \n\nwherein:\n\n \n \n \nY is a group of formula:\n\n \n \n\n\n \n \n \n \nin which:\n\n \nJ is NH, O or a bond;\n \nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero;\n \nK is NH, O or CH\n2;\n \n \nW is NH, O, a bond or CH\n2\n;\n \nQ is NH, O, a bond or CH\n2\n;\n \nn is 0 or 1;\n \nU1, U2, U3, U4 and U5 form an aromatic ring and are independently CH, N, O, S, or one of them may be absent.\n \n \n \n\n\n \n \n \nThe aromatic ring is optionally substituted with one or both R1 and R2 groups.\n\n\n \n \n \n \nWhen one of U1-U5 is absent, the general formula \nI\n also includes mono or bi-substituted five membered heterocycle rings (e.g. furan, imidazole, thiazole, triazole, oxazole, isoxazole, thiophene, pyrazole).\n\n\n \n \n \n \nR1 and R2 are independently selected from hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkoxy, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O, which can be optionally substituted by OH, phenyl, heterocycle.\n\n\n \n \n \n \nR3 is hydrogen or with n = 1 is CH2 and forms a cycle with R1 = CH2 or = CH2-CH2\n\n\n \n \n \n \nWhen one asymmetrical carbon is present in a compound of the formula (I), such a compound may exist in optically active form or in the form of mixtures of optical isomers, e. g. in the form of racemic mixtures. The present invention refers to all optical isomers and their mixtures, including the racemic mixtures.\n\n\n \n \n \n \nAccording to a first preferred embodiment, the invention relates to compounds of formula (IA) wherein Y is A or C and W and Q are NH\n\n \n \n\nand\n\nJ is NH, O or a bond;\n\nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero;\n\nK is NH, O or CH\n2;\n \n\nn is 0 or 1;\n\nU1, U2, U3, U4 and U5 form an aromatic ring and are independently CH, N, O, S, or one of them may be absent.\n\n\n \n \n \n \nThe aromatic ring is optionally substituted with one or both R1 and R2 groups.\n\n\n \n \n \n \nWhen one of U1-U5 is absent, the general formula \nIA\n also includes mono or bi-substituted five membered heterocycle rings (e.g. furan, imidazole, thiazole, triazole, oxazole, isoxazole, pyrazole).\n\n\n \n \n \n \nR1 is as defined above, more preferably hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, heterocycle, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O, in particular pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n \n \n \n \nR2 defined above, is preferably halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\nI\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O, in particular pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n \n \n \n \nR3, as defined above, is preferably hydrogen or when n = 1 is CH\n2\n and forms a cycle with R1 = CH2.\n\n\n \n \n \n \n\n\nExamples of compounds of formula IA are:\n\n\n \n \n\n\n1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1 H-benzo[d]imidazol-4-yl)urea\n\n\n1-(2-chloro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-morpholinobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(1H-1,2,4-triazol-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-fluorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-chlorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-chloro-2-(dimethylamino)benzyl)-3-(2,3-dihydro-2-oxo-1 H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-chloro-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(dimethylamino)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(2-(dimethylamino)-4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1 H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-methyl-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(2,3-dihydro-2-oxo-1 H-benzo[d]imidazol-4-yl)-3-((pyridin-4-yl)methyl)urea\n\n\n1-((6-chloropyridin-3-yl)methyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-chloro-2-(3-hydroxypyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(5-(trifluoromethyl-furan-2-yl)-methyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(2-chloro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(4-fluoro-2-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(4-chloro-2-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-morpholinobenzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(4-chlorobenzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea\n\n\n1-(4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n1-(5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-3-(2-oxoindolin-4-yl)urea\n\n\n1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n1-(4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea\n\n\n1-(4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(4-chlorobenzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(4-chloro-2-(dimethylamino)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(4-chloro-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-(4-methyl-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n1-((6-chloropyridin-3-yl)methyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n\n\n \n \n \nAccording to a second preferred embodiment, the invention relates to compounds of formula (IB) wherein Y is C, W is NH, Q is a bond and R3 is hydrogen\n\n \n \n\nand\n\nJ is NH, O or a bond;\n\nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero;\n\nK is NH, O or CH\n2;\n \n\nn is 0 or 1;\n\nR1 is hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O, in particular pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\nR2 is halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O, in particular pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n \n \n \n \nThe formula IB substantially corresponds to formula I wherein U1=U2=U3=U4=U5 are CH.\n\n\n \n \n \n \n\n\nExamples of compounds of formula IB are:\n\n\n \n \n\n\n2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)acetamide\n\n\n2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)acetamide\n\n\n2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)acetamide\n\n\n2-(4-(trifluoromethyl)phenyl)-N-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)acetamide\n\n\n\n\n \n \n \nAccording to a third preferred embodiment, the invention relates to compounds of formula (IC) wherein Y is C, Q is NH and R3 is hydrogen\n\n \n \n\nand\n\nJ is NH, O or a bond;\n\nm is 0, 1 or 2; with the proviso that when J is a bond, then m is not zero;\n\nK is NH, O or CH\n2;\n \n\nW is O or a bond;\n\nn is 0 or 1.\n\n\n \n \n \n \nThe formula IC substantially corresponds to formula I wherein U1=U2=U3=U4=U5 are CH.\n\n\n \n \n \n \nR1 is hydrogen, halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O, in particular pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n \n \n \n \nR2 is halogen, trifluoromethyl, (C\n1\n-C\n4\n)alkyl, (C\n1\n-C\n4\n)alkylamino, monocyclic ring system containing 0-4 heteroatoms independently selected from N and O, in particular pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl.\n\n\n \n \n \n \n\n\nExamples of compounds of formula IC are:\n\n\n \n \n\n\nN-(4-(trifluoromethyl)benzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide\n\n\nN-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide\n\n\nN-(4-(trifluoromethyl)-2-morpholinobenzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide\n\n\nN-(4-(trifluoromethyl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-5-carboxamide\n\n\nN-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-5-carboxamide\n\n\nN-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-8-carboxamide\n\n\n3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl 4-(trifluoromethyl)benzylcarbamate\n\n\n\n\n \n \n \nThe compounds of formula (IA) are ureas that can be prepared by reaction of a compound of formula 1 with a compound of formula 2 where one of them, more commonly 2 is firstly converted into isocyanate using triphosgene. Alternatively, CDI was used to form the uredyl derivative of one of the two amines and which reacts with the other to give the desired urea. Compounds 1 and 2 are prepared by standard procedures.\n\n \n \n \n\n\n \n \n \n \nThe compounds of formula (IB) and (IC) are amides or carbamates that can be prepared by standard procedures.\n\n\n \n \n \n \nIn a further aspect of the present invention, compounds of formula I bearing a solubilizing amine may be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.\n\n\n \n \n \n \nFor use in medicine, the salts of the compounds of formula I will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, nitric acid, maleic acid, citric acid, tartaric acid, phosphoric acid, p-toluenesulphonic acid, benzenesulphonic acid. Preferred pharmaceutically salts of the compounds of the present invention are those with the inorganic acids.\n\n\n \n \n \n \nThe salts may be formed by conventional means, such as by reacting the free base form of the suitable compounds of formula I with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble or in a solvent such as water which is removed under vacuum.\n\n\n \n\n\n\n\nCompositions of the invention\n\n\n\n\n\n\n \n \n \nThe present invention also provides pharmaceutical compositions that comprise compounds of the present invention. The pharmaceutical compositions comprise compounds of the present invention that may be formulated together with one or more non-toxic pharmaceutically acceptable carriers.\n\n\n \n \n \n \nThe pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), buccally or as an oral or nasal spray.\n\n\n \n \n \n \nSome examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as, but not limited to, lactose, glucose and sucrose; starches such as, but not limited to, corn starch and potato starch; cellulose and its derivatives such as, but not limited to, sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as, but not limited to, cocoa butter and suppository waxes; oils such as, but not limited to, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such a propylene glycol; esters such as, but not limited to, ethyl oleate and ethyl laurate; agar; buffering agents such as, but not limited to, magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as, but not limited to, sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.\n\n\n \n \n \n \nPharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), vegetable oils (such as olive oil), injectable organic esters (such as ethyl oleate) and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.\n\n\n \n \n \n \nThese compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.\n\n\n \n \n \n \nIn some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.\n\n\n \n \n \n \nInjectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.\n\n\n \n \n \n \nThe injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.\n\n\n \n \n \n \nSolid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.\n\n\n \n \n \n \nSolid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such carriers as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.\n\n\n \n \n \n \nThe solid dosage forms of tablets, drages, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient (s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.\n\n\n \n \n \n \nThe active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned carriers.\n\n\n \n \n \n \nLiquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.\n\n\n \n \n \n \nBesides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.\n\n\n \n \n \n \nSuspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.\n\n\n \n \n \n \nCompositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating carriers or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.\n\n\n \n \n \n \nCompounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono-or multi-lamellar hydrated liquid crystals, which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are natural and synthetic phospholipids and phosphatidyl cholines (lecithins) used separately or together.\n\n\n \n \n \n \nMethods to form liposomes are known in the art. See, for example, \nPrescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N. Y. (1976), p. 33\n et seq.\n\n\n \n \n \n \nDosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants that may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.\n\n\n \n \n \n \nIn the treatment of painful conditions such as those listed below, a suitable indicated dosage level is about 0.1mg to 1000mg/day, preferably from about 5mg to 500mg per day. The compounds may be administered on a regimen of 1 to 3 times a day.\n\n\n \n \n \n \nIt will be appreciated that the amount of a compound of formula I required for use in any treatment will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient.\n\n\n \n \n \n \nThe agents of invention are useful vanilloid receptor antagonists for the treatment of pain of various genesis or aetiology and as anti-inflammatory agents for the treatment of inflammatory reactions, diseases or conditions. They are useful for the treatment of inflammatory pain, for the treatment of hyperalgesia, and in particular for the treatment of severe chronic pain. They are, for example, useful for the treatment of pain, inflammation consequential to trauma, e.g. associated with burns or subsequent to surgical intervention, e.g. as post-operative analgesics, as well as for the treatment of inflammatory pain of diverse genesis, e.g. for the treatment of osteoarthritis and rheumatoid arthritis. They are suitable as analgesics for the treatment of pain associated with, e.g. angina or cancer.\n\n\n \n \n \n \nOther forms of pain associated with the activity of TRPV1 are headache, dental pain, pelvic pain, migraine, mastalgia and visceral pain.\n\n\n \n \n \n \nThe disorders in which TRPV1 is involved are not limited to pain. Such diseases include: nerve-related diseases, e.g. neuropathies, nerve injury and stroke; irritable bowel syndrome; gastrointestinal disorders, e.g. gastro-oesophageal reflux disease, Crohn's disease; respiratory diseases, e.g. asthma, chronic obstructive pulmonary disease, cough; urinary incontinence; urinary bladder hypersensitiveness; skin diseases, e.g. psoriasis, dermatitis; cardiac diseases e.g. myocardial ischemia; hair growth related disorders e.g. hirsutism, alopecia; rhinitis; pancreatitis; vulvodynia; psychiatric disorders, e.g. anxiety or fear; obesity.\n\n\n \n \n \n \nThe compounds of the present invention have potent analgesic effect and potential anti-inflammatory activity and their pharmaceutically formulations are thought to alleviate or to treat in particular neuropathic pain conditions such as diabetic neuropathy and post-herpetic neuralgia, urinary incontinence and cough.\n\n\n \n \n \n \nThe invention will be now illustrated by means of the following examples.\n\n\n \n\n\n\n\nEXAMPLES\n\n\n\n\n\n\n \n \n \nAll commercially available compounds were purchased from Vendors and were used without further purification. Reaction courses were monitored by thin-layer chromatography on silica gel (precoated F\n254\n Merck plates), the spots were examined with UV light and visualized with aqueous KMnO\n4\n. Flash chromatography was performed using Merck silica gel (230-240 mesh). \n1\nH-NMR spectra were recorded on Varian 400 MHz spectrometer or Varian 200MHz using TMS as internal standard. Mass spectra were obtained with a Waters-Micromass ZMD spectrometer.\n\n\n \n\n\nExample 1: 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-nitro-1H-benzo[d]imidazol-2(3H)-one \n4a\n (scheme 2) To 3-nitro-1,2-phenylenediamine \n3a\n (2g, 13.06mmol) dissolved in THF (50 ml) was added in one portion DCI (1.5equiv., 19.6mmol, 3.176g) and the reaction was refluxed for 2 hours. (TLC AcOEt 1 / petroleum ether 1). The reaction was filtrated and the yellow solid material was washed with THF and diethyl ether obtaining 2g of the product that was used for the following step without further purification. Yield = 88% \n1\nHNMR (DMSO, 200 MHz)  7.11 (1H, t, J = 7.6 Hz), 7.31 (1H, dd, J = 7.8 Hz, J' = 1.2 Hz), 7.74 (1H, dd, J = 8.6 Hz, J' = 1 Hz), 11.45 (2H, bs)\n\n\n \n \n \n \nPreparation of 4-amino-1H-benzo[d]imidazol-2(3H)-one \n1a\n (scheme 2) To compound \n4a\n (2g, 11.6mmol) dissolved in a mixture of 4/1 MeOH/THF (100ml) was added C/Pd 10% (500mg) and the reaction was hydrogenated at 60 psi overnight. (TLC AcOEt 9 / MeOH 1) The reaction was filtrated through a pad of Celite and the filtrate was evaporated under vacuum. The crude solid was crystallized from ether giving 1,5g of a white solid. Yield = 88%. \n1\nHNMR (DMSO, 200 MHz)  4.84 (2H, bs), 6.22 (2H, m), 6.65 (1H, t, J = 8 Hz), 9.98 (1H, bs), 10.33 (1H, bs)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nCommercially available 4-trifluoromethylbenzylamine (0.5 ml, 3.5 mmol) was dissolved in 20 ml of AcOEt and at OC triphosgene (1 g, 3.5 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (5 ml) of compound \n1a\n (350mg, 2.33mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30ml) and washed with water (1 X 20ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 290mg of a white solid. Yield = 36% \n1\nHNMR (DMSO, 400 MHz)  4.40 (2H, d, J = 6 Hz), 6.62 (1H, d, J = 7.2 Hz), 6.84 (2H, m), 6.96 (1H, d, J = 8 Hz), 7.54 (2H, d, J = 8 Hz), 7.70 (2H, d, J = 8.4 Hz), 8.30 (1H, s), 9.99 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 351.1 (C\n16\nH\n13\nF\n3\nN\n4\nO\n2\n requires 350.3).\n\n\n \n\n\nExample 2: 1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nCommercially available 2-fluoro-4-trifluoromethylbenzylamine (0.5 ml, 3.7 mmol) was dissolved in 20ml of AcOEt and at OC triphosgene (1.12 g, 3.7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (5 ml) of compound \n1a\n (360 mg, 2.4 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30ml) and washed with water (1 X 20ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 210mg of a white solid. Yield = 28% \n1\nHNMR (DMSO, 400 MHz)  4.42 (2H, d, J = 6 Hz), 6.63 (1H, dd, J = 8 Hz, J' = 1.2 Hz), 6.85 (2H, m), 6.95 (1H, d, J = 8 Hz), 7.62 (3H, m), 8.35 (1H, bs), 9.99 (1H, bs), 10.61 (1H, bs); [M\n+1\n] 369.1 (C\n16\nH\n12\nF\n4\nN\n4\nO\n2\n requires 368.29).\n\n\n \n\n\nExample 3: 1-(2-chloro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nCommercially available 2-chloro-4-trifluoromethylbenzylamine (700 mg, 3.3 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (989mg, 3.3mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (5 ml) of compound 1a (319 mg, 2.14 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 140 mg of a white solid. Yield = 18% \n1\nHNMR (DMSO, 400 MHz)  4.44 (2H, d, J = 5.6 Hz), 6.64 (1H, d, J = 7.2 Hz), 6.84 (1H, t, J = 8.4 Hz), 6.89 (1H, t), 6.96 (1H, d, J = 8 Hz), 7.64 (1H, d, J = 8.4 Hz), 7.74 (1H, d), 7.86 (1H, s), 8.43 (1H, bs), 9.99 (1H, bs), 10.61 (1H, bs); [M\n+1\n] 385.0 (C\n16\nH\n12\nC\n12\nC1F\n3\nN\n4\nO\n2\n requires 384.74).\n\n\n \n\n\nExample 4: 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 2-(dimethylamino)-4-(trifluoromethyl)benzonitrile \n14a\n (scheme 7)\n\n\n \n \n \n \nTo commercially available 2-chloro-4-benzonitrile (0.5 ml, 3.6 mmol) dimethylamine (4equiv., 0.95 ml) was added and the solution was heated in closed vessel at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 730 mg of a pale yellow oil. Yield = 94% \n1\nHNMR (CDCI\n3\n, 200 MHz)  3.13 (6H, s), 7.05 (1H, bs), 7.59 (1H, dd, J = 8.4 Hz, J' = 0.6 Hz), 7.99 (1H, bs)\n\n\n \n \n \n \nPreparation of 2-(aminomethyl)-5-(trifluoromethyl)-N,N-dimethylbenzenamine \n2a\n (scheme 7)\n\n\n \n \n \n \nBenzonitrile \n14a\n (730 mg, 3.4 mmol) dissolved in 5 ml of ether was added dropwise at OC to LiA1H\n4\n (2 equiv., 260mg) suspended in diethyl ether (40ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 720mg of a yellow oil. Yield = 97% \n1\nHNMR (CDCl\n3\n, 200 MHz)  2.78 (6H, s), 3.95 (2H, s), 7.36 (2H, m), 7.49 (1H, d)\n\n\n \n \n \n \nPreparation of 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea.\n\n\n \n \n \n \nAmine \n2a\n (1.3 g, 5.9 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (1.75 g, 5.9 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound 1a (860 mg, 5.77 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 650mg of a yellow solid. Yield = 28% \n1\nHNMR (DMSO, 200 MHz)  2.51 (6H, bs), 4.43 (2H, d, J = 5.6 Hz), 6.62 (1H, dd, J = 7.6 Hz, J' = 1 Hz), 6.82 (2H, m), 6.97 (1H, dd, J = 8 Hz, J' = 1 Hz), 7.32 (1H, s), 7.39 (1H, d), 7.49 (1H, d), 8.35 (1H, bs), 9.99 (1H, bs), 10.59 (1H, bs); [M\n+1\n] 394.1 (C\n18\nH\n18\nF\n3\nN\n5\nO\n2\n requires 393.36).\n\n\n \n\n\nExample 5: 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzonitrile \n14b\n (scheme 8)\n\n\n \n \n \n \nTo commercially available 2-chloro-4-benzonitrile (1ml, 7.2 mmol) pyrrolidine (4equiv., 2.38 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 940mg of a yellow solid. Yield = 54% \n1\nHNMR (DMSO, 200 MHz)  1.95 (4H, m), 3.58 (4H, m), 6.94 (2H, m), 7.73 (1H, dd, J = 8 Hz, J' = 0.8 Hz)\n\n\n \n \n \n \nPreparation of (4-(trifluoromethyl)-2-(pyrrolidin-1-yl)phenyl)-methanamine \n2b\n \n\n\n \n \n \n \nBenzonitrile \n14b\n (940mg, 3.9mmol) dissolved in 5ml of ether was added dropwise at 0C to LiAIH\n4\n (2equiv., 297 mg) suspended in diethyl ether (40 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 1g of a yellow oil. Yield = 99% \n1\nHNMR (DMSO, 200 MHz)  1.88 (4H, m), 3.17 (4H, m), 3.76 (2H, s), 7.00 ((1H, s), 7.14 (1H, m), 7.59 (1H, d, J = 8.2 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2b\n (0.5 ml, 2 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (580 mg, 2 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10ml) of compound \n1a\n (296mg, 1.99mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 170 mg of a yellow solid. Yield = 20% \n1\nHNMR (DMSO, 400 MHz)  1.91 (4H, bs), 3.22 (4H, bs), 4.38 (2H, d, J = 5.2 Hz), 6.62 (1H, d, J = 8 Hz), 6.72 (1H, t), 6.83 (1H, t), 6.95 (1H, d, J = 8 Hz), 7.08 (1H, s), 7.18 (1H, d, J = 7.6 Hz), 7.45 (1H, d, J = 7.6 Hz), 8.35 (1H, bs), 9.98 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 420.18 (C\n20\nH\n20\nF\n3\nN\n5\nO\n2\n requires 419.4).\n\n\n \n\n\nExample 6: 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-(trifluoromethyl)-2-(piperidin-1-yl)benzonitrile \n14c\n (scheme 7)\n\n\n \n \n \n \nTo commercially available 2-chloro-4-benzonitrile (1 ml, 7.2 mmol) was added piperidine (4equiv., 2.8ml) and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 1 g of a yellow oil. Yield = 56% \n1\nHNMR (DMSO, 200 MHz)  1.60 (6H, m), 3.20 (4H, m), 7.34 (2H, m), 7.89 (1H, dd, J = 8.6 Hz, J' = 0.4 Hz)\n\n\n \n \n \n \nPreparation of (4-(trifluoromethyl)-2-(piperidin-1-yl)phenyl)-methanamine \n2c\n \n\n\n \n \n \n \nBenzonitrile \n14c\n (1g, 4mmol) dissolved in 5 ml of ether was added dropwise at 0C to LiA1H\n4\n (2equiv., 305 mg) suspended in diethyl ether (40 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 980mg of a yellow oil. Yield = 95% \n1\nHNMR (DMSO, 200 MHz)  1.57 (6H, m), 1.80 (2H, bs), 2.81 (4H, m), 3.78 (2H, s), 7.23 (1H, s), 7.35 (1H, d, J = 7.8 Hz), 7.70 (1H, d, J = 8.2 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea.\n\n\n \n \n \n \nAmine \n2c\n (500 mg, 1.9 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (580 mg, 2 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (265 mg, 1.78 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 140 mg of a pale yellow solid. Yield = 18% \n1\nHNMR (DMSO, 400 MHz)  1.54 (2H, m), 1.68 (4H, m), 2.85 (4H, m), 4.42 (2H, d, J = 6 Hz), 6.63 (1H, d, J = 7.6 Hz), 6.76 (1H, t), 6.84 (1H, t, J = 8.4 Hz), 6.95 (1H, d, J = 8.4 Hz), 7.31 (1H, s), 7.41 (1H, d), 7.52 (1H, d, J = 8.4 Hz), 8.33 (1H, s), 10.01 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 434.11 (C\n21\nH\n22\nF\n3\nN\n5\nO\n2\n requires 433.43).\n\n\n \n\n\nExample 7: 1-(4-(trifluoromethyl)-2-morpholinobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-(trifluoromethyl)-2-morpholinobenzonitrile \n14d\n (scheme 7)\n\n\n \n \n \n \nTo commercially available 2-chloro-4-benzonitrile (4 ml, 29 mmol) morpholine (4equiv., 10 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 6.19 g of a yellow oil. Yield = 83% \n1\nHNMR (DMSO, 200 MHz)  3.24 (4H, m), 3.75 (4H, m), 7.94 (1H, m), 8.23 (1H, m).\n\n\n \n \n \n \nPreparation of (4-(trifluoromethyl)-2-morpholinophenyl)methanamine \n2d\n \n\n\n \n \n \n \nBenzonitrile \n14d\n (6.19 g, 24.2 mmol) dissolved in 15ml of ether was added dropwise at 0C to LiAIH\n4\n (2equiv., 1.83 g) suspended in diethyl ether (60 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 5.3 g of a yellow oil. Yield = 84% \n1\nHNMR (DMSO, 200 MHz)  2.88 (4H, m), 3.20 (2H, bs), 3.72 (4H, m), 3.77 (2H, s), 7.27 (1H, s), 7.38 (1H, dd, J = 7.8 Hz, J' = 1 Hz), 7.72 (1H, d, J = 8 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-morpholinobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2d\n (300 mg, 1.15mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (350 mg, 1 equiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound 1a (200 mg, 1.3 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 100mg of a pale yellow solid. Yield = 20% \n1\nHNMR (DMSO, 200 MHz)  2.91 (4H, m), 3.76 (4H, m), 4.44 (2H, d, J = 5.6 Hz), 6.63 (1H, d, J = 7.6 Hz), 6.88 (3H, m), 7.64 (1H, d, J = 8.2 Hz), 7.73 (1H, d), 7.85 (1H, bs), 8.44 (1H, bs), 9.99 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 436.2 (C\n20\nH\n20\nF\n3\nN\n5\nO\n3\n requires 435.4).\n\n\n \n \n \n \n\n\nExample 8: 1-(4-(trifluoromethyl)-2-(1H-1,2,4-triazol-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \n \nPreparation of 4-(trifluoromethyl)-2-(1H-1,2,4-triazol-1-yl)benzonitrile 14e (scheme7)\n\n\n \n \n \n \nTo commercially available 2-chloro-4-benzonitrile (1ml, 7.2 mmol) in DMF 1 equiv. of NaH and 1,2,4-tetrazole (4equiv., 1.98 g) were added and the mixture was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 900mg of a yellow solid. Yield = 53% \n1\nHNMR (DMSO, 200 MHz)  8.08 (1H, dd, J = 7.6 Hz, J' = 1 Hz), 8.33 (3H, m), 9.29 (1H, s).\n\n\n \n \n \n \nPreparation of (4-(trifluoromethyl)-2-(1H-1,2,4-triazol-1-yl)phenyl)-methanamine \n2e\n \n\n\n \n \n \n \nBenzonitrile \n14e\n (860 mg, 3.6 mmol) dissolved in 5ml of ether was added dropwise at 0C to LiAIH\n4\n (2equiv., 276 mg) suspended in diethyl ether (20 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 600 mg of a red oil. Yield = 70% \n1\nHNMR (DMSO, 200 MHz)  3.31 (2H, bs), 3.64 (2H,s), 7.85 (3H, m), 8.28 (1H, s), 9.02 (1H, s).\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(1H-1,2,4-triazol-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine 2e (600 mg, 2.48 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (755 mg, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (450 mg, 3 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 110 mg of an orange solid. Yield = 10% \n1\nHNMR (DMSO, 200 MHz)  4.30 (2H, d, J = 6 Hz), 6.64 (1H, dd, J = 7.4 Hz, J' = 1.2 Hz), 6.79 (2H, m), 6.91 (1H, dd), 7.83 (1H, d), 7.92 (2H, d), 8.33 (1H, bs), 8.42 (1H, bs), 9.07 (1H, bs), 9.94 (1H, bs), 10.59 (1H, bs); [M\n+1\n] 418.2 (C\n18\nH\n14\nF\n3\nN\n7\nO\n2\n requires 417.34).\n\n\n \n\n\nExample 9: 1-(4-fluorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-fluorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nCommercially available p-fluorobenzylamine (0.76 ml, 6.7 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (1.98 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (900 mg, 6 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 420 mg of a white solid. Yield = 23% \n1\nHNMR (DMSO, 200 MHz)  4.29 (2H, d, J = 6 Hz), 6.62 (1H, dd, J = 7.6Hz, J' = 1.2 Hz), 6.80 (2H, m), 6.95 (1H, dd, J = 8.2 Hz, J' = 1.2 Hz), 7.15 (2H, m), 7.35 (2H, m), 8.23 (1H, bs), 9.96 (1H, bs), 10.59 (1H, bs); [M\n+1\n] 301.1 (C\n15\nH\n13\nFN\n4\nO\n2\n requires 300.29).\n\n\n \n\n\nExample 10: 1-(4-chlorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-chlorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nCommercially available p-chlorobenzylamine (846 mg, 6 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (1.78 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound 1a (900 mg, 6 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 300 mg of a white solid. Yield = 16% \n1\nHNMR (DMSO, 200 MHz)  4.30 (2H, d, J = 6.2 Hz), 6.62 (1H, dd, J = 7.6 Hz, J' = 1.2 Hz), 6.83 (2H, m), 6.96 (1H, dd, J = 8 Hz, J' = 1 Hz), 7.35 (4H, m), 8.27 (1H, bs), 9.98 (1H, bs), 10.59 (1H, bs); [M\n+1\n] 317.1 (C\n15\nH\n13\nClN\n4\nO\n2\n requires 316.74).\n\n\n \n\n\nExample 11: 1-(4-chloro-2-(dimethylamino)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-chloro-2-(dimethylamino)benzonitrile \n16af\n (scheme 8) To commercially available 2-fluoro-4-chlorobenzonitrile (2 g, 12.8 mmol) dimethylamine (4equiv., 3.5 ml) was added and the solution was heated in closed vessel at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The residue was purified by chromatographic column using EtOAc 1 / petroleum ether 9 as eluant obtaining 1.95 g of a transparent oil. Yield = 87% \n1\nHNMR (DMSO, 200 MHz)  3.01 (6H, s), 6.91 (1H, dd, J = 8.4 Hz, J' = 2 Hz), 7.02 (1H, d, J = 2 Hz), 7.60 (1H, d, J = 8.4 Hz)\n\n\n \n \n \n \nPreparation of 2-(aminomethyl)-5-chloro-N,N-dimethylbenzenamine \n2af\n \n\n\n \n \n \n \nBenzonitrile \n16af\n (1.95 g, 10.8 mmol) dissolved in 5 ml of ether was added dropwise at 0C to LiAIH\n4\n (2equiv., 821 mg) suspended in diethyl ether (20 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 2 g of a pale yellow oil. Yield = 98% \n1\nHNMR (DMSO, 200 MHz)  1.72 (2H, bs), 2.61 (6H, s), 3.71 (2H, s), 6.99 (1H, m), 7.05 (1H, d, J = 2.2 Hz), 7.46 (1H, d, J = 8 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-chloro-2-(dimethylamino)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2af\n (1 g, 5.5 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.63 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound 1a (820 mg, 5.5 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 550mg of a white solid. Yield = 28% \n1\nHNMR (DMSO, 200 MHz)  2.64 (6H, s), 4.34 (2H, d, J = 5.8 Hz), 6.62 (1H, dd, J = 7.2 Hz, J' = 1 Hz), 6.73 (1H, t), 6.83 (1H, t, J = 7.6 Hz), 6.90 (1H, dd, J = 8.2 Hz, J' = 1Hz), 7.06 (2H, m), 7.31 (1H, d, J = 8.8 Hz), 8.33 (1H, bs), 9.98 (1H, bs), 10.59 (1H, bs); [M\n+1\n] 360.7 (C\n17\nH\n18\nClN\n5\nO\n2\n requires 359.81).\n\n\n \n\n\nExample 12: 1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-chloro-2-(pyrrolidin-1-yl)benzonitrile \n16ag\n (scheme 8)\n\n\n \n \n \n \nTo commercially available 2-fluoro-4-chlorobenzonitrile (3 g, 19.3 mmol) pyrrolidine (4equiv., 6.38 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The residue was purified by crystallization from water obtaining 3.86 g of a pale yellow solid. Yield = 97% \n1\nHNMR (DMSO, 200 MHz)  1.93 (4H, m), 3.51 (4H, m), 6.69 (1H, dd, J = 8.4 Hz, J' = 1.8 Hz), 6.76 (1H, d, J = 2 Hz), 7.49 (1H, d, J = 8.4 Hz)\n\n\n \n \n \n \nPreparation of (4-chloro-2-(pyrrolidin-1-yl)phenyl)methanamine \n2ag\n \n\n\n \n \n \n \nBenzonitrile \n16ag\n (3.8 g, 18.4 mmol) dissolved in 15 ml of ether was added dropwise at 0C to LiAIH\n4\n (2equiv., 1.4 g) suspended in diethyl ether (30 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 4 g of a yellow oil. Yield = 98% \n1\nHNMR (DMSO, 200 MHz)  1.72 (2H, bs), 1.86 (4H, m), 3.14 (4H, m), 3.68 (2H, s), 6.77 (1H, d, J = 2 Hz), 6.80 (1H, dd, J = 8.2 Hz), 7.36 (1H, d, J = 8 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine 2ag (1g, 4.76mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.4 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10ml) of compound \n1a\n (700 mg, 4.9 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 360 mg of a white solid. Yield = 19% \n1\nHNMR (DMSO, 200 MHz)  1.89 (4H, m), 3.17 (4H, m), 4.30 (2H, d, J = 5.4 Hz), 6.61 (1H, dd, J = 7.6 Hz, J' = 1 Hz), 6.69 (1H, t), 6.87 (4H, m), 7.24 (1H, d, J = 7.8 Hz), 8.38 (1H, bs), 10.00 (1H, bs), 10.59 (1H, bs); [M\n+1\n] 386.7 (C\n19\nH\n20\nClN\n5\nO\n2\n requires 385.85).\n\n\n \n\n\nExample 13: 1-(4-chloro-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n\n\n \n \n \nPreparation of 4-chloro-2-(piperidin-1-yl)benzonitrile \n16ah\n (scheme 8)\n\n\n \n \n \n \nTo commercially available 2-fluoro-4-chlorobenzonitrile (2.2 g, 12.87 mmol) piperidine (4equiv., 5.6 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and to the residue water was added and the solid material was filtrated, washed with water and dried obtaining 3 g of a pale yellow solid. Yield = 97% \n1\nHNMR (DMSO, 200 MHz)  1.54 (2H, m), 1.65 (4H, m), 3.14 (4H, m), 7.09 (1H, dd, J = 8.2 Hz, J' = 2 Hz), 7.14 (1H, m), 7.69 (1H, d, J = 8.4 Hz)\n\n\n \n \n \n \nPreparation of (4-chloro-2-(piperidin-1-yl)phenyl)methanamine \n2ah\n \n\n\n \n \n \n \nBenzonitrile \n16ah\n (3 g, 13.6 mmol) dissolved in 20ml of ether was added dropwise at 0C to LiAIH\n4\n (2equiv., 1.03 g) suspended in diethyl ether (30 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 2.92 g of a yellow oil. Yield = 96% \n1\nHNMR (DMSO, 200 MHz)  1.52 (2H, m), 1.61 (4H, m), 2.23 (2H, bs), 2.76 (4H, m), 3.69 (2H, s), 6.97 (1H, d, J = 2.2 Hz), 7.04 (1H, dd, J = 8.2 Hz, J' = 2.2 Hz), 7.46 (1H, d, J = 8 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-chloro-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2ah\n (1.34g, 6mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.78 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound 1a (900 mg, 6 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 40 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 750 mg of a white solid. Yield = 31% \n1\nHNMR (DMSO, 200 MHz)  1.58 (2H, m), 1.66 (4H, m), 2,78 (4H, M), 4.32 (2H, d, J = 6 Hz), 6.63 (1H, dd), 6.73 (1H, t), 6.94 (1H, t), 6.95 (1H, dd), 7.06 (2H, m), 7.29 (1H, d), 8.35 (1H, bs), 10.05 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 400.2 (C\n20\nH\n22\nClN\n5\nO\n2\n requires 399.87)\n\n\n \n\n\nExample 14: 1-(4-(dimethylamino)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of compound 4-(aminomethyl)-N,N-dimethylbenzenamine 2i (scheme 9)\n\n\n \n \n \n \nCommercially available 4-dimetylaminobenzonitrile (2 g, 13.7 mmol) dissolved in 15 ml of ether was added dropwise at OC to LiAIH\n4\n (2equiv., 1 g) suspended in diethyl ether (40ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 1.85 g of a pale yellow oil. Yield = 90% \n1\nHNMR (DMSO, 200 MHz)  1.60 (2H, bs), 2.84 (6H, s), 3.57 (2H, s), 6.67 (2H, d, J = 8.8 Hz), 7.12 (2H, d, J = 8.6 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-(dimethylamino)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \n4-(aminomethyl)-N,N-dimethylbenzenamine \n2i\n (1 g, 6.9 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (2 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (1 g, 6.9 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 350 mg of a white solid. Yield = 16% \n1\nHNMR (DMSO, 200 MHz)  2.51 (6H, s), 4.18 (2H, d, J = 5.6 Hz), 6.58 (2H, m), 6.69 (2H, d, J = 8.8 Hz), 6.86 (2H, m), 7.14 (2H, d, J = 8.8 Hz), 8.18 (1H, s), 9.98 (1H, bs), 10.58 (1H, bs); [M\n+1\n] 326.5 (C\n17\nH\n19\nN\n5\nO\n2\n requires 325.37).\n\n\n \n\n\nExample 15: 1-(4-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-(pyrrolidin-1-yl)benzonitrile \n181\n (scheme 9)\n\n\n \n \n \n \nTo commercially available 4-chlorobenzonitrile (5 g, 36 mmol) 12 ml of pyrrolidine were added and the reaction was heated at 100C for 24 hours in closed vessel. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The purification of the crude residue by chromatographic column using AcOEt 1 / Petroleum ether 9 as eluant gave 1.68 g of a pale yellow solid. Yield = 33% \n1\nHNMR (DMSO, 200 MHz)  1.96 (4H, m), 3.28 (4H, m), 6.58 (2H, d, J = 9 Hz), 7.51 (2H, d, J = 9 Hz)\n\n\n \n \n \n \nPreparation of (4-(pyrrolidin-1-yl)phenyl)methanamine \n21\n \n\n\n \n \n \n \nBenzonitrile \n181\n (1.68 g, 9.76 mmol) dissolved in 10 ml of ether was added drop wise at 0C to LiA1H\n4\n (2equiv., 742 mg) suspended in diethyl ether (40 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 1.48 g of a yellow oil. Yield = 86% \n1\nHNMR (DMSO, 200 MHz)  1.60 (2H, bs), 1.93 (4H, m), 3.17 (4H, m), 3.57 (2H, s), 6.46 (2H, d, J = 8.6 Hz), 7.09 (2H, d, J = 8.4 Hz).\n\n\n \n \n \n \nPreparation of 1-(4-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \n(4-(pyrrolidin-1-yl)phenyl)methanamine \n21\n (774 mg, 4.4 mmol) was dissolved in 40ml of AcOEt and at 0C triphosgene (1.3 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (660 mg, 4.4 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 250 mg of a white solid. Yield = 16% \n1\nHNMR (DMSO, 200 MHz)  1.92 (4H, m), 3.17 (4H,m), 4.17 (2H, d, J = 5.6 Hz), 6.58 (4H, m), 6.84 (2H, m), 7.12 (2H, d, J = 8.6 Hz), 8.16 (1H, bs), 9.93 (1H, bs), 10.58 (1H, bs); [M\n+1\n] 352.3 (C\n19\nH\n21\nN\n5\nO\n2\n requires 351.4).\n\n\n \n\n\nExample 16: 1-(4-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-(piperidin-1-yl)benzonitrile \n18m\n (scheme 9)\n\n\n \n \n \n \nTo commercially available 4-chlorobenzonitrile (1 g, 7.26 mmol) 3 ml of piperidine were added and the reaction was heated at 100C for 72 hours in closed vessel. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The purification of the crude residue by chromatographic column using AcOEt 1 / Petroleum ether 9 as eluant gave 1.2 g of a pale yellow oil. Yield = 89% \n1\nHNMR (DMSO, 200 MHz)  1.57 (6H, m), 3.34 (4H, m), 6.98 (2H, d, J = 9 Hz), 7.53 (2H, d, J = 9 Hz)\n\n\n \n \n \n \nPreparation of (4-(piperidin-1-yl)phenyl)methanamine \n2m\n \n\n\n \n \n \n \nBenzonitrile \n18m\n (1.2 g, 6.48 mmol) dissolved in 10 ml of ether was added dropwise at 0C to LiA1H\n4\n (2equiv., 493 mg) suspended in diethyl ether (40 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 1g of an orange oil. Yield = 82%. \n1\nHNMR (DMSO, 200 MHz)  1.57 (6H, m), 3.06 (4H, m), 3.58 (2H, s), 6.84 (2H, d, J = 8.6 Hz), 7.13 (2H, d, J = 8.4 Hz), 7.33 (2H, bs).\n\n\n \n \n \n \nPreparation of 1-(4-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \n(4-(piperidin-1-yl)phenyl)methanamine \n2m\n (1.47 g, 7.8 mmol) was dissolved in 40 ml of AcOEt and at OC triphosgene (2.3 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (1.15 g, 7.8 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 520 mg of a pale yellow solid. Yield = 18% \n1\nHNMR (DMSO, 200 MHz)  1.58 (6H, m), 3.08 (4H, m), 4.19 (2H, d, J = 6 Hz), 6.62 (2H, m), 6.86 (4H, m), 7.15 (2H, d, J = 8.8 Hz), 8.19 (1H, bs), 9.95 (1H, bs), 10.58 (1H, bs); [M\n+1\n] 366.3 (C\n20\nH\n23\nN\n5\nO\n2\n requires 365.43).\n\n\n \n\n\nExample 17: 1-(4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1-H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nCommercially available p-methylbenzylamine (0.88 ml, 6.97 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (2 g, lequiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20 ml of DMF. The solution of the isocyanate was added drop wise to a solution in DMF (10 ml) of compound \n1a\n (1 g, 6.97 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 350 mg of a white solid. Yield = 17% \n1\nHNMR (DMSO, 200 MHz)  6.61 (1H, dd, J = 7.6 Hz, J' = 1.2 Hz), 6.70 (1H, t), 6.83 (1H, t, J = 8 Hz), 6.92 (1H, dd, J = 8 Hz, J' = 1 Hz), 7.17 (4H, dd, J = 15.6 Hz, J' = 8.2 Hz), 8.22 (1H, bs), 9.96 (1H, bs), 10.58 (1H, bs); [M\n+1\n] 297.1 (C\n16\nH\n16\nN\n4\nO\n2\n requires 296.32).\n\n\n \n\n\nExample 18: 1-(2-(dimethylamino)-4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-(dimethylamino)-2-(piperidin-1-yl)benzonitrile \n16bf\n (scheme 8)\n\n\n \n \n \n \nTo commercially available 2-fluoro-4-methylbenzonitrile (2.5 g, 18.5 mmol) was added dimethylamine (4equiv., 4.8 ml) and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 2.96 g of a yellow oil. Yield = 99% \n1\nHNMR (DMSO, 200 MHz)  2.31 (3H, s), 2.93 (6H, s), 6.74 (1H, dd, J = 8 Hz, J' = 0.8 Hz), 6.85 (1H, s), 7.47 (1H, d, J = 8 Hz)\n\n\n \n \n \n \nPreparation of (4-(dimethylamino)-2-(piperidin-1-yl)phenyl)methanamine \n2bf\n \n\n\n \n \n \n \nBenzonitrile \n16bf\n (2.9 g, 18.1 mmol) dissolved in 25 ml of ether was added dropwise at 0C to LiA1H\n4\n (2equiv., 1.38 g) suspended in diethyl ether (40 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 2.35 g of an oil. Yield = 80% \n1\nHNMR (DMSO, 200 MHz)  2.65 (2H, bs), 2.25 (3H, s), 2.60 (6H, s), 3.70 (2H, s), 6.80 (2H, m), 7.27 (1H, d, J = 7.4Hz)\n\n\n \n \n \n \nPreparation 1-(2-(dimethylamino)-4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2bf\n (1.1 g, 6.7 mmol) was dissolved in 40ml of AcOEt and at 0C triphosgene (1.93 g, 6.7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 15ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (1 g, 6.7 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 450 mg of a pale yellow solid. Yield = 19% \n1\nHNMR (DMSO, 200 MHz)  2.26 (3H, s), 2.59 (6H, m), 4.33 (2H, d, J = 5.6 Hz), 6.60 (2H, m), 6.87 (4H, m), 7.18 (1H, d, J = 7.6 Hz), 8.28 (1H, s), 9.96 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 339.56 (C\n18\nH\n21\nN\n5\nO\n2\n requires 339.39).\n\n\n \n\n\nExample 19: 1-(4-methyl-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-(methyl)-2-(piperidin-1-yl)benzonitrile \n16bh\n (scheme 8)\n\n\n \n \n \n \nTo commercially available 2-fluoro-4-methylbenzonitrile (2.5 g, 18.5mmol) was added piperidine (4equiv., 7.3 ml) and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 2.3 g of a white solid. Yield = 65% \n1\nHNMR (DMSO, 200 MHz)  1.62 (6H, m), 2.32 (3H, s), 3.07 (4H, m), 6.87 (1H, dd, J = 7.8 Hz, \nJ'\n = 0.8 Hz), 6.95 (1H, s), 7.53 (1H, d, J = 7.8 Hz)\n\n\n \n \n \n \nPreparation of (4-(methyl)-2-(piperidin-1-yl)phenyl)methanamine \n2bh\n \n\n\n \n \n \n \nBenzonitrile \n16bh\n (2.3 g, 11.5 mmol) dissolved in 15 ml of ether was added dropwise at 0C to LiA1H\n4\n (2equiv., 873 mg) suspended in diethyl ether (40 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 2.25 g of an oil. Yield = 96% \n1\nHNMR (DMSO, 200 MHz)  1.59 (6H, m), 2.24 (3H, s), 2.76 (4H, m), 3.67 (2H, s), 6.80 (2H, m), 7.27 (1H, d, J = 8.4 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-methyl-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2bh\n (1.1 g, 5.4 mmol) was dissolved in 40ml of AcOEt and at 0C triphosgene (1.56 g, 5.4 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 15 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (1 g, 6.7 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 450 mg of a white solid. Yield = 22% \n1\nHNMR (DMSO, 200 MHz)  1.58 (6H, m), 2.78 (4H, m), 4.34 (2H, d, J = 5.8 Hz), 6.59 (2H, m), 6.90 (4H, m), 7.18 (1H, d, J = 7.6 Hz), 8.26 (1H, s), 10.01 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 379.51 (C\n21\nH\n25\nN\n5\nO\n2\n requires 379.46).\n\n\n \n\n\nExample 20: 1-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)-3-((pyridin-4-yl)methyl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)-3-((pyridin-4-yl)methyl)urea\n\n\n \n \n \n \nCommercially available 4-amino-methylpyridine (2 g, 20.8 mmol) was dissolved in 60 ml of AcOEt and at 0C triphosgene (5.8 g, 21 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (3.16 g, 21 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (80 ml) and washed with water (1 X 40ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 640 mg of a white solid. Yield = 11% \n1\nHNMR (DMSO, 200 MHz)  4.34 (2H, d, J = 5.8 Hz), 6.62 (1H, dd, J = 7.6 Hz, J' = 1 Hz), 6.92 (3H, m), 7.31 (2H, dd, J = 4.4 Hz, J' = 1.4 Hz), 8.49 (3H, m), 10.03 (1H, bs), 10.59 (1H, bs); [M\n+1\n] 284.1 (C\n14\nH\n13\nN\n5\nO\n2\n requires 283.29).\n\n\n \n\n\nExample 21: 1-((6-chloropyridin-3-yl)methyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-((6-chloropyridin-3-yl)methyl)-3-(2,3-dihydro-2-oxo-1 H-benzo [d] imidazol-4-yl)urea\n\n\n \n \n \n \nCommercially available (6-chloropyridin-3-yl)methanamine (1 g, 7 mmol) was dissolved in 40 ml of AcOEt and at OC triphosgene (1.93 g, 7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10ml) of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10ml) of compound \n1a\n (1 g, 6.7 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (80 ml) and washed with water (1 X 40 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 450 mg of a pale yellow solid. Yield = 21% \n1\nHNMR (DMSO, 200 MHz)  4.32 (2H, d, J = 5.8 Hz), 6.62 (1H, d, J = 7.2 Hz), 6.85 (3H, m), 7.48 (1H, d, J = 8.4 Hz), 7.81 (1H, dd, J = 8.2 Hz, J' = 2.4 Hz), 8.33 (2H, m), 10.02 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 317.8 (C\n14\nH\n12\nClN\n5\nO\n2\n requires 317.73).\n\n\n \n\n\nExample 22: 1-(4-chloro-2-(3-hydroxypyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-chloro-2-(3-hydroxypyrrolidin-1-yl)benzonitrile \n16ai\n (scheme 8)\n\n\n \n \n \n \nTo commercially available 2-fluoro-4-chlorobenzonitrile (1 g, 6.4 mmol) was added 3-pyrrolidinl-ol (2equiv., 1 g) and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 1.2 g of a white solid. Yield = 85% \n1\nHNMR (DMSO, 200 MHz)  1.91 (2H, m), 3.54 (4H, m), 4.37 (1H, b), 5.06 (1H, bd, J = 3.4 Hz), 6.72 (2H, m), 7.50 (1H, d, J = 8.2 Hz)\n\n\n \n \n \n \nPreparation of 1-(2-(aminomethyl)-5-chlorophenyl)pyrrolidin-3-ol \n2ai\n \n\n\n \n \n \n \nBenzonitrile \n16ai\n (1.2 g, 5.4 mmol) dissolved in 15 ml of ether was added dropwise at 0C to LiAlH\n4\n (2equiv., 410 mg) suspended in diethyl ether (40 ml). The mixture was stirred at room temperature for 24 hours. The reaction was quenched by addition of water and filtrated and the salts were washed with ether. The organic phase was separated, anhydrified and evaporated giving 1.18 g of an oil. Yield = 96% \n1\nHNMR (DMSO, 200 MHz)  1.90 (2H, m), 3.34 (4H, m), 3.67 (2H,s), 4.27 (1H, b), 4.90 (1H, b), 6.76 (2H, m), 7.34 (1H, d, J = 8 Hz)\n\n\n \n \n \n \nPreparation of 1-(4-chloro-2-(3-hydroxypyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \n1-(2-(aminomethyl)-5-chlorophenyl)pyrrolidin-3-ol \n2ai\n (1.18 g, 5.2 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (1.4 g, 5.2 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1a\n (674 mg, 4.52 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 8 / MeOH 2). The solvent was evaporated and the crude was dissolved in AcOEt (80 ml) and washed with water (1 X 40 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 390mg of a pale pink solid. Yield = 21% \n1\nHNMR (DMSO, 200 MHz)  2.20 (2H, m), 3.33 (4H, m), 3.69 (2H, s), 4.29 (1H, b), 5.20 (1H, b), 6.62 (2H, m), 6.90 (4H, m), 7.27 (1H, d, J = 8 Hz), 8.29 (1H, s), 9.95 (1H, bs), 10.60 (1H, bs); [M\n+1\n] 402.4 (C\n19\nH\n20\nClN\n5\nO\n3\n requires 401.85).\n\n\n \n\n\nExample 23: 1-(5-(trifluoromethyl-furan-2-yl)-methyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(5-(trifluoromethyl-furan-2-yl)-methyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea\n\n\n \n \n \n \nCommercially available 2-(aminomethyl)-5-(trifluoromethyl)furan (1 ml, 7.7 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (2.20 g, 7.7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added drop wise to a solution in DMF (5ml) of compound \n1a\n (720 mg, 4.8 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 780 mg of a white solid. Yield = 29% \n1\nHNMR (DMSO, 400 MHz)  4.38 (2H, d, J = 6 Hz), 6.51 (d, 1H, J=2), 6.64 (d,1H), 6.85 (m, 2H), 6.87 (m, 1H), 7.15 (m, 1H), 8.30 (s, 1H), 9.97 (s, 1H), 10.60 (s, 1H); [M\n+1\n] 340.5 (C\n14\nH\n11\nF\n4\nN\n4\nO\n3\n requires 340.26).\n\n\n \n\n\nExample 24: 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-nitrobenzo[d]oxazol-2(3H)-one \n4b\n (scheme 2)\n\n\n \n \n \n \nTo 2-hydroxy-6-nitrophenol \n3b\n (2 g, 13.00 mmol) dissolved in THF (50 ml) was added in one portion DCI (1.5equiv., 19.6 mmol, 3.176 g) and the reaction was refluxed for 4 hours. (TLC AcOEt 1 / petroleum ether 1). The reaction was evaporated and the crude material was dissolved in HCL 2N and extracted 3 times with chloroform. The combined organic phases were washed with water, brine, dried over sodium sulfate and concentrated under vacuum. The crude solid was crystallized from ether giving 1,5g of a beige solid. Yield = 65% \n1\nHNMR (DMSO, 200 MHz)  7.27 (1H, t, J = 7.8 Hz), 7.72 (1H, dd, J = 8.2 Hz, J' = 1 Hz), 7.93 (1H, dd, J = 8.4 Hz, J' = 0.6 Hz), 12.64 (1H, bs)\n\n\n \n \n \n \nPreparation of 4-aminobenzo[d]oxazol-2(3H)-one \n1b\n (scheme 2)\n\n\n \n \n \n \nTo compound \n4b\n (1 g, 5.72 mmol) dissolved in a mixture of 4/1 MeOH/THF (50 ml) C/Pd 10% (250 mg) was added and the reaction was hydrogenated at 60 psi overnight. (TLC AcOEt) The reaction was filtrated through a pad of Celite and the filtrate was evaporated under vacuum. The crude solid was crystallized from ether giving 476mg of a white solid. Yield = 55.5%. \n1\nHNMR (DMSO, 200 MHz)  5.07 (2H, bs), 6.47 (2H, m), 6.79 (1H, t, J = 8 Hz), 10.93 (1H, bs)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nCommercially available 4-trifluoromethylbenzylamine (0.5 ml, 3.5 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1 g, 3.5 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (5 ml) of compound \n1b\n (350 mg, 2.33 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 200 mg of a white solid. Yield = 24% \n1\nHNMR (DMSO, 400 MHz)  4.41 (2H, d, J = 6 Hz), 6.98 (3H, m), 7.05 (1H, m), 7.55 (2H, d), 7.70 (2H, d, J = 8 Hz), 8.49 (1H, bs), 11.00 (1H, bs); [M\n+1\n] 352.1 (C\n16\nH\n12\nF\n3\nN\n3\nO\n3\n requires 351.28).\n\n\n \n\n\nExample 25: 1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nCommercially available 2-fluoro-4-trifluoromethylbenzylamine (0.5 ml, 3.7 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (1.12 g, 3.7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added drop wise to a solution in DMF (5 ml) of compound \n1b\n (360 mg, 2.4 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 100 mg of a white solid. Yield = 11% \n1\nHNMR (DMSO, 400 MHz)  4.43 (2H, d, J = 6 Hz), 6.99 (3H, m), 7.05 (1H, m), 7.62 (3H, m), 8.53 (1H, bs), 10.98 (1H, bs); [M\n+1\n] 370.1 (C\n16\nH\n11\nF\n4\nN\n3\nO\n3\n requires 369.27).\n\n\n \n\n\nExample 26: 1-(2-chloro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(2-chloro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nCommercially available 2-chloro-4-trifluoromethylbenzylamine (572 mg, 2.7 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (809 mg, 2.7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (5 ml) of compound \n1b\n (270 mg, 1.8 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 70 mg of a white solid. Yield = 10% \n1\nHNMR (DMSO, 400 MHz)  4.45 (2H, d, J = 6 Hz), 6.97 (2H, d, J = 4.4 Hz), 7.07 (2H, m), 7.63 (1H, d, J = 8 Hz), 7.74 (2H, d), 7.86 (1H, s), 8.61 (1H, bs), 10.90 (1H, bs); [M\n+1\n] 386.6 (C\n16\nH\n11\nClF\n3\nN\n3\nO\n3\n requires 385.7).\n\n\n \n\n\nExample 27: 1-(4-fluoro-2-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-fluoro-2-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nCommercially available 4-fluoro-2-trifluoromethylbenzylamine (0.5 ml, 3.7 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.12 g, 3.7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (5ml) of compound \n1b\n (360 mg, 2.4 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 4 / petroleum ether 6). The solvent was evaporated and the crude was dissolved in AcOEt (30ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 90 mg of a white solid. Yield = 10% \n1\nHNMR (DMSO, 200 MHz)  4.36 (2H, d, J = 5.6 Hz), 6.71 (1H, t, J = 6 Hz), 6.98 (2H, m), 7.56 (4H, m), 8.55(1H, bs), 11.09 (1H, bs); [M\n+1\n] 370.2 (C\n16\nH\n11\nF\n4\nN\n3\nO\n3\n requires 369.27).\n\n\n \n\n\nExample 28: 1-(4-chloro-2-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-chloro-2-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nCommercially available 4-chloro-2-trifluoromethylbenzylamine (1 g, 4.77 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (1.41 g, 4.77 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (5 ml) of compound \n1b\n (475 mg, 3.2 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 4 / petroleum ether 6). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 120 mg of a white solid. Yield = 9.7% \n1\nHNMR (DMSO, 200 MHz)  4.45 (2H, d, J = 5.6 Hz), 6.99 (4H, m), 7.65 (1H, d), 7.73 (1H, d), 7.85 (1H, bs), 8.62 (1H, bs), 11.04 (1H, bs); [M\n+1\n] 386.6 (C\n16\nH\n11\nClF\n3\nN\n3\nO\n3\n requires 385.73).\n\n\n \n\n\nExample 29: 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2a\n (1.2 g, 5.5 mmol) was dissolved in 40ml of AcOEt and at 0C triphosgene (1.63 g, 5.5 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1b\n (820 mg, 5.5 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 7 / petroleum ether 3). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 3 0ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 300 mg of a white solid. Yield = 14% \n1\nHNMR (DMSO, 200 MHz)  2.51 (6H, s), 4.71 (2H, d, J = 5.6 Hz), 6.55 (2H, d, J = 8.2 Hz), 7.05 (1H, t, J = 7.6 Hz), 7.40 (1H, m), 7.51 (1H, d), 10.06 (1H, bt), 11.53 (1H, bs), 11.80 (1H, bs); [M\n+1\n] 395.1 (C\n18\nH\n17\nF\n3\nN\n4\nO\n3\n requires 394.35).\n\n\n \n\n\nExample 30: 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2b\n (289 mg, 1.2 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (356 mg, 1.2 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1b\n (180 mg, 1.2 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 100mg of a white solid. Yield = 20% \n1\nHNMR (DMSO, 200 MHz)  1.94 (4H, m), 3.23 (4H, m), 4.67 (2H, d, J = 5.6 Hz), 6.55 (2H, dd, J = 8.8 Hz, J' = 1.2 Hz), 7.05 (1H, t, J = 8.2 Hz), 7.17 (2H, d, J = 7.2 Hz), 7.46 (1H, d), 9.98 (1H, t), 11.53 (1H, bs), 11.80 (1H, bs); [M\n+1\n] 421.2 (C\n2\n0H\n19\nF\n3\nN\n4\nO\n3\n requires 420.39).\n\n\n \n\n\nExample 31: 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2c\n (350 mg, 1.33 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (395 mg, 1.33 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1b\n (100 mg, 0.66 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 40 mg of a white solid. Yield = 14% \n1\nHNMR (DMSO, 400 MHz)  1.55 (2H, m), 1.68 (4H, m), 2.85 (4H, m), 4.43 (2H, d, J = 5.6 Hz), 6.88 (1H, t), 6.98 (2H, m), 7.05 (1H, m), 7.31 (1H, s), 7.42 (1H, d), 7.52 (1H, d, J = 8 Hz), 8.52 (1H, s), 11.00 (1H, bs); [M\n+1\n] 435.3 (C\n21\nH\n21\nF\n3\nN\n4\nO\n3\n requires 434.41).\n\n\n \n\n\nExample 32: 1-(4-(trifluoromethyl)-2-morpholinobenzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-morpholinobenzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nAmine \n2d\n (362 mg, 3.8 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.12 g, 1equiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1b\n (384 mg, 2.56 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 200 mg of a pale rose solid. Yield = 18% \n1\nHNMR (DMSO, 400 MHz)  2.91 (4H, m), 3.76 (4H, m), 4.46 (2H, d, J = 5.6 Hz), 6.97 (3H, m), 7.05 (1H, m), 7.36 (1H, s), 7.46 (1H, d), 7.54 (1H, d), 8.53 (1H, s), 11.00 (1H, bs); [M\n+1\n] 437.1 (C\n20\nH\n19\nF\n3\nN\n4\nO\n4\n requires 436.4).\n\n\n \n\n\nExample 33: 1-(4-chlorobenzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-chlorobenzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea\n\n\n \n \n \n \nCommercially available p-chlorobenzylamine (1.6 g, 11.4 mmol) was dissolved in 60ml of AcOEt and at 0C triphosgene (3.38 g, 1equiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 30 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1b\n (1.7 g, 11.4 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 7 / petroleum ether 3). The solvent was evaporated and the crude was dissolved in AcOEt (80 ml) and washed with water (1 X 50 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 500mg of a white solid. Yield = 14% \n1\nHNMR (DMSO, 200 MHz)  4.57 (2H, d, J = 5.8 Hz), 6.53 (2H, m), 7.04 (1H, m), 7.41 (4H, s), 9.88 (1H, t), 11.53 (1H, s), 11.80 (1H, bs); [M\n+1\n] 318.5 (C\n15\nH\n12\nClN\n3\nO\n3\n requires 317.73).\n\n\n \n\n\nExample 34: 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 5-chloro-7-nitrobenzo[d]oxazol-2(3H)-one \n6\n \n\n\n \n \n \n \nDCI (36.4 mmol, 5.9 g) was added in one portion to 2-amino-4-chloro-6-nitrophenol \n5\n (5 g, 26.5 mmol) suspended in AcOEt (150ml) and the reaction was stirred vigorously for 2 hours. 100 ml of water were added to the reaction and then the organic phase was eliminated by evaporation. HCl 20% was added (20 ml) and the resulting solid material was filtered and washed with HCl 1N, cold water, MeOH and ether obtaining 5.6 g of a beige solid. Yield = 98% \n1\nHNMR (DMSO, 200 MHz)  7.59 (1H, d, J = 2.2 Hz), 7.86 (1H, d, J = 2.2Hz), 12.56 (1H, bs)\n\n\n \n \n \n \nPreparation of 7-aminobenzo[d]oxazol-2(3H)-one \n1c\n \n\n\n \n \n \n \nTo compound \n6\n (4 g, 18.56 mmol) dissolved in a mixture of 4/1 MeOH/DMF (50 ml) C/Pd 10% (500 mg) was added and the reaction was hydrogenated at 60 psi overnight. (TLC AcOEt 3 / petroleum ether 7) The reaction was filtrated through a pad of Celite and the filtrate was evaporated under vacuum. The crude solid was crystallized from ether giving 2,8 g of a beige solid. Yield = 99%. \n1\nHNMR (DMSO, 200 MHz)  5.31 (2H, bs), 6.26 (1H, dd, J = 7.6 Hz, J' = 1 Hz), 6.38 (1H, dd, J = 8.4 Hz, J' = 1.2 Hz), 6.80 (1H, t, J = 8 Hz), 11.32 (1H, bs)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea\n\n\n \n \n \n \nCommercially available 4-trifluoromethylbenzylamine (1 ml, 7 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (2 g, 7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1c\n (700 mg, 4.66 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 4 / petroleum ether 6). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 320 mg of a white solid. Yield = 19.5% \n1\nHNMR (DMSO, 400 MHz)  4.41 (2H, d, J = 6 Hz), 6.67 (1H, dd, J = 7.6 Hz, J' = 1.2 Hz), 7.00 (1H, t, J = 8 Hz), 7.09 (1H, t), 7.51 (2H, d, J = 8 Hz), 7.70 (3H, m), 8.73 (1H, s), 10.60 (1H, bs); [M\n+1\n] 352.1 (C\n16\nH\n12\nF\n3\nN\n3\nO\n3\n requires 351.3).\n\n\n \n\n\nExample 35: 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea\n\n\n \n \n \n \nAmine \n2b\n (795 mg, 3.3 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (979 mg, 3.3 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1c\n (330 mg, 2.2 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 240 mg of a white solid. Yield = 26% \n1\nHNMR (DMSO, 200 MHz)  1.91 (4H, m), 3.22 (4H, m), 4.38 (2H, d, J = 5.4 Hz), 6.66 (1H, dd, J = 7.6 Hz, J' = 1.2 Hz), 7.00 (3H, m), 7.19 (1H, d, J = 8 Hz), 7.39 (1H, d), 7.72 (1H, dd, J = 8.6 Hz, J' = 1), 8.72 (1H, bs), 11.63 (1H, bs); [M\n+1\n] 421.3 (C\n20\nH\n19\nF\n3\nN\n4\nO\n3\n requires 420.4).\n\n\n \n\n\nExample 36: 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea\n\n\n \n \n \n \nAmine \n2c\n (1 g, 3.8 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.13 g, 3.8 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1c\n (390 mg, 2.6 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 160 mg of a white solid. Yield = 14% \n1\nHNMR (DMSO, 200 MHz)  1.56 (2H, bs), 1.69 (4H, bs), 2.85 (4H, m), 4.42 (2H, d, J = 5.6 Hz), 6.66 (1H, dd, J = 8 Hz, J' = 0.8 Hz), 7.01 (2H, m), 7.32 (1H, s), 7.44 (2H, dd, J = 7.6 Hz), 7.72 (1H, dd, J = 8.6 Hz, J' = 1 Hz), 8.73 (1H, bs), 11.68 (1H, bs); [M\n+1\n] 435.2 (C\n21\nH\n21\nF\n3\nN\n4\nO\n3\n requires 434.4).\n\n\n \n\n\nExample 37: 1-(4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 4-aminoindolin-2-one \n1d\n (scheme 4)\n\n\n \n \n \n \nDimethylmalonate (5.92 ml, 51.9 mmol) was added dropwise to a suspension of sodium hydride (2.9 g, 61.75 mmol) in DMF (60 ml) at 0C. The mixture was heated at 100C for 1 hour, cooled to room temperature and then 2-chloro-1,3-dinitrobenzene \n7\n (5 g, 24.7 mmol) was added and the reaction heated at 100C for 3 hours. The reaction was cooled to room temperature and the solvent was evaporated under vacuum. The residue was diluted with AcOEt and washed one time with saturated NH\n4\nCl, water and brine. The organic phase was dried over sodium sulphate and evaporated. The resulting solid was dissolved in acetic acid (20 ml) and p-toluenesulphonic acid (150 mg) added following by heating to reflux for 3 hours. The solvent was evaporated and the crude was dissolved in AcOEt and washed with water and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 2 / petroleum ether 8 as eluant gave 3.34 g of a yellow oil. \n1\nHNMR (DMSO, 200 MHz)  3.64 (3H, s), 4.11 (2H, s), 7.85 (1H, t, J = 8 Hz), 8.35 (1H, s), 8.40 (1H, s) The oil was diluted in EtOH (40 ml) and C/Pd 10% (300 mg) was added and the solution hydrogenated at 60 psi overnight. After filtering through celite to remove palladium, the solution was heated with p-toluenesulphonic acid (100 mg) at reflux for 2 hours. The reaction was concentrated and the product crystallized from water and filtered to give 1.52 g of a beige solid. Overall yield: 42%. \n1\nHNMR (DMSO, 200 MHz)  3.16 (2H, s), 5.02 (2H, bs), 6.06 (1H, d, J = 7.4 Hz), 6.20 (1H, dd, J = 8.2 Hz, J' = 0.8 Hz), 6.84 (1H, t, J = 7.6 Hz), 10.10 (1H, bs)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n \n \n \n \nCommercially available 4-trifluoromethylbenzylamine (0.5 ml, 3.5 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1 g, 3.5 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1d\n (345 mg, 2.33 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 4 / petroleum ether 6). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 110 mg of a white solid. Yield = 13.5% \n1\nHNMR (DMSO, 200 MHz)  3.33 (2H, s), 4.39 (2H, d, J = 5.6 Hz), 6.45 (1H, d, J = 6.8 Hz), 7.05 (2H, m), 7.49 (3H, m), 7.71 (2H, d, J = 8 Hz), 8.14 (1H, s), 10.32 (1H, bs); [M\n+1\n] 350.1 (C\n17\nH\n14\nF\n3\nN\n3\nO\n2\n requires 349.31).\n\n\n \n\n\nExample 38: 1-(5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-3-(2-oxoindolin-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n \n \n \n \nCommercially available racemic 5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-amine (1 g, 4.97 mmol) was dissolved in 30 ml of AcOEt and at 0C triphosgene (1.42 g, 4.97 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added drop wise to a solution in DMF (10 ml) of compound \n1d\n (710 mg, 4.8 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 7 / petroleum ether 3). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 225 mg of a beige solid. Yield = 12.5% \n1\nHNMR (DMSO, 200 MHz)  1.82(1H, m), 2.50 (1H, m), 2.95 (2H, m), 3.33 (2H, s), 5.22 (1H, q, J = 7.6 Hz), 6.45 (1H, d, J = 7.4 Hz), 6.87 (1H, d, J = 7.8 Hz), 7.07 (1H, t, J = 7.8 Hz), 7.56 (4H, m), 7.94 (1H, s), 10.34 (1H, bs); [M\n+1\n] 375.7 (C\n19\nH\n16\nF\n3\nN\n3\nO\n2\n requires 375.34).\n\n\n \n\n\nExample 39: 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n \n \n \n \nAmine \n2a\n (508 mg, 2.33 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (691 mg, 2.33 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added drop wise to a solution in DMF (10 ml) of compound \n1d\n (237 mg, 1.6 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 130 mg of a beige solid. Yield = 20% \n1\nHNMR (DMSO, 200 MHz)  2.51 (6H, s), 3.34 (2H, s), 4.40 (2H, d, J = 5.8 Hz), 6.44 (1H, d, J = 7.2 Hz), 6.89 (1H, t), 7.05 (1H, t), 7.43 (4H, m), 8.14 (1H, bs), 10.32 (1H, bs); [M\n+1\n] 393.1 (C\n19\nH\n19\nF\n3\nN\n4\nO\n2\n requires 392.4).\n\n\n \n\n\nExample 40: 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2-oxoindolin-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n \n \n \n \nAmine \n2b\n (765 mg, 1.18 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (935 mg, 3.15 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10ml) of compound \n1d\n (316 mg, 2.1 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 120 mg of a white solid. Yield = 13.6% \n1\nHNMR (DMSO, 200 MHz)  1.91 (4H, m), 3.23 (4H, m), 4.37 (2H, d, J = 5.4 Hz), 6.44 (1H, d, J = 7.6 Hz), 6.90 (1H, t), 7.05 (3H, m), 7.47 (2H, m), 8.11 (1H, s), 10.38 (1H, bs); [M\n+1\n] 419.2 (C\n21\nH\n21\nF\n3\nN\n4\nO\n2\n requires 418.4).\n\n\n \n\n\nExample 41: 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2-oxoindolin-4-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2-oxoindolin-4-yl)urea\n\n\n \n \n \n \nAmine \n2c\n (1 g, 3.8 mmol) was dissolved in 20ml of AcOEt and at 0C triphosgene (1.13 g, 3.8 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1d\n (450 mg, 3 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 200 mg of a white solid. Yield = 15% \n1\nHNMR (DMSO, 200 MHz)  1.58 (2H, bs), 1.68 (4H, bs), 2.85 (4H, m), 3.34 (2H, s), 4.41 (2H, d, J = 6 Hz), 6.44 (1H, d, J = 7 Hz), 6.87 (1H, t), 7.05 (1H, t), 7.32 (1H, s), 7.47 (3H, m), 8.14 (1H, s), 10.32 (1H, bs); [M\n+1\n] 433.3 (C\n22\nH\n23\nF\n3\nN\n4\nO\n2\n requires 432.4).\n\n\n \n\n\nExample 42: 1-(4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 5-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one \n11\n (scheme 5)\n\n\n \n \n \n \nTo a solution of 2-amino-3-nitrophenol (4.62 g, 30 mmol) in DMF (20 ml) ethylbromoacetate (3.3 ml, 30 mmol) and K\n2\nCO\n3\n (4.56 g, 33 mmol) were added and the reaction was stirred at room temperature for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by crystallization from ether / hexane gave 4.65 g of a yellow solid. Yield: 80%. \n1\nHNMR (DMSO, 200 MHz)  4.74 (2H, s), 7.15 (1H, t, J = 8.4 Hz), 7.41 (1H, dd, J = 8.2 Hz, J' = 1.6 Hz), 7.77 (1H, dd, J = 8.4 Hz, J' = 1.2 Hz), 10.38 (1H, bs)\n\n\n \n \n \n \nPreparation of 5-amino-2H-benzo[b][1,4]oxazin-3(4H)-one \n1e\n \n\n\n \n \n \n \nTo compound \n11\n (2.3g, 11.85 mmol) dissolved in a mixture of 4/1 MeOH/THF (50 ml) C/Pd 10% (500 mg) was added and the reaction was hydrogenated at 60 psi overnight. (TLC AcOEt 3 / petroleum ether 7) The reaction was filtrated through a pad of Celite and the filtrate was evaporated under vacuum. The crude solid was crystallized from ether giving 1,75 g of a beige solid. Yield = 90%. \n1\nHNMR (DMSO, 200 MHz)  4.44 (2H, s), 6.18 (1H, dd, J = 8 Hz, J' = 1.2 Hz), 6.31 (1H, dd, J = 8 Hz, J' = 1.2 Hz), 6.64 (1H, t, J = 7.8 Hz), 9.96 (1H, bs)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea\n\n\n \n \n \n \nCommercially available 4-trifluoromethylbenzylamine (1 ml, 7 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (2 g, 7 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10ml) of compound \n1e\n (766 mg, 4.66 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt\n\n\n \n \n \n \n(30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 550 mg of a white solid. Yield = 32% \n1\nHNMR (DMSO, 400 MHz)  4.40 (2H, d, J = 5.6 Hz), 4.52 (2H, s), 6.70 (1H, dd, J = 8 Hz, J' = 1.2 Hz), 6.86 (2H, t, J = 8 Hz), 7.16 (1H, dd, J = 8 Hz, J' = 1.2 Hz), 7.54 (2H, d, J = 8 Hz), 7.70 (2H, d, J = 8.4 Hz), 8.18 (1H, s), 10.11 (1H, bs); [M\n+1\n] 366.2 (C\n17\nH\n14\nF\n3\nN\n3\nO\n3\n requires 365.31).\n\n\n \n\n\nExample 43: 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea\n\n\n \n \n \n \nAmine \n2b\n (471 mg, 1.94 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (576 mg, 1.94 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1e\n (213 mg, 1.3 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 120 mg of a white solid. Yield = 21% \n1\nHNMR (DMSO, 400 MHz)  1.91 (4H, m), 3.21 (4H, m), 4.48 (2H, d, J = 6 Hz), 4.63 (2H, s), 6.64 (2H, dd, J = 10.8 Hz, J' = 8 Hz), 6.88 (1H, t, J = 8 Hz), 7.12 (1H, s), 7.19 (1H, d, J = 8.8 Hz), 7.34 (1H, d, J = 8 Hz), 8.63 (1H, t), 10.68 (1H, bs), 10.90 (1H, bs); [M\n+1\n] 435.2 (C\n21\nH\n21\nF\n3\nN\n4\nO\n3\n requires 434.4).\n\n\n \n\n\nExample 44: 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)urea\n\n\n \n \n \n \nAmine \n2c\n (1 g, 3.8 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.13 g, 3.8 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1e\n (425 mg, 2.6 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 530 mg of a white solid. Yield = 45% \n1\nHNMR (DMSO, 400 MHz)  1.56 (2H, bs), 1.69 (4H, bs), 4.55 (2H, d, J = 5.6 Hz), 4.64 (2H, s), 6.64 (2H, dd, J = 14 Hz, J' = 7.6 Hz), 6.88 (1H, t, J = 8 Hz), 7.32 (1H, s), 7.39 (2H, s), 8.64 (1H, t), 10.66 (1H, bs), 10.88 (1H, bs); [M\n+1\n] 449.2 (C\n22\nH\n23\nF\n3\nN\n4\nO\n3\n requires 448.4).\n\n\n \n\n\nExample 45: 1-(4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 6-chloro-8-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one \n12\n (scheme 6)\n\n\n \n \n \n \nTo a solution of 2-amino-4-chloro-6-nitrophenol (5 g, 26.5 mmol) in DMF (20 ml) ethylbromoacetate (3 ml, 26.5 mmol) and K\n2\nCO\n3\n (4 g, 29.15 mmol) were added and the reaction was stirred at room temperature for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with NaOH 5%, water and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by crystallization from ether / AcOEt gave 1.13 g of a beige solid. Yield: 19%. \n1\nHNMR (DMSO, 200 MHz)  4.79 (2H, s), 7.15 (1H, d, J = 2.6 Hz), 7.66 (1H, d, J =.2.8 Hz), 11.21 (1H, bs)\n\n\n \n \n \n \nPreparation of 8-amino-2H-benzo[b][1,4]oxazin-3(4H)-one \n1f\n \n\n\n \n \n \n \nTo compound \n12\n (1.13 g, 4.92 mmol) dissolved in a mixture of 4/1/1 MeOH/THF/DMF (60 ml) C/Pd 10% (500 mg) was added and the reaction was hydrogenated at 60 psi overnight. (TLC AcOEt 3 / petroleum ether 7) The reaction was filtrated through a pad of Celite and the filtrate was evaporated under vacuum. The crude solid was crystallized from ether giving 484 mg of a beige solid. Yield = 49%. \n1\nHNMR (DMSO, 200 MHz)  3.80 (2H, bs), 4.60 (2H, s), 6.63 (1H, dd, J = 7.2 Hz, J' = 1.4 Hz), 6.83 (2H, m), 10.79 (1H, bs)\n\n\n \n \n \n \nPreparation of 1-(4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nCommercially available 4-trifluoromethylbenzylamine (0.6 ml, 4.2 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.2 g, 4.2 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1f\n (460 mg, 2.8 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt). The solvent was evaporated and the crude was dissolved in AcOEt (30ml) and washed with water (1 X 20ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 250 mg of a white solid. Yield = 24% \n1\nHNMR (DMSO, 200 MHz)  4.31 (2H, d, J = 6.2 Hz), 6.46 (1H, dd), 6.70 (2H, t), 6.81 (1H, t), 7.45 (2H, d, J = 8 Hz), 7.70 (4H, m), 8.16 (1H, s), 10.72 (1H, bs); [M\n+1\n] 366.1 (C\n17\nH\n14\nF\n3\nN\n3\nO\n3\n requires 365.3).\n\n\n \n\n\nExample 46: 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nAmine \n2a\n (480 mg, 2.2 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (653 mg, 2.2 mmol) was added to the solution. The mixture was warmed at 80C for \n4\n hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1f\n (320 mg, 1.6 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 130 mg of a white solid. Yield = 19% \n1\nHNMR (DMSO, 200 MHz)  2.70 (6H, s), 4.39 (2H, d, J = 5.2 Hz), 4.62 (2H, s), 6.48 (1H, dd, J = 7.8 Hz, J' = 1.2 Hz), 6.81 (1H, t), 7.32 (1H, s), 7.42 (3H, m), 7.72 (1H, dd, J' = 1.4 Hz), 8.19 (1H, s), 10.65 (1H, bs); [M\n+1\n] 409.1 (C\n19\nH\n19\nF\n3\nN\n4\nO\n3\n requires 408.37).\n\n\n \n\n\nExample 47: 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b] [1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nAmine 2b (750 mg, 3.1 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (920 mg, 3.1 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1f\n (620 mg, 3.1 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 120 mg of a white solid. Yield = 9% \n1\nHNMR (DMSO, 200 MHz)  1.89 (4H, m), 3.20 (4H, m), 4.33 (2H, d, J= 5.6 Hz), 4.60 (2H, s), 6.45 (1H, dd, J = 8 Hz, J' = 1.2 Hz), 6.79 (1H, t, J = 8.4 Hz), 7.04 (1H, bs), 7.16 (1H, d), 7.23 (1H, t), 7.35 (1H, d), 7.72 (1H, dd, J = 8.2 Hz, J' = 1.4 Hz), 8.16 (1H, bs), 10.63 (1H, bs); [M\n+1\n] 435.1 (C\n21\nH\n21\nF\n3\nN\n4\nO\n3\n requires 434.41).\n\n\n \n\n\nExample 48: 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nAmine \n2c\n (420 mg, 1.6 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (475 mg, 1.6 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and dissolved in 5ml of DMF. The solution of the isocyanate was added drop wise to a solution in DMF (10 ml) of compound \n1f\n (180 mg, 1.1 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 160 mg of a white solid. Yield = 32% \n1\nHNMR (DMSO, 200 MHz)  1.57 (2H, bs), 1.68 (4H, bs), 2.85 (4H, m), 4.39 (2H, d, J = 5.6 Hz), 4.62 (2H, s), 6.47 (1H, dd, J = 7.8 Hz, J' = 1.2 Hz), 6.81 (1H, t, J = 8 Hz), 7.31 (2H, m), 7.43 (2H, m), 7.74 (1H, dd, J = 8.4 Hz, J' = 1.2 Hz), 8.18 (1H, bs), 10.65 (1H, bs); [M\n+1\n] 449.2 (C\n22\nH\n23\nF\n3\nN\n4\nO\n3\n requires 448.4).\n\n\n \n\n\nExample 49: 1-(4-chlorobenzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-chlorobenzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nCommercially available p-chlorobenzylamine (0.98 ml, 8 mmol) was dissolved in 40 ml of AcOEt and at 0C triphosgene (2.37 g, 1equiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 20ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1f\n (1.42 g, 7.11 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and to the crude 5% HCl was added. The solid was filtrated, washed with water, MeOH and diethyl ether obtaining 1.6 g of a white product. Yield = 68% \n1\nHNMR (DMSO, 200 MHz)  4.27 (2H, d, J = 5.6 Hz), 4.61 (2H, s), 6.47 (1H, dd, J = 7.8 Hz, J' = 1.2 Hz), 6.81 (1H, t, J = 8.2 Hz), 7.35 (5H, m), 7.73 (1H, dd, J = 8.2 Hz, J' = 1.2 Hz), 8.10 (1H, bs), 10.65 (1H, bs); [M\n+1\n] 332.4 (C\n16\nH\n14\nClN\n3\nO\n3\n requires 331.75).\n\n\n \n\n\nExample 50: 1-(4-chloro-2-(dimethylamino)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-chloro-2-(dimethylamino)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nAmine 2f (1 g, 5.5 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1.63 g, 1equiv.) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1f\n (860 mg, 4.31 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 450 mg of a white solid. Yield = 28% \n1\nHNMR (DMSO, 200 MHz)  2.63 (6H, m), 4.31 (2H, d, J = 5.6 Hz), 4.61 (2H, s), 6.47 (1H, dd, J = 7.8 Hz, J' = 1.6 Hz), 6.81 (1H, t, J = 8.4 Hz), 7.07 (2H, m), 7.25 (2H, m), 7.75 (1H, dd, J = 8.4 Hz, J' = 1.4 Hz), 8.14 (1H, bs), 10.65 (1H, bs); [M\n+1\n] 374.8 (C\n17\nH\n18\nClN\n4\nO\n3\n requires 374.82).\n\n\n \n\n\nExample 51: 1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nAmine \n2g\n (1 g, 4.9 mmol) was dissolved in 40ml of AcOEt and at 0C triphosgene (1.46 g, 4. 9mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (20 ml) of compound \n1f\n (980 mg, 4.9 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 3 0ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 250 mg of a white solid. Yield = 13% \n1\nHNMR (DMSO, 200 MHz)  1.89 (4H, m), 3.17 (4H, m), 4.35 (2H, d), 4.61 (2H, s), 6.47 (1H, dd), 6.80 (3H, m), 7.17 (2H, m), 7.82 (1H, dd), 8.15 (1H, bs), 10.75 (1H, bs); [M\n+1\n] 401.2 (C\n20\nH\n21\nClN\n4\nO\n3\n requires 400.86).\n\n\n \n\n\nExample 52: 1-(4-chloro-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-chloro-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nAmine \n2h\n (1.7 g, 7.59 mmol) was dissolved in 50 ml of AcOEt and at 0C triphosgene (2.26 g, 7.59 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (20 ml) of compound \n1f\n (1.5 g, 7.51 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 210 mg of a white solid. Yield = 7% \n1\nHNMR (DMSO, 200 MHz)  1.54 (2H, m), 1.66 (4H, m), 2.78 (4H, m), 4.29 (2H, d, J = 5.6 Hz), 4.35 (2H, d), 4.61 (2H, s), 6.47 (1H, dd, J = 7.8 Hz, J' = 1.2 Hz), 6.81 (1H, t, J = 8 Hz), 7.13 (4H, m), 7.75 (1H, dd, J = 8.2 Hz, J' = 1.4 Hz), 8.14 (1H, bs), 10.66 (1H, bs); [M\n+1\n] 414.9 (C\n21\nH\n23\nClN\n4\nO\n3\n requires 414.89).\n\n\n \n\n\nExample 53: 1-(4-methyl-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-(4-methyl-2-(piperidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nAmine \n2bh\n (1.08 g, 5.3 mmol) was dissolved in 40ml of AcOEt and at 0C triphosgene (1.56 g, 5.4 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 15 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10ml) of compound \n1f\n (1 g, 5.46 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 1 / petroleum ether 9). The solvent was evaporated and the crude was dissolved in AcOEt (50 ml) and washed with water (1 X 30 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 150 mg of a white solid. Yield = 7% \n1\nHNMR (DMSO, 200 MHz)  1.63 (6H, m), 2.25 (3H,s), 2.76 (4H, m), 4.28 (2H, d, J = 5.4 Hz), 4.61 (2H, s), 6.46 (1H, dd, J = 7.8 Hz, J' = 1.4 Hz), 6.81 (3H, m), 7.12 (2H, m), 7.75 (1H, dd, J = 8.2 Hz, J'= 1.6 Hz), 8.11 (1H, s), 10.66 (1H, bs); [M\n+1\n] 395.0 (C\n22\nH\n26\nN\n4\nO\n3\n requires 394.5).\n\n\n \n\n\nExample 54: 1-((6-chloropyridin-3-yl)methyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea (scheme 1)\n\n\n\n\n \n \n \nPreparation of 1-((6-chloropyridin-3-yl)methyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea\n\n\n \n \n \n \nCommercially available (6-chloropyridin-3-yl)methanamine (800 mg, 5.61 mmol) was dissolved in 40ml of AcOEt and at 0C triphosgene (1.54 g, 5.6 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 10ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n1f\n (900 mg, 4.51 mmol) and the mixture was warmed at 80C for 8 hours. (TLC AcOEt 9.5 / MeOH 0.5). The solvent was evaporated and the crude was dissolved in AcOEt (80 ml) and washed with water (1 X 40 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 180 mg of a beige solid. Yield = 12% \n1\nHNMR (DMSO, 200 MHz)  4.31 (2H, d, J = 5.6 Hz), 4.60 (2H, s), 6.47 (1H, dd), 6.81 (1H, t), 7.40 (1H, t), 7.50 (1H, d, J = 8.2 Hz), 7.72 (2H, m), 8.13 (1H, bs), 8.34 (1H, bs), 10.66 (1H, bs); [M\n+1\n] 332.8 (C\n15\nH\n13\nClN\n4\nO\n3\n requires 332.74).\n\n\n \n\n\nExample 55: 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)acetamide (scheme 10)\n\n\n\n\n \n \n \nPreparation of 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)acetamide\n\n\n \n \n \n \n4-trifluoromethylphenylacetic acid (300 mg, 1.47 mmol) was dissolved in 20 ml of THF and at 0C DEPC (0.28 ml, 1.3equiv) and amine \n1a\n (260 mg, 1.2equiv.) were added to the solution. The mixture was warmed at 80C overnight, then evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt as eluant gave 150 mg of a white solid. Yield = 30% \n1\nHNMR (DMSO, 400 MHz)  3.78 (2H, s), 6.75 (1H, d), 6.84 (1H, t), 7.05 (1H, d), 7.56 (2H, d, J = 8 Hz), 7.70 (2H, d, J = 8 Hz), 9.80 (1H, bs), 10.18 (1H, bs), 10.64 (1H, bs); [M\n+1\n] 336.1 (C\n16\nH\n12\nF\n3\nN\n3\nO\n2\n requires 335.3).\n\n\n \n\n\nExample 56: 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)acetamide (scheme 10)\n\n\n\n\n \n \n \nPreparation of 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)acetamide\n\n\n \n \n \n \n4-trifluoromethylphenylacetic acid (453 mg, 2.2 mmol) was dissolved in 20 ml of THF and at 0C DEPC (0.43 ml, 1.3equiv) and amine \n1b\n (400 mg, 2.66 mmol) were added to the solution. The mixture was warmed at 80C overnight, then evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt as eluant gave 360 mg of a white solid. Yield = 48% \n1\nHNMR (DMSO, 200 MHz)  3.80 (2H, s), 7.10 (3H, m), 7.58 (2H, d, J = 8.4 Hz), 7.70 (2H, d, J = 8.2 Hz), 10.06 (1H, bs), 11.14(1H, bs); [M\n+1\n] 336.9 (C\n16\nH\n11\nF\n3\nN\n2\nO\n3\n requires 336.3).\n\n\n \n\n\nExample 57: 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)acetamide (scheme 10)\n\n\n\n\n \n \n \nPreparation of 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)acetamide\n\n\n \n \n \n \n4-trifluoromethylphenylacetic acid (453 mg, 2.2 mmol) was dissolved in 20 ml of THF and at 0C DEPC (0.43 ml, 1.3equiv) and amine \n1c\n (400 mg, 2.66 mmol) were added to the solution. The mixture was warmed at 80C overnight, then evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 3 /petroleum ether 7 as eluant gave 340 mg of a white solid. Yield = 46% \n1\nHNMR (DMSO, 200 MHz)  3.86 (2H, s), 6.86 (1H, d), 7.06 (1H, t), 7.58 (3H, m), 7.70 (2H, d, J = 8.4 Hz), 10.32 (1H, bs), 8.73 (1H, bs), 11.80 (1H, bs); [M\n+1\n] 337.2 (C\n16\nH\n11\nF\n3\nN\n2\nO\n3\n requires 336.3).\n\n\n \n\n\nExample 58: 2-(4-(trifluoromethyl)phenyl)-N-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)acetamide (scheme 10)\n\n\n\n\n \n \n \nPreparation of 2-(4-(trifluoromethyl)phenyl)-N-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl)acetamide\n\n\n \n \n \n \n4-trifluoromethylphenylacetic acid (408 mg, 2 mmol) was dissolved in 20 ml of THF and at 0C DEPC (0.358 ml, 1.2equiv) and amine \n1d\n (427 mg, 2.6 mmol) were added to the solution. The mixture was warmed at 80C overnight, then evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt as eluant gave 550 mg of a white solid. Yield = 78.5% \n1\nHNMR (DMSO, 200 MHz)  3.81 (2H, s), 4.55 (2H, s), 6.87 (2H, m), 7.05 (1H, dd, J = 7.6 Hz, J' = 6 Hz), 7.56 (2H, d, J = 8.2 Hz), 7.70 (2H, d, J = 8 Hz), 9.69 (1H, bs), 10.38 (1H, bs); [M\n+1\n] 351.2 (C\n17\nH\n13\nF\n3\nN\n2\nO\n3\n requires 350.3).\n\n\n \n\n\nExample 59: N-(4-(trifluoromethyl)benzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide (scheme 11)\n\n\n\n\n \n \n \nPreparation of 2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxylic acid \n21\n \n\n\n \n \n \n \n2-amino-3-hydroxybenzoic acid (1.2 g, 7.8 mmol) was suspended in 20 ml of THF and at 0C CDI (1.9g, 1.5equiv.) was added. The mixture was warmed at 80C for 5 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by crystallization from EtOAc/ether gave 520 mg of an orange solid. Yield = 37% \n1\nHNMR (DMSO, 200 MHz)  7.45 (3H, m), 10.40 (1H, bs), 12.00 (1H, bs)\n\n\n \n \n \n \nPreparation of N-(4-(trifluoromethyl)benzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide\n\n\n \n \n \n \n2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxylic acid \n21\n (260 mg, 1.45 mmol) was dissolved in 20 ml of THF and at 0C DEPC (0.260 ml, 1.2equiv) and 4-chloro-2-trifluorobenzylamine (0.25 ml, 1.2equiv.) were added to the solution. The mixture was warmed at 80C overnight, then evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 3 / petroleum ether 7 as eluant gave 110mg of a white solid. Yield = 22.5% \n1\nHNMR (DMSO, 200 MHz)  4.58 (2H, d, J = 5.8 Hz), 7.16 (1H, t, J = 8 Hz), 7.42 (1H, dd, J = 8.2 Hz, J' = 1 Hz), 7.55 (2H, d, J = 8.2 Hz), 7.65 (3H, m), 9.29 (1H, bt), 11.60 (1H, bs); [M\n+1\n] 336.9 (C\n16\nH\n11\nF\n3\nN\n2\nO\n3\n requires 336.3).\n\n\n \n\n\nExample 60: N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide (scheme 10)\n\n\n\n\n \n \n \nPreparation of N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide\n\n\n \n \n \n \n2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxylic acid \n21\n (560 mg, 3.1 mmol) was dissolved in 20 ml of THF and at 0C DEPC (0.55 ml, 1.2equiv) and amine \n2c\n (964 mg, 1.2equiv.) were added to the solution. The mixture was warmed at 80C overnight, then evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 4 / petroleum ether 6 as eluant gave 250 mg of a pale yellow solid. Yield = 19% \n1\nHNMR (DMSO, 200 MHz)  4.58 (2H, d, J = 5.8 Hz), 7.14 (1H, t, J = 8 Hz), 7.41 (4H, m), 7.68 (1H, dd, J = 8 Hz, J' = 0.8 Hz), 9.20 (1H, bt), 11.59 (1H, bs); [M\n+1\n] 420.2 (C\n21\nH\n20\nF\n3\nN\n3\nO\n3\n requires 419.4).\n\n\n \n\n\nExample 61: N-(4-(trifluoromethyl)-2-morpholinobenzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide (scheme 11)\n\n\n\n\n \n \n \nPreparation of N-(4-(trifluoromethyl)-2-morpholinobenzyl)-2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxamide\n\n\n \n \n \n \n2,3-dihydro-2-oxobenzo[d]oxazole-4-carboxylic acid \n21\n (240 mg, 1.3mmol) was dissolved in 20 ml of THF and at 0C DEPC (0.23 ml, 1.2equiv) and amine \n2d\n (420 mg, 1.2equiv.) were added to the solution. The mixture was warmed at 80C overnight, then evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 4 / petroleum ether 6 as eluant gave 100 mg of a white solid. Yield = 18% \n1\nHNMR (DMSO, 200 MHz)  2.94 (4H, bs), 3.78 (4H, bs), 4.64 (2H, d, J = 5.6 Hz), 7.18 (1H, t), 7.43 (4H, m), 7.66 (1H, d), 9.35 (1H, bs), 11.60 (1H, bs); [M\n+1\n] 422.2 (C\n20\nH\n18\nF\n3\nN\n3\nO\n4\n requires 421.37).\n\n\n \n\n\nExample 62: N-(4-(trifluoromethyl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-5-carboxamide (scheme 11)\n\n\n\n\n \n \n \nPreparation of N-(4-(trifluoromethyl)benzyl)-2-amino-3-hydroxybenzamide \n22a\n \n\n\n \n \n \n \n2-amino-3-hydroxybenzoic acid (2 g, 13 mmol) was dissolved in 20 ml of DMF and at 0C EDCI (2.7 g, 1.2equiv.), hydroxybenzotriazole (1.9 g, 1.2equiv.) and 4-trifluoromethylbenzylamine (2ml, 1.2equiv.) were added. The mixture was stirred at rt for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by crystallization from EtOAc/ether gave 3.5 g of a beige solid. Yield = 86% \n1\nHNMR (DMSO, 200 MHz)  4.49 (2H, d, J = 5.6 Hz), 6.00 (2H, bs), 6.41 (1H, t, J = 8 Hz), 6.76 (1H, d, J = 7.6 Hz), 7.11 (1H, d, J = 8.2 Hz), 7.51 (2H, d, J = 8 Hz), 7.69 (2H, d, J = 8 Hz), 8.81 (1H, bt), 9.58 (1H, bs); [M\n+1\n] 311.1 (C\n15\nH\n13\nF\n3\nN\n2\nO\n2\n requires 310.27).\n\n\n \n \n \n \nPreparation of N-(4-(trifluoromethyl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-5-carboxamide\n\n\n \n \n \n \nN-(4-(trifluoromethyl)benzyl)-2-amino-3-hydroxybenzamide \n22a\n (1 g, 3.2 mmol) was dissolved in 20 ml of DMF and at 0C TEA (0.9 ml, 2equiv.) and chloroacetyl chloride (0.3 ml, 1.2equiv.) were added. The mixture was stirred at rt for 2 hours. K\n2\nCO\n3\n (885 mg, 2equiv.) was added and the reaction was stirred at rt for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 1 / petroleum ether 1 as eluant gave 500mg of a white solid. Yield = 44% \n1\nHNMR (DMSO, 200 MHz)  4.56 (2H, d, J = 5.4 Hz), 4.65 (2H, s), 7.04 (2H, t), 7.17 (1H, d, J = 7.8 Hz), 7.55 (2H, d, J = 8 Hz), 7.71 (2H, d, J = 8.2 Hz), 9.52 (1H, bs), 10.96 (1H, bs); [M\n+1\n] 351.1 (C\n17\nH\n13\nF\n3\nN\n2\nO\n3\n requires 350.3).\n\n\n \n\n\nExample 63: N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-5-carboxamide (scheme 11)\n\n\n\n\n \n \n \nPreparation of N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-2-amino-3-hydroxybenzamide \n22b\n \n\n\n \n \n \n \n2-amino-3-hydroxybenzoic acid (1 g, 6.5 mmol) was dissolved in 20 ml of DMF and at 0C EDCI (1.4g, 1.2equiv.), hydroxybenzotriazole (1 g, 1.2equiv.) and amine \n2c\n (2 g, 1.2equiv.) were added. The mixture was stirred at rt for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by crystallization from EtOAc/ether gave 1.6 g of a beige solid. Yield = 62.5% [M\n+1\n] 393.4 (C\n20\nH\n22\nF\n3\nN\n3\nO\n2\n requires 393.4).\n\n\n \n \n \n \nPreparation of N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-5-carboxamide\n\n\n \n \n \n \nN-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-2-amino-3-hydroxybenzamide \n22b\n (2.5 g, 6.4 mmol) was dissolved in 20 ml of DMF and at 0C TEA (1.8 ml, 2equiv.) and chloroacetyl chloride (0.6 ml, 1.2equiv.) were added. The mixture was stirred at rt for 2 hours. K\n2\nCO\n3\n (1.77 g, 2equiv.) was added and the reaction was stirred at rt for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 1 / petroleum ether 1 as eluant gave 1g of a white solid. Yield = 36% \n1\nHNMR (DMSO, 200 MHz)  1.57 (2H, bs), 1.69 (4H, bs), 2.82 (4H, m), 4.60 (2H, d, J = 5.4 Hz), 4.67 (2H, s), 7.09 (1H, t, J = 7.8 Hz), 7.20 (1H, dd, J = 8 Hz, J' = 1.2 Hz), 7.33 (1H, m), 7.41 (2H, m), 7.57 (1H, m), 9.38 (1H, bt), 11.02 (1H, bs); [M\n+1\n] 434.3 (C\n22\nH\n22\nF\n3\nN\n3\nO\n3\n requires 433.4).\n\n\n \n\n\nExample 64: N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-8-carboxamide (scheme 11)\n\n\n\n\n \n \n \nPreparation of N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-amino-2-hydroxybenzamide \n24b\n \n\n\n \n \n \n \n3-amino-2-hydroxybenzoic acid (1 g, 6.5 mmol) was dissolved in 20 ml of DMF and at 0C EDCI (1.4 g, 1.2equiv.), hydroxybenzotriazole (1 g, 1.2equiv.) and amine 2c (2 g, 1.2equiv.) were added. The mixture was stirred at rt for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 1 / petroleum ether 9 as eluant gave 1.3 g of a beige solid. Yield = 51% [M\n+1\n] 393.4 (C\n20\nH\n22\nF\n3\nN\n3\nO\n2\n requires 393.4).\n\n\n \n \n \n \nPreparation of N-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazine-8-carboxamide\n\n\n \n \n \n \nN-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-amino-2-hydroxybenzamide \n24b\n (830 mg, 2.1 mmol) was dissolved in 10ml of DMF and at 0C TEA (0.58 ml, 2equiv.) and chloroacetyl chloride (0.2 ml, 1.2equiv.) were added. The mixture was stirred at rt for 2 hours. K\n2\nCO\n3\n (580 mg, 2equiv.) was added and the reaction was stirred at rt for 20 hours. The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column using AcOEt 1 / petroleum ether 1 as eluant gave 460 mg of a white solid. Yield = 50% \n1\nHNMR (DMSO, 200 MHz)  1.57 (2H, bs), 1.69 (4H, bs), 2.84 (4H, m), 4.58 (2H, d, J = 5.2 Hz), 4.69 (2H, s), 7.03 (2H, m), 7.30 (2H, m), 7.45 (2H, m), 8.70 (1H, bt), 10.85 (1H, bs); [M\n+1\n] 434.1 (C\n22\nH\n22\nF\n3\nN\n3\nO\n3\n requires 433.4).\n\n\n \n\n\nExample 65: 3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl 4-(trifluoromethyl)benzylcarbamate (scheme 12)\n\n\n\n\n \n \n \nPreparation of 5-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one \n25\n \n\n\n \n \n \n \nTEA (3,34 ml, 2equiv.) and after chloroacetyl chloride (1,15 ml, 1.2equiv.) were added dropwise to a solution of commercially available 2-aminobenzene-1,3-diol (1,5 g, 11.99 mmol) in 20 ml of DMF. After one hours of stirring at room temperature, K\n2\nCO\n3\n (3,3 g, 2equiv.) was added and the reaction was stirred at room temperature overnight. The solvent was evaporated and to the residue water was added. After filtration, the solid material was washed with MeOH and diethyl ether giving 410 mg of a grey solid. Yield = 21% \n1\nHNMR (DMSO, 200 MHz)  3.47 (1H, bs), 4.47 (2H, s), 6.44 (2H, m), 6.72 (1H, t, J = 8 Hz)\n\n\n \nPreparation of 3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl 4-(trifluoromethyl)benzylcarbamate\n\n\n \n \n \n4-trifluoromethylbenzylamine (0.52 ml, 3.6 mmol) was dissolved in 20 ml of AcOEt and at 0C triphosgene (1 g, 3.6 mmol) was added to the solution. The mixture was warmed at 80C for 4 hours then evaporated and the residue was dissolved in 5 ml of DMF. The solution of the isocyanate was added dropwise to a solution in DMF (10 ml) of compound \n25\n (400 mg, 2.42 mmol) and TEA (0.34 ml, 1equiv.) and the mixture was stirred at rt for 8 hours. (TLC AcOEt 1 / petroleum ether 1). The solvent was evaporated and the crude was dissolved in AcOEt (30 ml) and washed with water (1 X 20 ml) and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The purification of the crude residue by chromatographic column gave 400 mg of a white solid. Yield = 45% \n1\nHNMR (DMSO, 200 MHz)  4.38 (2H, d, J = 6.4 Hz), 4.57 (2H, s), 6.85 (3H, m), 7.59 (2H, d, J = 8.2 Hz), 7.72 (2H, d, J = 8.4 Hz), 8.15 (1H, bt), 10.61 (1H,bs); [M\n+1\n] 367.1 (C\n17\nH\n13\nF\n3\nN\n2\nO\n4\n requires 366.3).\n\n \n \n \n\n\n \n \n \n \nReagents: i) isocyanate freshly prepared from amine 2 or sometimes alternatively from amine 1 with triphosgene in AcOEt at 80C for 4 hrs, DMF, 80C, 8 hr\n\n \n \n \n\n\n \n \n \n \nReagents: i) DCI, THF, Rfx, 2 or 4 hrs; ii) H2, C/Pd 10%, MeOH/THF, 60 psi, overnight\n\n \n \n \n\n\n \n \n \n \nReagents: i) DCI, AcOEt, rt; 2 hrs; ii) H2, C/Pd 10%, TEA, MeOH/DMF, 60 psi, overnight\n\n \n \n \n\n\n \n \n \n \nReagents: i) NaH 60%, dimethylmalonate, DMF, 4h, 100C; ii) ptSO\n3\nH, CH\n3\nCOOH, 3h, Rfx; iii) C/Pd 10%, EtOH, overnight; iv) ptSO\n3\nH, EtOH, Rfx, 2h\n\n \n \n \n\n\n \n \n \n \nReagents: i) K\n2\nCO\n3\n, ethylbromoacetate, DMF, rt, 24h; ii) C/Pd 10%, CH\n3\nOH/THF, 60 psi, overnight\n\n \n \n \n\n\n \n \n \n \nReagents: i) K\n2\nCO\n3\n, ethylbromoacetate, DMF, rt, 2h, 80C, overnight ii) C/Pd 10%, CH\n3\nOH/THF, 60 psi, overnight\n\n \n \n\n2 with R2 = CF3, R3 = H, n =1\n\n\n \n \n \n \nReagents: i) R1, 80C, 4h; ii) LiAlH\n4\n, diethylether, rt, overnight\n\n \n \n\n2 with R2 = Cl or CH3, R3 = H, n =1\n\n\n \n \n \n \nReagents: i) R1, 80C, overnight; ii) LiAlH\n4\n, diethylether, rt, overnight\n\n \n \n\n2 with R1 = R3 = H, n = 1\n\n\n \n \n \n \nReagents: i) R2, 100C, 36hrs ii) LiAlH\n4\n, diethylether, rt, overnight\n\n \n \n \n\n\n \n \n \n \nReagents: i) DEPC, THF, 80C, overnight\n\n \n \n \n\n\n \n \n \n \nReagents: i) CDI, THF, Reflux; ii) DEPC, THF, rfx, overnight; i') EDCI, HObt, DMF, rt, overnight; ii') chloroacetyl chloride, TEA, 4h, rt, K\n2\nCO\n3\n, 20 h, rt\n\n \n \n \n\n\n \n \n \n \nReagents: i) TEA, DMF, rt, overnight\n\n\n \n\n\nPHARMACOLOGY\n\n\n\n\n \n \n \nDrugs and reagents were obtained from the indicated companies: capsaicin, ionomycin, laminin, poly-L-lysine, collagenase, trypsin, L-glutamine, penicillin/streptomycin, DMEM, HBSS, mouse-NGF-7S, ARA-C, HEPES, Tween80, Complete Freund's Adjuvant (CFA) and BSA (Sigma, Italy); FBS and HS (Gibco, Italy); Fura-2-AM-ester (Vinci-Biochem, Italy) and Methylcellulose (Fluka, Switzerland). The stock concentration (10 mM) of capsaicin, Fura-2-AM-ester, ionomycin and all tested compounds were prepared in 100% DMSO.\n\n\n \n\n\nCa\n2+\n fluorescence measurements in cultured rat dorsal root\n\n\n\n\n \n \n \nMale SD rats ( 50 g, Charles River, Italy) were terminally anaesthetized and decapitated. Dorsal root ganglia were removed and placed in cold Hank's balanced salt solution (HBSS) before being transferred to collagenase (2 mg/ml) and trypsin (1 mg/ml) for 35 min at 37C. The ganglia, placed in cold DMEM supplemented with 10% fetal bovine serum, 10% horse serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin, were dissociated in single cells by several passages through a series of syringe needles (23G down to 25G). The medium and the ganglia were filtered to remove debris, topped up with 4 ml of DMEM medium and centrifuged (1100 rpm for 6 min). The final cell pellet was re-suspended in DMEM medium [supplemented with 100 ng/ml mouse Nerve Growth Factor (mouse-NGF-7S) and cytosine--D-arabinofuranoside free base (ARA-C) 2.5 M]. The cells were plated on poly-L-lysine (8.3 M)- and laminin (5 M)-coated 25 mm glass cover slips and kept for 2 days at 37C in a humidified incubator gassed with 5% CO\n2\n and air, then treated with Fura-2-AM-ester (5 M) in a Ca\n2+\n buffer solution having the following composition (mM): CaCl\n2\n 1.4, KCl 5.4, MgSO\n4\n 0.4, NaCl 135, D-glucose 5, HEPES 10 with BSA (0.1%), at pH 7.4, for 40 min at 37C. The cells were then washed twice with the Ca\n2+\n buffer solution and transferred to a chamber on the stage of a Nikon eclipse TE300 microscope. Fura-2-AM-ester was excited at 340 nM and 380 nM to indicate relative [Ca\n2+\n]\ni\n changes by the F\n340\n/F\n380\n ratio recorded with a dynamic image analysis system (Laboratory Automation 2.0, RCS, Florence, Italy) and the cells were allowed (at least 10 min) to attain a stable fluorescence before beginning the experiment. A calibration curve was set up using buffer containing Fura-2-AM-ester and determinant concentrations of free Ca\n2+\n. This curve was then used to convert the data obtained from the F\n340\n/F\n380\n ratio to [Ca\n2+\n]\ni\n (nM).\n\n\n \n \n \n \nAll exemplified compounds were tested at the concentration of 300 nM against the calcium uptake induced by 30 nM capsaicin. For selected molecules, the IC\n50\n value was calculated.\n\n\n \n\n\nCFA-induced thermal hyperalgesia in rats\n\n\n\n\n \n \n \nThis method was used for the determination of acute nociceptive thermal threshold and combines a chemical stimulus and heat for measuring pain sensitivity. Male SD rats (Charles River, Italy) weighing 100 to 250 gr. were used. Anti-hyperalgesic effects were investigated by using the Hargreaves' test. Complete Freund's Adjuvant (CFA; Sigma, USA) was used to induce thermal hyperalgesia. CFA contains killed \nMycobacterium tuberculosis\n and is designed to provide continuous release of antigens necessary for stimulating a strong, persistent immune response. This effect causes the reduction of the hind paw withdrawal response latency induced by heat during the Hargreaves' test. Thermal stimulation was performed 30, 60, 120 and 180 (240 min only if needed) minutes after the oral administration of the antagonists. During the CFA-induced thermal hyperalgesia experiments two different solubilization protocols were used: when items presented an amino group, a pH=2 aqueous solution of HCl and 2.5% Tween80 was used; otherwise molecules were suspended in 0.5% Methocel and 2.5% Tween80. Compounds were orally administrated (30 mol/kg/10ml) to rats 24 hours after the CFA treatment. CFA was injected into the plantar surface of a rat's hind paw at a fixed dose of 50l by the use of a micro syringe.\n\n\n \n\n\nCFA-induced Tactile Allodynia in rats\n\n\n\n\n \n \n \nMale SD rats (Charles River, Italy) weighing 100 to 250 g were put into a clean plastic cage on an elevated glass plate for 30 min before the test. This lets the animals accommodate to their new environment before testing. Complete Freund's adjuvant (CFA, 50 l) was injected into the plantar surface of the right hind paw. Tactile stimulation was performed with von Frey filaments (from 0.07 to 26 g). All antagonists were orally administered 22 hours after to the CFA administration. Von Frey filaments were applied 30, 60, 120, 180, 240, 300 and 360 min after compound administrations. Median 50% (EG\n50\n) threshold of von Frey filaments was calculated by using the up-down method as previously described. All tested compounds were suspended in 0.5% Methocel and 2.5% Tween80 and orally administrated (30 mol/kg/10ml) to rats by gavage 24 hours after the CFA treatment. CFA was injected into the plantar surface of a rat's hind paw at a fixed dose of 50l by the use of a micro syringe.\n\n\n \n\n\nRectal temperature measurements in rats\n\n\n\n\n \n \n \nBody temperature was measured by a digital thermometer inserted at a depth of approximately 3 cm into the rectum of each animal (male SD rats, Charles River, Italy, 100 to 250 g). A pre-dose value of body temperature was measured prior to the administration of the test substance or vehicles. Animals were distributed among groups by the manual method to achieve the almost same mean values of body temperature of the groups based on the pre-dose value. All compounds were dissolved in 6% DMSO/ 6% Tween80 and then intraperitoneally (10 mol/Kg/5 ml) administrated to rats.\n\n\n \n\n\nCCI-induced mechanical hyperalgesia\n\n\n\n\n \n \n \nMale SD rats (Charles River, Italy) weighing 250 g were anaesthetized with sodium pentobarbital (60 mg/kg, intraperitoneal (i.p.), 0.1 ml/10 g) and, under a dissecting microscope, the right common sciatic nerve was exposed at the level of the mid thigh and, proximal to the trifurcation of the nerve; four ligatures (4/0 chromic silk, Ethicon) were loosely tied around it, at about 0.5 mm spacing, until they elicited a brief twitch in the respective hind, taking care to preserve epineural circulation. Sham-operated animals (sciatic exposure without ligation) were used as controls. 14 days after the surgery, mechanical hyperalgesia was assessed using an analgesimeter (Ugo Basile, Italy, Randall-Selitto analgesic apparatus). This device generated a mechanical force on the affected paw and the nociceptive threshold was defined as the force (in g) at which the rat withdraws the paw (with a cut-off of 450 g). Two baseline measurement values were obtained 75 and 45 min before the actual test. After the second baseline measurement, animals were randomly allocated to the different treatment groups. Paw pressure test was performed 0, 75, 120, 165, 210 and 300 min after the oral administration of the compounds. All tested compounds were orally administrated (30 mol/kg/10ml) to rats by gavage.\n\n\n \n\n\n\n\nRESULTS\n\n\n\n\n\n\n\n\nCa\n2+\n fluorescence measurements in cultured rat dorsal root ganglia neurons\n\n\n\n\n \n \n \nCapsaicin (0.3 M) caused an increase in [Ca\n2+\n] in the vast majority (95%) of dorsal root ganglia neurons, which were thereby identified as TRPV1 expressing neurons. All synthesized derivatives were tested and all were able to inhibit the calcium uptake and several compounds exhibited more than 80% inhibition, e.g. compounds of Examples 1, 3, 4, 5, 6, 10, 11, 12, 13, 16, 23, 31, 32, 35, 36, 39, 40, 41, 45, 46, 47, 48, 51, 53, 63. Among them, derivatives such as compounds of Examples 4, 5, 6, 13, 31, 36, 39, 40, 41, 45, 46, 23, 47, 48 and 51 appeared the most potent TRPV1 antagonists exhibiting a complete abolition of capsaicin response (around 100%) at 300 nM.\n\n\n \n \n \n \nThe IC\n50\n values of the compounds of Examples 4, 5, 6, 12, 13, 31, 46, 47, 48, and 51 calculated against capsaicin-evoked [Ca\n2+\n]\n1\n mobilization were 4.07 nM, 1 nM, 0.51 nM, 6 nM, 1.8 nM, 1.9 nM, 3 nM, 0.7 nM, 0.13 nM and 0.1 nM, respectively.\n\n\n \n \n \n \nTables 1, 2 and 3 describe the calcium assay data for all exemplified compounds of formula IA, IB and IC respectively.\n\n \n \nTable 1\n \n \n \n \n \nCompound of Example\n \n \n \n% inhibition at 300nM\n \n \n \nIC50 (nM)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nExample 1\n \n \n84\n \n \n \n \n \n \nExample 2\n \n \n28\n \n \n \n \n \n \nExample 3\n \n \n93\n \n \n \n \n \n \nExample 4\n \n \n100\n \n4.07\n \n \n \n \nExample 5\n \n \n100\n \n1\n \n \n \n \nExample 6\n \n \n95\n \n0.51\n \n \n \n \nExample 7\n \n \n33\n \n \n \n \n \n \nExample 8\n \n \n2\n \n \n \n \n \n \nExample 9\n \n \n18\n \n \n \n \n \n \nExample 10\n \n \n89\n \n79\n \n \n \n \nExample 11\n \n \n82\n \n12\n \n \n \n \nExample 12\n \n \n88\n \n6\n \n \n \n \nExample 13\n \n \n96\n \n1.8\n \n \n \n \nExample 14\n \n \n32\n \n \n \n \n \n \nExample 15\n \n \n54\n \n \n \n \n \n \nExample 16\n \n \n86\n \n \n \n \n \n \nExample 17\n \n \n44\n \n \n \n \n \n \nExample 18\n \n \n54\n \n \n \n \n \n \nExample 19\n \n \n99\n \n \n \n \n \n \nExample 20\n \n \n18\n \n \n \n \n \n \nExample 21\n \n \n79\n \n \n \n \n \n \nExample 22\n \n \n48\n \n \n \n \n \n \nExample 23\n \n \n82\n \n108\n \n \n \n \nExample 24\n \n \n40\n \n \n \n \n \n \nExample 25\n \n \n40\n \n \n \n \n \n \nExample 26\n \n \n55\n \n \n \n \n \n \nExample 27\n \n \n45\n \n \n \n \n \n \nExample 28\n \n \n40\n \n \n \n \n \n \nExample 29\n \n \n8\n \n \n \n \n \n \nExample 30\n \n \n44\n \n \n \n \n \n \nExample 31\n \n \n100\n \n1.9\n \n \n \n \nExample 32\n \n \n93\n \n \n \n \n \n \nExample 33\n \n \n16\n \n \n \n \n \n \nExample 34\n \n \n19\n \n \n \n \n \n \nExample 35\n \n \n90\n \n \n \n \n \n \nExample 36\n \n \n100\n \n \n \n \n \n \nExample 37\n \n \n64\n \n \n \n \n \n \nExample 38\n \n \n99\n \n \n \n \n \n \nExample 39\n \n \n81\n \n \n \n \n \n \nExample 40\n \n \n100\n \n \n \n \n \n \nExample 41\n \n \n100\n \n \n \n \n \n \nExample 42\n \n \n30\n \n \n \n \n \n \nExample 43\n \n \n23\n \n \n \n \n \n \nExample 44\n \n \n47\n \n \n \n \n \n \nExample 45\n \n \n100\n \n \n \n \n \n \nExample 46\n \n \n94\n \n3\n \n \n \n \nExample 47\n \n \n100\n \n0.7\n \n \n \n \nExample 48\n \n \n100\n \n0.13\n \n \n \n \nExample 49\n \n \n68\n \n \n \n \n \n \nExample 50\n \n \n52\n \n \n \n \n \n \nExample 51\n \n \n100\n \n0.1\n \n \n \n \nExample 52\n \n \n98\n \n \n \n \n \n \nExample 53\n \n \n90\n \n \n \n \n \n \nExample 54\n \n \n55\n \n \n \n \n \n \n\n\n \n \nTable 2\n \n \n \n \n \nCompound of Example\n \n \n \n% inhibition at 300nM\n \n \n \n \n \n \nExample 55\n \n \n10\n \n \n \n \nExample 56\n \n \n31\n \n \n \n \nExample 57\n \n \n7\n \n \n \n \nExample 58\n \n \n43\n \n \n \n \n\n\n \n \nTable 3\n \n \n \n \n \nCompound of Example\n \n \n \n% inhibition at 300nM\n \n \n \n \n \n \nExample 59\n \n \n5\n \n \n \n \nExample 60\n \n \n8\n \n \n \n \nExample 61\n \n \n15\n \n \n \n \nExample 62\n \n \n8\n \n \n \n \nExample 63\n \n \n79\n \n \n \n \nExample 64\n \n \n65\n \n \n \n \nExample 65\n \n \n4\n \n \n \n \n \n\n\n \n\n\nCFA-induced Thermal Hyperalgesia in rats\n\n\n\n\n \n \n \nThe more potent antagonists were orally administered at 30 mol/kg. The compound of Example 51 was able to counteract the CFA effects producing a maximal reversal activity of 30%. In contrast, the compounds of Examples 5, 12, 13, 23, 31, 46, 47, 48, 49 produced a sustained anti-hyperalgesic effect showing 53%, 65%, 60%, 46%, 47%, 50%, 46%, 45% and 52% of reversion respectively.\n\n\n \n\n\nCFA-induced Tactile Allodynia in rats\n\n\n\n\n \n \n \nThe compound of Example 5 (30 mol/kg, oral) significantly reversed CFA-induced tactile allodynia (60% of reversal) up to 240 min post-treatment while the same dose of the compound of Example 51 provoked 61% of reversal but showed a shorter duration. The compound of Example 12 produced a statistically significant anti-hyperalgesic effect up to 300 min post-treatment. (62% of reversal). The compound of example 49 joined 72% of reversal.\n\n\n \n\n\nRectal temperature measurement in rats\n\n\n\n\n \n \n \nNone of the more potent compounds affected rectal rat body temperature apart from the compound of Example 31 which induced hypothermia (-1.5C), and the compound of Example 46 which caused hyperthermia. (+0.8C).\n\n\n \n\n\nCCI-induced Mechanical Hyperalgesia\n\n\n\n\n \n \n \nAll selected compounds exhibited a significant anti-hyperalgesic effect. Particularly, derivatives the compounds of Examples 1, 5, 6, 31, 13, 46 and 49 induced relevant and long lasting anti-hyperalgesic activity. Moreover, all the above mentioned compounds produced at least 80% reversal of hyperalgesia within the first 2 hours of experimentation.\n\n\n \n\n\nReferences\n\n\n\n\n \n \n \n\n\n \n \n\n\n(1) \nCortright, D. N. and Szallasi, A. TRP channels and pain Current Pharmaceutical Design 2009, 15, 1736-1749\n.\n\n\n(2) \nGunthorpe M. J. and Szallasi, A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms Current Pharmaceutical Design 2008, 14, 32-41\n.\n\n\n(3) \nNachman R. J. 1,1-carbonyldiimidazole Journal of Heterocyclic Chemistry 1982, 19, 1545-1547\n.\n\n\n(4) Eijgendaal, I.; Klein, G.; Terhorst-Van Amstel, M. J. L.; Zwier, K.; Bruins, N.; Rigter, H. T.; Gout, E.; Boon, C.; De Vries, M. H. Stable crystalline form of bifeprunox mesylate, dosage forms thereof and therapeutic uses for CNS disorders. \n \nWO 2006087369\n \n Solvay Pharmaceuticals B.V.\n\n\n(5) Kath, J. C.; Luzzio, M. J. Pyrimidine derivatives for the treatment of abnormal cell growth, their preparation and pharmaceutical compositions. \n \nUS 2005256125\n \n Pfizer Inc.\n\n\n(6) Singh, J.; Gurney, M.; Hategan, G.; Yu, P.; Zembower, D.; Zhou, N.; Polozov, A.; Zeller, W. Carboxylic acid peri-substituted bicyclics and their preparation, pharmaceutical compositions, and prostanoid EP3 receptor binding activity for treatment of occlusive artery disease. \n \nWO 2006044415\n \n Decode Chemistry, Inc.\n\n\n(7) \nCeccarelli, S. M.; Jaeschke, G.; Buettelmann, B.; Huwyler, J.; Kolczewski, S.; Peters, J.-U.; Prinssen, E.; Porte, R.; Spooren, W. and Vieira, E. Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure Bioorganic & Medicinal Chemistry Letters 2007, 17, 1302-1306\n.\n\n\n(8) Hossain, N.; Ivanova, S.; Mensonides-Harsema, M. Preparation of spiroheterocyclic-piperidine or -pyrrolidine derivatives as chemokine receptor modulators. \n \nWO 2005054249\n \n Astrazeneca AB.\n\n\n(9) \nKudo, Y.; Ozaki, K.; Miyakawa, A.; Amano, T.; Ogura, A. Monitoring of intracellular Ca2+ elevation in a single neural cell using a fluorescence microscope/video-camera system. Japanese Journal of Pharmacology 1986, 41, 345-351\n.\n\n\n(10)\n Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32, 77-88\n.\n\n\n(11) \nGalbraith, J.A.; Mrosko, B.J.; Myers, R.R. A system to measure thermal nociception. Journal of Neuroscience Methods 1993, 49, 63-68\n.\n\n\n(12) \nChaplan, S.R.; Bach, F.W.; Pogrel, J.W.; Chung, J.M.; Yaksh, T.L. Quantitative assessment of tactile allodynia in the rat paw. Journal of Neuroscience Methods. 1994, 53, 55-63\n.\n\n\n(13) \nLeighton, G.E.; Rodriguez, R.E.; Hill, R.G.; Hughes, J. kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. British Journal of Pharmacology 1988, 93, 553-560\n."
  }
]